{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "import glob\n",
    "import math\n",
    "import os\n",
    "import shutil\n",
    "import chromadb\n",
    "\n",
    "from llama_index.core.node_parser import SimpleNodeParser\n",
    "from llama_index.core.schema import BaseNode, Document\n",
    "from llama_index.core import VectorStoreIndex, StorageContext\n",
    "from llama_index.vector_stores.chroma import ChromaVectorStore\n",
    "from llmsherpa.readers import LayoutPDFReader\n",
    "from llmsherpa.readers.layout_reader import Block\n",
    "\n",
    "from embedding import get_ollama_embedding"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "DATA_PATH = \"./pdf\"\n",
    "CHROMA_PATH = \"chroma\"\n",
    "LLM_SHERPA_API_URL = \"https://readers.llmsherpa.com/api/document/developer/parseDocument?renderFormat=all\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "./pdf/PMC10166749.pdf k= 1\n"
     ]
    }
   ],
   "source": [
    "pdf_reader = LayoutPDFReader(LLM_SHERPA_API_URL)\n",
    "blocks = []\n",
    "documents = []\n",
    "i = 0\n",
    "for file in glob.glob(DATA_PATH + \"/*.pdf\"):\n",
    "    if i > 0:\n",
    "        break\n",
    "    i += 1\n",
    "    print(file, \"k=\", i)\n",
    "    doc = pdf_reader.read_pdf(file)\n",
    "    block: Block\n",
    "    for block in doc.chunks():\n",
    "        parent = block.parent\n",
    "        metadata = {\n",
    "            \"page\": block.page_idx,\n",
    "            \"source\": os.path.basename(file),\n",
    "            \"tag\": block.tag,\n",
    "        }\n",
    "        document = Document(text=block.to_text(), metadata=metadata)\n",
    "        documents.append(document)\n",
    "        # blocks.append(block)\n",
    "# blocks"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'page': 0, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 0, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 0, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 0, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 0, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 0, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 0, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 0, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 0, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 1, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 1, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 1, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 1, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 1, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 1, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 2, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 2, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 2, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 2, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 2, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 2, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 2, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 2, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 2, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 2, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 2, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 2, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 2, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 2, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 3, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 3, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 3, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 3, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 3, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 3, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 3, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 3, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 3, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 4, 'source': 'PMC10166749.pdf', 'keyword': 'table'}\n",
      "{'page': 4, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 4, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 4, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 5, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 5, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 5, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 5, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 5, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 5, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 5, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 5, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 5, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 6, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 6, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 6, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 6, 'source': 'PMC10166749.pdf', 'keyword': 'table'}\n",
      "{'page': 6, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 7, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 7, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 7, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 7, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 7, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 7, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 7, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 7, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 8, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 8, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 8, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 8, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 8, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 8, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 8, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 8, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 8, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 8, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 8, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 8, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 8, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 8, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 8, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 8, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 8, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 8, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 8, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 8, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 8, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 8, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 8, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 8, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 9, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 9, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 9, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 9, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 9, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 9, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 9, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 9, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 9, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 9, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 9, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 9, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 9, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 9, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 9, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 9, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 9, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 9, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 9, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 9, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 9, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 9, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 9, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 9, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 10, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 10, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 10, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 10, 'source': 'PMC10166749.pdf', 'keyword': 'list_item'}\n",
      "{'page': 10, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 10, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n",
      "{'page': 10, 'source': 'PMC10166749.pdf', 'keyword': 'para'}\n"
     ]
    }
   ],
   "source": [
    "for document in documents:\n",
    "    print(document.metadata)\n",
    "    # print(document.text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(id_='8e1267ed-fbb5-4494-a866-ca099ceaf837', embedding=None, metadata={'metadata': ['Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review', 'M.Y Jayachandra, R. Gayathiri, C.N.Aruna, Padma K. Bhat, P.M. Arumugam']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Department of Public Health Dentistry, Rajarajeswari Dental College and Hospital, Bengaluru, Karnataka, India', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='fb0f6f55-3fc3-4d6f-9f46-4e2f5101bbc5', embedding=None, metadata={'metadata': ['Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review', 'ABSTRACT']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Background: The burden of oral diseases is increasing, which constitute a major public health problem.\\nThe use of probiotics as an adjuvant, along with routine dental care practice by an individual, can produce additional benefits in the maintenance of one’s oral health.\\nThe study aimed to investigate the effect of Bifidobacterium as a probiotic on oral health.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='163f7525-afa6-4069-9ea2-9d2cf20deba0', embedding=None, metadata={'metadata': ['Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review', 'ABSTRACT', 'Address for correspondence:']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Dr. R. Gayathiri, Rajarajeswari Dental College and Hospital, No 14, Ramohalli Cross, Mysore Road, Kumbalgodu, Bengaluru ‑ 560 074, Karnataka, India.\\nE‑mail: gayuharin95@gmail.\\ncom', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='76d1ece0-0da8-4647-a998-e1436d7b78a2', embedding=None, metadata={'metadata': ['Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review', 'ABSTRACT', 'Address for correspondence:']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Material and Methods: Six databases and registers were searched from the start of the database to December 2021 without any restrictions.\\nRandomized controlled trials (RCTs) evaluating the clinical effects of Bifidobacterium as a probiotic on oral health were included in the study.\\nThe Preferred Reporting Items for Systematic Reviews and Meta‑analyses (PRISMA) guidelines were followed to conduct this systematic review.\\nThe included studies were analyzed for the risk of bias using the Cochrane risk‑of‑bias tool for randomized trial (RoB 2) tool as well as quality of available evidence using GRADE criteria.\\nResults: From the 22 qualified studies, four studies showed non‑significant results.\\nThere was a high risk of bias in 13 studies and some concerns of bias in nine studies.\\nNo adverse effects were reported, and the quality of available evidence was moderate.\\nConclusion: The effect of Bifidobacterium on oral health is questionable.\\nFurther high‑quality RCTs are required on the clinical effects of bifidobacteria and also the optimum level of probiotic needed, and ideal mode of administration to provide oral health benefits.\\nFurthermore, synergistic effects of the combined use of various strains of probiotics need to be studied.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='bca540fb-f3f6-4587-b69b-899db4a43952', embedding=None, metadata={'metadata': ['Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review', 'ABSTRACT', 'Address for correspondence:']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Keywords: Bifidobacterium, oral health, probiotics', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='48ddb449-c6ae-4a76-8b67-460c1187fcb1', embedding=None, metadata={'metadata': ['Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review', 'INTRODUCTION']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Recently, there is a growing interest in the use of probiotic products for restoring dysbiotic microbiota.\\n[1] The Food and Agriculture Organization FAO and the World Health Organization (WHO) in 2001 defined probiotics as “live microorganisms which when administered in adequate amounts confer a health benefit on the host.\\n”[2] Because of their potential health‑promoting attributes, probiotic supplements are usually directed towards Lactobacilli and/or bifidobacteria.\\nThe beneficial effects may result from the suppression of harmful microorganisms or stimulation of organisms which contribute positively to the nutrition and health of human beings and animals.\\nThe extent to which this may be achieved can be difficult to assess.\\n[3] Probiotic effects are strain specific; thus, each individual bacterial strain must be tested separately for the health This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution‑NonCommercial‑ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non‑commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='5631db6f-6606-44c2-85c6-a3c39d25ca13', embedding=None, metadata={'metadata': ['Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review', 'INTRODUCTION', 'Access this article online']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Website: www.drj.ir www.drjjournal.net www.ncbi.nlm.nih.gov/pmc/journals/1480 How to cite this article: Jayachandra MY, Gayathiri R, Aruna CN, For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='2fc8655d-25a2-4ca7-b7ab-868da23a0f97', embedding=None, metadata={'metadata': ['Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review', 'INTRODUCTION', 'Access this article online']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Bhat PK, Arumugam PM.\\nClinical effects of Bifidobacterium as a probiotic on oral health: A systematic review.\\nDent Res J 2023;20:32.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='651fb614-9d17-4746-a916-b3a6d91c27b5', embedding=None, metadata={'metadata': ['Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review', 'INTRODUCTION', 'Access this article online']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='1© 2023 Dental Research Journal | Published by Wolters Kluwer - Medknow', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='8d8faa43-f568-4f1a-b7ea-330405973521', embedding=None, metadata={'metadata': ['Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review', 'INTRODUCTION', 'Access this article online']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='benefit in question, and the effects described for one strain cannot be directly applied to others.\\n[4] Bifidobacteria occur naturally in the oral cavity and are among the most predominant anaerobic bacteria within the intestinal lumen.\\n[5] It is generally thought that bifidobacteria have combined local and systemic effects involving adhesion, co‑aggregation, competitive inhibition, production of organic acids and bacteriocin‑like compounds, and immune modulation.\\n[6] A body of evidence suggests that bifidobacteria play a critical role in maintaining the equilibrium of the normal gut flora, and a number of probiotic‑induced benefits on general health have been proposed, such as reduced susceptibility to infections, reduction of allergies and lactose intolerance, as well as lowered blood pressure and serum cholesterol values.\\n[7] In vitro studies using bifidobacteria have demonstrated beneficial effects against oral pathogens.\\n[8‑22] Although various experimental studies support the beneficial effect of Bifidobacterium on oral pathogens and oral diseases such as dental caries, gingivitis and periodontitis other clinical trials have failed to show similar results.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='77614139-4a34-43c7-89da-0c876f97fc51', embedding=None, metadata={'metadata': ['Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review', 'Objectives']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='The burden of oral diseases is increasing, which constitutes a major public health problem.\\nThe use of probiotics as an adjuvant, along with routine dental care practice by an individual, can produce additional benefits in the maintenance of one’s oral health.\\nHowever, short‑term trials focusing on the clinical effects of probiotics on oral health have not been reviewed in an evidence‑based manner.\\nOur aim was to systematically assess the available evidence from the randomized controlled trials (RCTs) on the benefits Bifidobacterium on oral health.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='f70dd0ce-1f01-4a1f-82db-f91fec9015ec', embedding=None, metadata={'metadata': ['MATERIALS AND METHODS', 'Protocol development and registration']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Before starting the systematic review, the study protocol was registered on the PROSPERO database (http://www.crd.york.ac.uk/PROSPERO, ID: CRD42022306243).\\nThe preferred reporting items for systematic reviews and meta‑analyses (PRISMA 2020)[23,24] was used.\\nSince it is a systematic review, ethical approval was not taken.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='3dccc788-926a-42cd-85ab-d7dbd91f5e37', embedding=None, metadata={'metadata': ['MATERIALS AND METHODS', 'Eligibility criteria']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='The criteria were established using PICOS (Participants, Interventions, Comparators, Outcomes, and Study design) approach.\\nRandomized clinical trials investigating the effect of Bifidobacterium as a probiotic on oral health conditions were included in the study.\\nNo language and publication date restrictions were imposed.\\nAccepted manuscripts were also included.\\nParticipants without any age restrictions were included.\\nParticipants should receive probiotics containing Bifidobacterium in any form, such as milk, curd, yogurt, ice cream, or lozenges, in any dosage and should be compared with participants who received a placebo, control, or no interventions at all.\\nThe outcome parameters included Streptococcus, Lactobacillus, and Porphyromonas gingivalis count in saliva and plaque, occurrence of dental caries in deciduous and permanent teeth, occurrence of periodontitis.\\nStudies without human participants, control or placebo groups, <1 week of intervention, and reviews were excluded from the study.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='39816a40-4b0f-40ce-b250-0e31cbb5c6bb', embedding=None, metadata={'metadata': ['MATERIALS AND METHODS', 'Information sources and search strategy']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Clinical trials were identified and included in this study using various electronic databases and registers such as (MEDLINE, CENTRAL, Scopus, Web of Science, Cochrane library, and Clinical Trials Registry).\\nThe search was from the beginning of each database and registers till December 2021. No restrictions were imposed on the publication dates and foreign languages.\\nForeign language articles were translated into English.\\nThe list of references which was included in each study was also cross‑verified so that all the relevant trials were included.\\nThe various search terms used to identify the relevant clinical trials from each database were Bifidobacterium and oral health, Bifidobacterium and dentistry, Bifidobacterium and dental caries, Bifidobacterium as probiotic.\\nThe search strategies were peer‑reviewed as a part of the systematic review process.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='e913d749-25a3-48da-908a-e35e571afa50', embedding=None, metadata={'metadata': ['MATERIALS AND METHODS', 'Study selection and data collection']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='The list of clinical trials gathered through electronic databases was assessed by two independent researchers in an unblinded, standardized manner.\\nBoth the researches reviewed each included study and extracted the following details of the publication date, authors name, title, study design, randomization, study population, sample size, duration of intervention and follow‑up, number of dropouts, loss to follow‑up form, and dosage of Bifidobacterium administered, any adverse reactions and outcome of the study such as Streptococcus, Lactobacillus and P. gingivalis count in saliva and plaque, the occurrence of dental caries in deciduous and permanent teeth, the occurrence of periodontitis were included.\\nDisagreements were resolved by the third researcher.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='aeb244fa-1287-481f-8501-b338d4313504', embedding=None, metadata={'metadata': ['DATA ITEMS', 'Risk of bias in individual studies']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Two reviewers worked independently to assess the risk of bias for individual studies at the study as well as at the outcome level.\\nThey determined the adequacy involved in the various stages of randomization such as random allocation sequence (selection bias), allocation concealment (selection bias), blinding of the investigator, participants or outcome assessors (performance bias), loss of follow‑up, incomplete outcome data (attrition bias), and selective reporting (reporting bias)', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='5ca5fce1-53b5-4edb-89bc-83a26262f45f', embedding=None, metadata={'metadata': ['DATA ITEMS', 'Summary measures', 'Planned methods of analysis']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Two independent reviewers checked each of the trials for risk of bias and quality of available evidence.\\nThe risk of bias in the selected studies was analyzed using the Cochrane risk‑of‑bias tool for randomized trial (RoB 2), which is the recommended tool for use in Cochrane Reviews, and the quality of available evidence was analyzed using GRADE criteria.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='41a9723e-31b3-4b46-bf92-274dff5129e6', embedding=None, metadata={'metadata': ['DATA ITEMS', 'Summary measures', 'Risk of bias across studies and additional analyses']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Overall, the quality of evidence from these trials was moderate.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='01bc3e15-cf4d-413e-a0d5-4bd6592a7298', embedding=None, metadata={'metadata': ['RESULTS', 'Study selection']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='The study selection is shown in Figure 1.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='8de09018-d79a-4e55-bd14-99c8b389e8c0', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', '1) Ice cream']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Nagarajappa et al.\\n[7] and Caglar et al.\\n[25] assessed the effect on salivary Streptococcus mutans and lactobacilli for 18 days and 10 days, respectively.\\nAshwin et al.\\n[26] assessed the effect on salivary S. mutans for 7 days, and Singh et al.\\n[27] assessed the effect of Bifidobacterium and Lactobacilli‑containing probiotic on S. mutans and lactobacilli for 10 days.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='72e87b1e-d6f5-4740-8023-b1f67d541aa0', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', '2) Yogurt']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Caglar et al.,[28] Nozari et al.,[29] and Zare Javid et al.\\n[30] assessed the effect on salivary S. mutans and lactobacilli for 14 days.\\nPinto et al.\\n[31] and Caglar[32] assessed the effect on the dental plaque for 14 days.\\nKuru et al.\\n[33] assessed the effect on gingival health for 28 days.\\nCildir et al.\\n[34] assessed the effect on S. mutans for 14 days.\\nBafna et al.\\n[35] assessed the effect of Bifidobacterium and Lactobacilli containing', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='589c4e9f-0f59-4f78-b429-c04679708749', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', '2) Yogurt']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='probiotic on S. mutans for 14 days', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='ec9b1ae5-0c0f-4aa9-b65e-01ded6360716', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', '3) Tablet']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Taipale et al.\\n[36] assessed the effect on oral colonization of S. mutans for 2 years.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='06fef409-793b-4bfb-a3fb-971ec2531aff', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', '4) Lozenges']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Toiviainen et al.\\n[37] assessed the effect of on salivary S. mutans, amount of plaque, gingival inflammation, and oral microbiome.\\nJäsberg et al.\\n[38] assessed the effect on the salivary levels of matrix metalloproteinase (MMP)‑9 and tissue inhibitors of metalloproteinases (TIMP)‑1.\\nAlanzi et al.\\n[39] assessed the effect on gingival health, dental plaque, and periodonto‑pathogens for 4 weeks.\\nInvernici et al.\\n[40] evaluated the effects on clinical periodontal parameters (plaque accumulation and gingival bleeding), on the immunocompetence of gingival tissues (expression of beta‑defensin‑3, toll‑like receptor 4, cluster of differentiation [CD]‑57 and CD‑4), and on immunological properties of saliva (immunoglobulin A [IgA] levels) in nonsurgical periodontal therapy in generalized chronic periodontitis patients', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='c6fc6190-1968-4819-b494-d027fdad21aa', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', '5) Chewing gum']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Gueimonde et al.\\n[41] assessed the effect on saliva flow rate, saliva IgA levels, and saliva pH.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='d4886c19-7a53-49e6-a9ef-6fcaa339eba5', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', '6) Capsule']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Ishikawa et al.\\n[42] assessed the effect on the colonization of candida species on dentures for 5 weeks.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='400da1ae-22fa-477b-b899-4abd91726862', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', '7) Probiotic drop']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Tehrani et al.\\n[43] assessed the effect on salivary S. mutans and Lactobacillus for 2 weeks.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='04b4c149-b064-49d3-bc8e-e05e6d4854dc', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', '8) Freeze‑dried powder']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Jindal et al.\\n[44] assessed the effect on salivary S. mutans for 14 days, and Yousuf et al.\\n[45] assessed the effect on the gingival status and plaque inhibition for 21 days.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='a0818e66-19b6-422b-87aa-8a54ba3458e6', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', 'Participants']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Twenty‑two included studies involved 1175 participants.\\nThe inclusion criteria in these studies were orally and systemically healthy non‑medicating participants having good oral health with no untreated caries lesions and daily toothbrushing habits with fluoride toothpaste.\\nThe exclusion criteria were habitual consumption of other forms of probiotics, systemic antibiotic medication within 6 weeks, topical 3Dental Research Journal fluoride treatments within 4 weeks, allergic to dairy products, receiving Xylitol‑containing products, use of antibiotics, antimicrobials, cavitated or active carious lesions, and lactose intolerance.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='ce366e32-9fd2-4f19-91dd-913560267cf7', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', 'Participants']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Figure 1: Flow diagram of the record through the review process.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='96cb13f7-11fa-4939-9666-5cd315e05e77', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', 'Intervention']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='The participants received probiotic Bifidobacterium in any (ice cream, yogurt, lozenges, tablet, chewing gum, capsule, freeze‑dried powder, or probiotic drop) form or placebo minimum of once a day.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='4ea5a68c-2803-4a3f-b656-17bc48f50631', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', 'Outcomes']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='The outcomes that were assessed include changes in oral microbiota, dental plaque, gingival health, levels of MMP‑9, and TIMP‑1 at baseline and after the intervention.\\nNo study included mortality and costs as the outcome.\\nThe timing of outcome measures varied between studies', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='afede53e-b41a-4c5c-8f1b-1d3c10a39050', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='(i) Bias arising from randomization process', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='3f6ab23e-ef98-4746-a827-d5e9473a7f9a', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='(ii) Bias due to deviations from intended interventions', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='a6d65e74-3f48-40be-8727-69b84567d44b', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='(iii) Bias due to missing outcome', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='334a2192-6f7d-49f8-b195-51c2b1f73f9c', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='(iv) Bias in the measurement of the outcome', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='0b01ecbf-153b-48a1-bdca-5bfab6e92fdf', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='(v) Bias in selection of the reported result [Table 1 and Table 2][46,47]', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='b71c7b58-b1c5-4e00-8b42-eb08268183fc', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:', '1) Ice cream']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Postingestion (after 1 h) in the test group, a statistically significant reduction (P < 0.05) of salivary S. mutans was recorded, but a nonsignificant trend was seen for Lactobacilli.\\nSignificant results were also observed between follow‑ups.\\n[7] A statistically significant (P < 0.05) reduction of salivary mutans streptococci was registered after the 10‑day consumption of probiotic ice‑cream.\\nA certain decline of high mutans streptococci counts (>105) was also evident after intake of the control ice cream, but the difference compared to baseline was not statistically significant.\\nDuring the period of test product consumption, the number of subjects with high mutans streptococci counts (105 colony‑forming unit) decreased from 56% to 0.\\n[25] There was reduction of MS in the children who consumed probiotic ice‑cream when compared to baseline which was statistically significant (P < 0.001).\\nThe effect of which reduced over the washout period and throughout the study period, there was constant increase of MS count in the control group who consumed normal ice cream.\\nThere was no synergistic effect of probiotic organisms for as long as 6 months.\\n[26] Probiotic ice cream brought about a statistically significant reduction (P 0.003)', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='ea4a0e5e-f371-4a45-960d-7cb9b5527c83', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:', '1) Ice cream', 'Table 1: Risk of bias within studies ‑ Parallel trials']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text=' | Trials | Bias arising from\\n | --- | ---\\n |  | randomization process | Bias due to deviations from intended interventions | Bias due to missing outcome | Bias in the measurement of the outcome | Bias in selection of the reported result | Overall risk of bias judgement\\n | --- | --- | --- | --- | --- | --- | ---\\n | Parallel group trials\\n | Nagarajappa et al., 2015[7] | Some concerns | Low risk of bias | Low risk of bias | Some concerns | Low risk of bias | Some concerns\\n | Ashwin et al., 2015[26] | Some concerns | Low risk of bias | Low risk of bias | Some concerns | Low risk of bias | Some concerns\\n | Nozari et al., 2021[29] | Some concerns | Some concerns | Low risk of bias | Some concerns | Low risk of bias | High risk of bias\\n | Kuru et al., 2017[33] | Low risk of bias | Low risk of bias | Low risk of bias | Some concerns | Low risk of bias | Some concerns\\n | Bafna et al., 2018[35] | Some concerns | Some concerns | Low risk of bias | Some concerns | Low risk of bias | High risk of bias\\n | Javid et al., 2019[30] | Some concerns | Low risk of bias | Low risk of bias | Low risk of bias | Low risk of bias | Some concerns\\n | Taipale et al., 2012[36] | Some concerns | Some concerns | Low risk of bias | Some concerns | Low risk of bias | High risk of bias\\n | Toiviainen et al., 2014[37] | Some concerns | Some concerns | Low risk of bias | Some concerns | Low risk of bias | High risk of bias\\n | Jasberg et al., 2017[38] | Some concerns | Some concerns | Low risk of bias | Some concerns | Low risk of bias | High risk of bias\\n | Alanzi et al., 2018[39] | Some concerns | Low risk of bias | Low risk of bias | Some concerns | Low risk of bias | Some concerns\\n | Invernici et al., 2020[40] | Low risk of bias | Low risk of bias | Low risk of bias | Some concerns | Low risk of bias | Some concerns\\n | Gueimonde et al., 2016[41] | Some concerns | Some concerns | Low risk of bias | Some concerns | Low risk of bias | High risk of bias\\n | Ishikawa et al., 2014[42] | Some concerns | Some concerns | Low risk of bias | Some concerns | Low risk of bias | High risk of bias\\n | Tehrani et al., 2021[43] | Some concerns | Low risk of bias | Low risk of bias | Some concerns | Low risk of bias | Some concerns\\n | Jindal et al., 2011[44] | Some concerns | Some concerns | Low risk of bias | Some concerns | Low risk of bias | High risk of bias\\n | Yousuf et al., 2017[45] | Some concerns | Some concerns | Low risk of bias | Some concerns | Low risk of bias | High risk of bias\\n | Table 2: Risk of bias within studies ‑ Crossover trials\\n | Trials Bias arising from | Bias arising from period and carryover effects |  |  | Bias in the measurement of the outcome | Bias in selection of the reported result | Overall risk of bias judgement\\n | Crossover trials\\n |  |  | Bias due to deviations from intended interventions | Bias due to missing outcome |  |  | \\n | randomization process\\n | Caglar et al., 2009[25] Some concerns Some concerns Low risk of bias |  |  | Low risk of bias Some concerns Low risk of bias High risk of bias |  |  | \\n | Singh et al., 2011[27] Low risk of bias | Some concerns Low risk of bias |  | Low risk of bias Some concerns Low risk of bias Some concerns |  |  | \\n | Caglar et al., 2005[28] Some concerns Some concerns Low risk of bias |  |  | Low risk of bias Some concerns Low risk of bias High risk of bias |  |  | \\n | Pinto et al., 2014[31] Low risk of bias | Low risk of bias | Low risk of bias | Low risk of bias Some concerns Low risk of bias Some concerns |  |  | \\n | Caglar et al., 2014[32] Some concerns Some concerns Some concerns Low risk of bias Some concerns Low risk of bias High risk of bias Cildir et al., 2009[34] Some concerns Some concerns Low risk of bias |  |  | Low risk of bias Some concerns Low risk of bias High risk of bias |  |  | \\n', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='62adec12-22b0-45b4-8273-a67acb316a8c', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:', '1) Ice cream', 'Table 1: Risk of bias within studies ‑ Parallel trials']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='in salivary mutans streptococci levels with no significant effect on lactobacilli levels.\\n[27]', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='cfa144b8-2cfa-4a72-9c41-cfc510a4090e', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:', '2) Yogurt']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='A statistically significant reduction (P < 0.05) of salivary mutans streptococci was recorded after the probiotic yogurt consumption, which was in contrast to the controls.\\n[28] In the case group, neither the S. mutans count nor the Lactobacilli count was significantly reduced.\\nHowever, there was a reduction in S. mutans and Lactobacillus counts in the control group.\\n[29] Similarly, there was no difference between the yogurt containing probiotics and the control yogurt for any of the studied variables (all P > 0.05).\\nA reduction in counts of total cultivable microorganisms was observed in dental plaque samples after ingestion of either yogurts (both P 0.05 vs. baseline) but not in saliva (P < 0.05).\\n[31] In addition, there were no statistically differences between transition scores of test and placebo groups regarding different dental plaque sampling sites (P > 0.05).\\n[32] No intergroup differences could be detected before and after the intake of the study products.\\nHowever, after plaque accumulation, significantly better results for all parameters could be seen in the probiotic group compared to the control group (P < 0.001): lower plaque and gingivitis scores, less bleeding on probing, less increase in GCF volume, and lower total interleukin‑1 β amount/concentration.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='4ac743d7-33a8-4ae8-bb70-383016c0467c', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:', '2) Yogurt']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='[33] Daily consumption of probiotic yogurt for 2 weeks decreased the mutans streptococci counts in saliva (P < 0.05), which was in contrast to the control yogurt.\\nNo significant alterations in the salivary lactobacilli counts were observed.\\n[34] A statistically 5Dental Research Journal significant reduction (P < 0.05) of salivary S. mutans was recorded after probiotic yogurt consumption with minimal residual effect in case group, which was in contrast to the controls.\\n[35] A significant reduction in salivary S. mutans (P = 0.001) and Lactobacillus counts (P = 0.001) was observed in the intervention group as compared to their baseline and compared to the control group.\\nWhile the reduction in S. mutans (P = 0.594) and lactobacilli (P = 0.071) was not significant in the control group after the intervention.\\n[30]', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='6d038432-425a-427b-bad8-29cf0061da45', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:', '3) Tablet']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='In the Bifidobacterium animalis subsp.\\nlactis BB‑12 (BB‑12) group, only 6.3% of the children harbored mutans streptococci at the age of 2 years.\\nThis percentage was lower as compared to the xylitol control group (31.4%; P = 0.009) but did not differ from the sorbitol control group (10.3%; P = 0.56).\\n[36]', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='b91acbf0-71ff-45a2-98b7-dff1c0d3a281', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:', '4) Lozenges']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='The probiotic lozenge decreased both PI and GI (P < 0.05), while no changes were observed in the control group.\\nHowever, no probiotic‑induced changes were found in the microbial compositions of saliva in either group.\\nNo study‑induced changes in the MS counts were detected either in the probiotic or the control group.\\n[37] In the probiotic group (n = 29), salivary MMP‑9 levels increased (P < 0.01) and TIMP‑1 levels decreased (P < 0.01) significantly during the intervention.\\nFurthermore, MMP‑9/ TIMP‑1 ratio differed significantly from the baseline level (P < 0.01).\\nProbiotic consumption did not affect the saliva flow rate.\\nProbiotic intervention did not affect the salivary levels of MMP‑8.\\n[38] A reduction in plaque index was found for both groups, with no difference observed between the groups after intervention (P = 0.819).\\nProbiotic lozenges significantly reduced the levels of Aggregatibacter actinomycetemcomitans and Fusobacterium nucleatum in saliva and plaque (P < 0.05) and levels of P. gingivalis in plaque (P < 0.05), while no significant changes were found in the control group.\\nA significant reduction (P < 0.001) was also noted in the total salivary bacterial counts of the test group.\\nThe short‑term daily consumption of LGG and BB‑12 probiotic lozenges improved the gingival health in adolescents and decreased the microbial counts of', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='091f545e-c63f-4de1-b235-65154183bee8', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:', '4) Lozenges']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='The test group also demonstrated significantly fewer periodontal pathogens of red and orange complexes, as well as lower proinflammatory cytokine levels when compared to the control group.\\nOnly the test group showed an increase in the number of Bifidobacterium animalis subsp.\\nlactis HN019 DNA copies on subgingival biofilm at 30 and 90 days.\\nThe control group presented higher levels of IL‑1 β (30 and 90 days) and of IL‑8 (30 days) when compared with the test group.\\n[40]', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='63a9871e-67ec-467d-968e-dc7670f58626', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:', '5) Chewing gum']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='However, no statistically significant differences were found between probiotic and placebo groups for any of the parameters analyzed.\\n[41]', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='f2770d32-8419-494d-88c0-fed904578d34', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:', '6) Capsule']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='The detection rate of Candida spp.\\nwas 92.0% in the placebo group after the experimental period, whereas it was reduced to 16.7% in the probiotic group.\\n[42]', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='4cbb428e-14e6-4c35-b3a5-9abff186ce64', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:', '7) Probiotic drop']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='S. mutans level decreased significantly in the probiotic group after intervention (P = 0.045), and there were significant differences in salivary SM counts after intervention between the two groups (P = 0.04).\\nIn the probiotic group, LB counts decreased significantly after intervention (P = 0.048); however, there were no significant differences between the two groups (P = 0.216).\\n[43]', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='0c58625e-e6a3-4414-a250-b8a0c58db717', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:', '8) Freeze dried powder']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='A statistically significant postintervention change was observed in the study groups (P < 0.001).\\nA significant reduction in MS counts was observed after the administration of probiotics (Group B and Group C) for 14 days.\\n[44] For both the probiotic groups, a statistically significant reduction (P < 0.05) in gingival status and plaque inhibition was recorded up to the 2nd week of probiotic ingestion.\\nHowever, no significant difference was observed in the placebo group.\\n[45]', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='3cdbea6b-bb02-41ba-9ae8-cc2fcb484bbc', embedding=None, metadata={'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:', 'Risk of bias across studies and additional analyses']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='The confidence obtained from the trials included in this study is moderate [Table 3].\\n[48]', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='049f5e14-f74e-4340-be1d-15b11ffedf63', embedding=None, metadata={'metadata': ['DISCUSSION', 'Summary of evidence']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Probiotic technology represents a breakthrough approach to maintaining oral health by utilizing natural beneficial bacteria commonly found in healthy mouths to provide a natural defense against those bacteria thought to be harmful to teeth and gums.\\n[7] Bifidobacteria have a wide commercial use and are Generally Regarded As Safe (GRAS) for use as ingredients in milk‑based infant formulas.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='43102163-bfd9-439c-be05-cbfcfc1543ef', embedding=None, metadata={'metadata': ['DISCUSSION', 'Summary of evidence']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='[25] Bifidobacteria are the predominant anaerobic bacteria naturally occurring within the intestinal lumen and play a critical role in maintaining the equilibrium among normal intestinal flora.\\n[28] Acidogenic and aciduric species of dairy products can inhibit other competing organisms and make their local environment, for example, the dental plaque, even more acidic.\\nHowever, some species of Bifidobacterium may also have a role in maintaining health by promoting a microbiological balance in the oral cavity and oral defense factors, such as the peroxidase system, which may inhibit the acidogenicity of bacteria.\\n[33] Various clinical trials have been performed on the different forms of probiotics to check its effectiveness and substantivity in the oral cavity so that it can be used as an adjuvant in oral care measures as well as a preventive aid in the occurrence of various dental diseases.\\nTo the best of our knowledge, studies solely focusing on the clinical effects of Bifidobacterium have not been previously summarized in an evidence‑based manner.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='7a02a3c5-fa4a-4e4f-9250-68de3b387544', embedding=None, metadata={'metadata': ['DISCUSSION', 'Summary of evidence']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Studies investigating the effect of probiotics on various microbiological parameters during the consumption of probiotics have been conflicting.\\nApart from specific strains of Bifidobacterium or the mode/duration of administration, patients’ compliance could also affect the results.\\nAlthough compliance was found to be good, they were self‑reported by the participants which cannot be completely relied on.\\nOther factors that could have affected the reported results were dietary habits, use of antibacterial agents, cleansing the mouth after consumption of probiotic, thus washing‑out the probiotic from the mouth.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='463b6558-fd69-4434-a54e-e3d3fd0c47da', embedding=None, metadata={'metadata': ['DISCUSSION', 'Summary of evidence']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Probiotic icecream‑containing Bifidobacterium reduced the levels of salivary mutans streptococci and a non‑significant trend was observed for Lactobacillus count.\\n[7,27] However, the study conducted by Caglar et al.\\n[25] showed the high risk of bias due to selection and performance bias.\\nHence the results from that study are not reliable.\\nAll the studies using ice cream as a vehicle of probiotic delivery showed the moderate quality of evidence.\\n[7‑27] In yogurt containing Bifidobacterium, there was a significant reduction of salivary mutans streptococci.\\nHowever, there was selection and performance bias.\\n[28] On contrary, S. mutans and Lactobacillus count did not reduce in the case group; however, there was a significant reduction in the control group.\\nThis study had inadequate information regarding randomization process and blinding, leading to selection bias.\\nPerformance bias was also encountered.\\n[29] Both the studies showed high risk of bias.\\nFurthermore, the study conducted by Pinto et al.\\n[31] showed a reduction in the counts of total cultivable microorganisms in the dental plaque in both the control and the case groups, which implied that daily ingestion of yogurt with or without Bifidobacterium reduced the total microbial count, and this study showed some concerns of bias.\\nSimilar study conducted by Caglar.\\n[32] showed no statistical significance in the reduction of salivary mutans streptococci in the dental plaque sample.\\nThis study also had inadequate information regarding the', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='b8c22017-f4bb-4352-98e4-ff5bec3722cf', embedding=None, metadata={'metadata': ['DISCUSSION', 'Summary of evidence', 'Table 3: Quality of available evidence']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text=' | Study | Risk of bias | Inconsistency Indirectness | Imprecision Others | No of patients Probiotic control | Effect | Quality\\n | --- | --- | --- | --- | --- | --- | ---\\n | Ice cream | Serious | Not serious | Not serious | Serious | None | 107 107 | No difference | Moderate\\n | --- | --- | --- | --- | --- | --- | --- | --- | ---\\n | Yogurt | Serious | Not serious | Not serious | Serious | None | 241 238 | Difference present | Moderate\\n | Tablet | Serious | No serious | Not serious | Serious | None | 32 64 | No difference | Moderate\\n | Lozenges | Serious | Not serious | Not serious | Serious | None | 127 111 | No difference | Moderate\\n | Chewing gum | Serious | Not serious | Not serious | Serious | None | 17 19 | No difference | Moderate\\n | Capsule | Serious | Not serious | Not serious | Serious | None | 30 29 | No difference | Moderate\\n | Drop | Serious | Not serious | Not serious | Serious | None | 30 | No difference | Moderate\\n', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='14e6ad3e-4186-45ef-9c75-b1e86eb24bb9', embedding=None, metadata={'metadata': ['DISCUSSION', 'Summary of evidence', 'Table 3: Quality of available evidence']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='7Dental Research Journal', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='aaa3c91a-18ab-4b80-b7a1-93be059aa179', embedding=None, metadata={'metadata': ['DISCUSSION', 'Summary of evidence', 'Table 3: Quality of available evidence']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='randomization process and blinding.\\nPerformance bias was encountered giving rise to a high risk of bias.\\nA study conducted by Kuru et al.\\n[33] showed lower plaque and gingivitis scores, less bleeding on probing, less increase in GCF volume and lower total interleukin‑1B amount/concentration with some concerns of bias.\\nSimilar to ice cream‑containing probiotic, a study conducted by Cildir et al.\\n[34] showed a reduction in the levels of salivary mutans streptocooci and not Lactobacillus.\\nHowever, there was the selection and performance bias giving rise to a high risk of bias in this study.\\nA study conducted by Bafna et al.\\n[35] showed a reduction in mutans streptococci with minimal residual effect and the result had some concerns of bias.\\nA study conducted by Zare Javid et al.\\n[30] showed a significant reduction in both S. mutans and Lactobacillus count.\\nHowever, participants were aware of their assigned intervention during the trial, and hence, high risk of bias is anticipated.\\nAll the studies using yogurt as a vehicle of probiotic delivery showed either high risk or some concerns of bias and hence the results obtained from these studies are either not reliable or questionable.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='141f95c0-68a1-4351-b233-e604a51498eb', embedding=None, metadata={'metadata': ['DISCUSSION', 'Summary of evidence', 'Table 3: Quality of available evidence']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='A study conducted by Taipale et al.\\n[36] concluded that when Bifidobacterium administered in the form of a tablet in newborns, it did not result in permanent colonization of this probiotic or significantly affect the levels of mutans streptococci colonization.\\nOnly one study was conducted using probiotic tablet.\\nThis study had inadequate information regarding the blinding of the participants and outcome assessors, and thus, the result obtained is questionable, giving rise to high risk of bias and moderate quality of available evidence.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='3f545193-0272-4c81-909e-93c0f1e97d04', embedding=None, metadata={'metadata': ['DISCUSSION', 'Summary of evidence', 'Table 3: Quality of available evidence']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='The use of probiotic lozenge by Toiviainen et al.\\n[37] showed improved periodontal status without affecting the oral microbiota and adhesion properties of plaque.\\nAnother study conducted by Jäsberg et al.\\n[38] showed increased MMP‑9 and decreased TIMP‑1 levels in saliva, suggesting immunomodulatory effects in the oral cavity.\\nHowever, both the studies had some concerns of bias arising from the randomization process as well has inadequate information on blinding of the study participants and outcome assessors, giving rise to a high risk of bias.\\nHence, the results are questionable.\\nAlanzi et al.\\n[39] suggested the use of lozenges as a simple adjunct to standard oral care, but the results had some concerns of bias.\\nThe overall quality of available evidence is moderate.\\nInvernici et al.\\n[40] suggested the use of B. lactis HN019 as an adjunct to SRP for promoting additional clinical, microbiological, and immunological benefits in the treatment of chronic periodontitis Only one study was conducted using probiotic chewing gums by Gueimonde et al.\\n[41] which concluded a positive impact on the salivary flow rate, salivary pH, and IgA levels with or without the use of Bifidobacterium probiotic.\\nThis result is questionable because of inadequate information regarding the blinding of the participants and outcome assessors.\\nHence, this study had a high risk of bias as well as the moderate quality of available evidence.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='01c776da-5735-4fac-9d5c-804702e662f1', embedding=None, metadata={'metadata': ['DISCUSSION', 'Summary of evidence', 'Table 3: Quality of available evidence']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='A study conducted by Ishikawa et al.\\n[42] using probiotic capsules, concluded that there was the reduction in the colonization of Candida species, suggesting the use of probiotics as an alternative treatment in elderly denture wearers.\\nThis result is also questionable because of the high risk of bias due to inadequate information on the awareness of participants and outcome assessors of their assigned intervention during the trial and moderate quality of available evidence.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='5069b8fc-1309-41a1-be9a-db22ab0b979a', embedding=None, metadata={'metadata': ['DISCUSSION', 'Summary of evidence', 'Table 3: Quality of available evidence']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='A study conducted by Tehrani et al.\\n[43] on probiotic drop decreased salivary counts of mutans streptococci and Lactobacillus in children with higher salivary counts.\\nThere were some concerns of bias and moderate quality of available evidence in this study, so the results obtained are questionable.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='0691c7a8-9bf4-4311-93ff-9441e7db2c48', embedding=None, metadata={'metadata': ['DISCUSSION', 'Summary of evidence', 'Table 3: Quality of available evidence']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Studies done by Jindal et al.\\n[44] and Yousuf et al.\\n[45] showed that freeze‑dried probiotic powder reduced Mutans streptococci count and improved gingival status and plaque inhibition, respectively.\\nBoth the studies have not mentioned whether the participants, as well as carers and people delivering the interventions, were aware of the assigned intervention during the trial or not, giving rise to high risk of bias and moderate quality of available evidence.\\nHence, the reliability of these studies is questionable.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='323fed8d-5b1b-4376-9c42-67e3f2e923a8', embedding=None, metadata={'metadata': ['DISCUSSION', 'Summary of evidence', 'Table 3: Quality of available evidence']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Overall, the risk of bias for all the studies included in this review ranged from some concerns to high risk and the quality of available evidence was also moderate.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='268e66aa-0192-41b1-8c03-520f8a11d115', embedding=None, metadata={'metadata': ['DISCUSSION', 'Strengths and limitations']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='RCTs represent the highest level of evidence in health care interventions, and we adhered to the well‑established guidelines in this review.\\nAs to our knowledge, there has been no systematic review done so far to evaluate the clinical effectiveness of Bifidobacterium as a probiotic in oral health care.\\nThe search did not have any restrictions on languages or publication date and was extensive.\\nThe studies that were included in this review did pose some limitations.\\nThe strains of Bifidobacterium used, its dosage, duration, mode of administration differed among studies.\\nMajority of the studies had recruited less participants, which can pose a threat to the precision as well as reduce the generalizability of the results retrieved.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='0739fa79-d604-4887-8eac-2e2d05299e8f', embedding=None, metadata={'metadata': ['DISCUSSION', 'Recommendations for future research']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='The proven effects of probiotics on general health have led to more research in the oral health field.\\nIts antimicrobial and immune‑modulating ability provides a new therapeutic approach for preventing infectious disease.\\n[40] Although there are various studies on probiotics done so far, further researches are needed to conclude the optimum level of probiotic required and the ideal mode of administration to maximize the use of probiotic in preventing oral diseases.\\nIt is also essential to evaluate the effects of using a single strain as well as the synergistic effect of combining multiple species of probiotics into a single entity.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='1f8c232c-d739-4892-b808-b8d5879e4cfa', embedding=None, metadata={'metadata': ['DISCUSSION', 'Recommendations for future research']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Future researches have to be carried out with a larger sample size so that it can be extrapolated, long duration of interventions assessing the long‑term effects of probiotic use, washout period extending more than 2 weeks in case of cross‑over trials, combinations of probiotic strains so that it provides additional benefits on oral health.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='b567c4a7-4e03-459f-8767-faafe6c5345b', embedding=None, metadata={'metadata': ['CONCLUSION']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='To conclude, from the evidences available from these trials, the effect of Bifidobacterium in oral health is questionable.\\nFurther high‑quality RCTs are required on the clinical effects of Bifidobacteria and also the optimum level of probiotic needed, ideal mode of administration to provide oral health benefits.\\nFurthermore, synergistic effects of the combined use of various strains of probiotics need to be studied.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='3954dc27-ba66-479e-a38f-fe0e0034cfa0', embedding=None, metadata={'metadata': ['CONCLUSION', 'Financial support and sponsorship']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Nil.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='078e2d1c-7e00-44e5-a141-a68ee336bc43', embedding=None, metadata={'metadata': ['CONCLUSION', 'Conflicts of interest']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='The authors of this manuscript declare that they have no conflicts of interest, real or perceived, financial or nonfinancial in this article.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='712072ea-f76f-44b9-ade4-3c998ba0065f', embedding=None, metadata={'metadata': ['REFERENCES', '1. FAO/WHO']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Report of a Joint FAO/WHO Expert consultation on evaluation of Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='931baa90-ec8e-415d-8c80-d6307e490f21', embedding=None, metadata={'metadata': ['REFERENCES', '1. FAO/WHO']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Cordoba, Argentina.\\n2001.\\nOctober 1‑4.\\nAccessed from:http:// who.int/foodsafety/fs_management/ en/probiotic_guidelines.\\npdf.\\n[Last accessed on 2022 Jan 01].', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='0dc79e92-4ff0-43d3-9125-942dd96d330f', embedding=None, metadata={'metadata': ['REFERENCES', '2. FAO/WHO']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food.\\nLondon, Ontario, Canada.\\n2002.\\nApril 30 and May 1.\\nAvailable from: http://www.who.int/foodsafety/publications/fs_management/ probiotics2/en/ [Last accessed on 2022 Jan 01].', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='7f256400-843d-432d-87b2-31c60d3d1fd1', embedding=None, metadata={'metadata': ['REFERENCES', '3. Fuller R, Gibson GR']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Modification of the intestinal microflora using probiotics and prebiotics.\\nScand J Gastroenterol Suppl 1997;222:28‑31.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='c3307ec8-6993-43a7-8e80-06446c25ad03', embedding=None, metadata={'metadata': ['REFERENCES', '4. Haukioja A']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Probiotics and oral health.\\nEur J Dent 2010;4:348‑55.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='9a945bb0-6231-4adb-aa63-8bb6dfabd6c9', embedding=None, metadata={'metadata': ['REFERENCES', '4. Haukioja A']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='5. Teughels W, Van Essche M, Sliepen I, Quirynen M. Probiotics and oral healthcare.\\nPeriodontol 2000 2008;48:111‑47.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='b3a861f8-3438-44bb-b5b8-03694d0bde92', embedding=None, metadata={'metadata': ['REFERENCES', '4. Haukioja A']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='6. Reid G, Jass J, Sebulsky MT, McCormick JK.\\nPotential uses of probiotics in clinical practice.\\nClin Microbiol Rev 2003;16:658‑72.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='e8ec5d63-0a44-47a2-9b9b-ed426c58bcd3', embedding=None, metadata={'metadata': ['REFERENCES', '4. Haukioja A']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='7. Nagarajappa R, Daryani H, Sharda AJ, Asawa K, Batra M, Sanadhya S, et al.\\nEffect of Chocobar ice cream containing Bifidobacterium on salivary Streptococcus mutans and lactobacilli: A randomised controlled trial.\\nOral Health Prev Dent 2015;13:213‑8.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='ef9199df-fba0-429c-b040-cf24440eaf1f', embedding=None, metadata={'metadata': ['REFERENCES', '4. Haukioja A']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='8. Haukioja A, Loimaranta V, Tenovuo J. Probiotic bacteria affect the composition of salivary pellicle and streptococcal adhesion in vitro.\\nOral Microbiol Immunol 2008;23:336‑43.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='60fb1005-28cb-46ec-ba47-c4158d64b0fd', embedding=None, metadata={'metadata': ['REFERENCES', '4. Haukioja A']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='9. Chen YT, Hsieh PS, Ho HH, Hsieh SH, Kuo YW, Yang SF, et al.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='b11d3a20-c1c7-40a6-a9d4-288975ac1146', embedding=None, metadata={'metadata': ['REFERENCES', '4. Haukioja A']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Antibacterial activity of viable and heat‑killed probiotic strains against oral pathogens.\\nLett Appl Microbiol 2020;70:310‑7.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='f2eba103-855d-4225-8e01-58710240534e', embedding=None, metadata={'metadata': ['REFERENCES', '4. Haukioja A']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='10.\\nWang L, Vuletic I, Deng D, Crielaard W, Xie Z, Zhou K, et al.\\nBifidobacterium breve as a delivery vector of IL‑24 gene therapy for head and neck squamous cell carcinoma in vivo.\\nGene Ther 2017;24:699‑705.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='3cd4a6ca-d8b6-4581-89ea-47807d7e86ee', embedding=None, metadata={'metadata': ['REFERENCES', '4. Haukioja A']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='11.\\nShimabukuro N, Cataruci AC, Ishikawa KH, de Oliveira BE, Kawamoto D, Ando‑Suguimoto ES, et al.\\nBifidobacterium strains present distinct effects on the control of alveolar bone loss in a periodontitis experimental model.\\nFront Pharmacol 2021;12:713595.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='2d0f07af-9568-4670-bb6e-f9c33edbcee5', embedding=None, metadata={'metadata': ['REFERENCES', '4. Haukioja A']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='12.\\nSilva GA, Moreira AL, Silva PH, Salvador SL, Casarin RC, Vicente RM, et al.\\nThe use of probiotics can reduce the severity of experimental periodontitis in rats with metabolic syndrome: An immunoenzymatic and microtomographic study.\\nJ Periodontol 2022;93:e1‑12.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='97cff920-6115-4bbe-ba4c-fdc19efb4b4c', embedding=None, metadata={'metadata': ['REFERENCES', '4. Haukioja A']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='13.\\nSchwendicke F, Horb K, Kneist S, Dörfer C, Paris S. Effects of heat‑inactivated Bifidobacterium BB12 on cariogenicity of Streptococcus mutans in vitro.\\nArch Oral Biol 2014;59:1384‑90.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='296bd7aa-c4b0-46bd-a82c-e8277f786952', embedding=None, metadata={'metadata': ['REFERENCES', '4. Haukioja A']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='14.\\nJäsberg H, Söderling E, Endo A, Beighton D, Haukioja A. Bifidobacteria inhibit the growth of Porphyromonas gingivalis but not of Streptococcus mutans in an in vitro biofilm model.\\nEur J Oral Sci 2016;124:251‑8.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='9d5d48fd-484b-426a-9989-e10550e8af58', embedding=None, metadata={'metadata': ['REFERENCES', '4. Haukioja A']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='15.\\nRicoldi MS, Furlaneto FA, Oliveira LF, Teixeira GC, Pischiotini JP, Moreira AL, et al.\\nEffects of the probiotic Bifidobacterium animalis subsp.\\nlactis on the non‑surgical treatment of periodontitis.\\nA histomorphometric, microtomographic and immunohistochemical study in rats.\\nPLoS One 2017;12:e0179946.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='f54e5560-1b4d-4459-a70a-240be08e4e16', embedding=None, metadata={'metadata': ['REFERENCES', '4. Haukioja A']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='16.\\nHaukioja A, Yli‑Knuuttila H, Loimaranta V, Kari K, Ouwehand AC, Meurman JH, et al.\\nOral adhesion and survival of probiotic and other lactobacilli and bifidobacteria in vitro.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='0581b759-c12e-49e4-9d4f-13b0ae6a5718', embedding=None, metadata={'metadata': ['REFERENCES', '4. Haukioja A']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='9Dental Research Journal', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='42a22cd5-0c71-4920-8992-ce8ce47f611c', embedding=None, metadata={'metadata': ['REFERENCES', '4. Haukioja A']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Oral Microbiol Immunol 2006;21:326‑32.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='1e166877-6d3a-4140-900d-ece4423ff772', embedding=None, metadata={'metadata': ['REFERENCES', '19. Mendi A, Aslım B']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Antioxidant lactobacilli could protect gingival fibroblasts against hydrogen peroxide: A preliminary in vitro study.\\nProbiotics Antimicrob Proteins 2014;6:157‑64.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='b7343c2e-39a8-47b3-ab56-f8311d018351', embedding=None, metadata={'metadata': ['REFERENCES', '19. Mendi A, Aslım B']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='20.\\nAlbuquerque‑Souza E, Balzarini D, Ando‑Suguimoto ES, Ishikawa KH, Simionato MR, Holzhausen M, et al.\\nProbiotics alter the immune response of gingival epithelial cells challenged by Porphyromonas gingivalis.\\nJ Periodontal Res 2019;54:115‑27.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='8ce4576d-3990-4219-ba37-8e999b4d389a', embedding=None, metadata={'metadata': ['REFERENCES', '21. Bohora A, Kokate S']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Evaluation of the role of probiotics in endodontic treatment: A preliminary study.\\nJ Int Soc Prev Community Dent 2017;7:46‑51.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='6ea48b49-a4a6-4727-89a1-f6d4f4216b26', embedding=None, metadata={'metadata': ['REFERENCES', '21. Bohora A, Kokate S']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='22.\\nCardoso RS, Messora MR, Silva PH, Oliveira LF, Leite‑Panissi C, Salvador S, et al.\\nEffects of Bifidobacterium animalis subsp.\\nlactis HN019 on ligature‑induced periodontitis in rats with experimental rheumatoid arthritis.\\nBenef Microbes 2020;11:33‑46.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='7cefa871-ed23-4c31-abe0-9ba73a769191', embedding=None, metadata={'metadata': ['REFERENCES', '21. Bohora A, Kokate S']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='23.\\nMoher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group.\\nPreferred reporting items for systematic reviews and meta‑analyses: The PRISMA statement.\\nJ Clin Epidemiol 2009;62:1006‑12.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='6f907f79-b9bf-45f8-a0e2-6961cabb0769', embedding=None, metadata={'metadata': ['REFERENCES', '21. Bohora A, Kokate S']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='24.\\nLiberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al.\\nThe PRISMA statement for reporting systematic reviews and meta‑analyses of studies that evaluate health care interventions: Explanation and elaboration.\\nJ Clin Epidemiol 2009;62:e1‑34.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='2d0258f7-d33d-4d7e-aff0-ff4c0ba13250', embedding=None, metadata={'metadata': ['REFERENCES', '21. Bohora A, Kokate S']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='25.\\nCaglar E, Kuscu OO, Selvi Kuvvetli S, Kavaloglu Cildir S, Sandalli N, Twetman S. Short‑term effect of ice‑cream containing Bifidobacterium lactis Bb‑12 on the number of salivary mutans streptococci and lactobacilli.\\nActa Odontol Scand 2008;66:154‑8.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='90a3e7e4-507a-4df3-b01c-7923497a4a4b', embedding=None, metadata={'metadata': ['REFERENCES', '21. Bohora A, Kokate S']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='26.\\nAshwin D, Ke V, Taranath M, Ramagoni NK, Nara A, Sarpangala M. Effect of probiotic containing ice‑cream on salivary mutans streptococci (SMS) levels in children of 6‑12 years of age: A randomized controlled double blind study with six‑months follow up.\\nJ Clin Diagn Res 2015;9:ZC06‑9.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='f6c04e3e-b735-445b-ad00-5caca5043cf5', embedding=None, metadata={'metadata': ['REFERENCES', '21. Bohora A, Kokate S']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='27.\\nSingh RP, Damle SG, Chawla A. Salivary mutans streptococci and lactobacilli modulations in young children on consumption of probiotic ice‑cream containing Bifidobacterium lactis Bb12 and Lactobacillus acidophilus La5.\\nActa Odontol Scand 2011;69:389‑94.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='9a1d8aff-9934-4251-9f0e-ac747223b7fe', embedding=None, metadata={'metadata': ['REFERENCES', '21. Bohora A, Kokate S']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='28.\\nCaglar E, Sandalli N, Twetman S, Kavaloglu S, Ergeneli S, Selvi S. Effect of yogurt with Bifidobacterium DN‑173 010 on salivary mutans streptococci and lactobacilli in young adults.\\nActa Odontol Scand 2005;63:317‑20.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='28229797-8e2f-4656-b9c8-20e7c5e7794e', embedding=None, metadata={'metadata': ['REFERENCES', '21. Bohora A, Kokate S']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='29.\\nNozari A, Motamedifar M, Seifi N, Hatamizargaran Z, Ranjbar MA.\\nThe effect of Iranian customary used probiotic yogurt on the children’s salivary cariogenic microflora.\\nJ Dent (Shiraz) 2015;16:81‑6.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='9a1bceae-43ed-4abc-a531-bcb86b4769a7', embedding=None, metadata={'metadata': ['REFERENCES', '21. Bohora A, Kokate S']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='30.\\nZare Javid A, Amerian E, Basir L, Ekrami A, Haghighizadeh MH, Maghsoumi‑Norouzabad L. Effects of the consumption of', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='142fb6b6-19ba-4abe-bb84-08e70ce22942', embedding=None, metadata={'metadata': ['REFERENCES', '21. Bohora A, Kokate S']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='probiotic yogurt containing Bifidobacterium lactis Bb12 on the levels of Streptococcus mutans and Lactobacilli in saliva of students with initial stages of dental caries: A double‑blind randomized controlled trial.\\nCaries Res 2020;54:68‑74.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='bf07568d-08dc-472b-9522-46031d9dbd73', embedding=None, metadata={'metadata': ['REFERENCES', '32. Caglar E']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Effect of Bifidobacterium bifidum containing yoghurt on dental plaque bacteria in children.\\nJ Clin Pediatr Dent 2014;38:329‑32.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='2f25bb1e-ea96-4d98-b67f-90b82c0fb295', embedding=None, metadata={'metadata': ['REFERENCES', '32. Caglar E']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='33.\\nKuru BE, Laleman I, Yalnızoğlu T, Kuru L, Teughels W. The influence of a Bifidobacterium animalis probiotic on gingival health: A randomized controlled clinical trial.\\nJ Periodontol 2017;88:1115‑23.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='ec1dcf2c-a56c-433d-ae0c-21f649169135', embedding=None, metadata={'metadata': ['REFERENCES', '32. Caglar E']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='34.\\nCildir SK, Germec D, Sandalli N, Ozdemir FI, Arun T, Twetman S, et al.\\nReduction of salivary mutans streptococci in orthodontic patients during daily consumption of yoghurt containing probiotic bacteria.\\nEur J Orthod 2009;31:407‑11.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='f3e1b504-3a3e-4ab0-87f2-dbc7da6b6c3a', embedding=None, metadata={'metadata': ['REFERENCES', '32. Caglar E']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='35.\\nBafna HP, Ajithkrishnan CG, Kalantharakath T, Singh RP, Kalyan P, Vathar JB, et al.\\nEffect of short‑term consumption of amul probiotic yogurt containing Lactobacillus acidophilus La5 and Bifidobacterium lactis Bb12 on salivary Streptococcus mutans count in high caries risk individuals.\\nInt J Appl Basic Med Res 2018;8:111‑5.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='dc7c73b1-450c-4503-9442-0066ef036f9b', embedding=None, metadata={'metadata': ['REFERENCES', '32. Caglar E']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='36.\\nTaipale T, Pienihäkkinen K, Salminen S, Jokela J, Söderling E. Bifidobacterium animalis subsp.\\nlactis BB‑12 administration in early childhood: A randomized clinical trial of effects on oral colonization by mutans streptococci and the probiotic.\\nCaries Res 2012;46:69‑77.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='b72220ad-c70f-42ad-8395-b6735c185a47', embedding=None, metadata={'metadata': ['REFERENCES', '32. Caglar E']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='37.\\nToiviainen A, Jalasvuori H, Lahti E, Gursoy U, Salminen S, Fontana M, et al.\\nImpact of orally administered lozenges with Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp.\\nlactis BB‑12 on the number of salivary mutans streptococci, amount of plaque, gingival inflammation and the oral microbiome in healthy adults.\\nClin Oral Investig 2015;19:77‑83.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='112e68f2-e063-49e7-a4f7-f2b67a036143', embedding=None, metadata={'metadata': ['REFERENCES', '32. Caglar E']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='38.\\nJäsberg H, Tervahartiala T, Sorsa T, Söderling E, Haukioja A. Probiotic intervention influences the salivary levels of Matrix Metalloproteinase (MMP)‑9 and Tissue Inhibitor of metalloproteinases (TIMP)‑1 in healthy adults.\\nArch Oral Biol 2018;85:58‑63.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='1847fcf9-ac99-4b1c-99ed-310b27cba8fb', embedding=None, metadata={'metadata': ['REFERENCES', '32. Caglar E']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='39.\\nAlanzi A, Honkala S, Honkala E, Varghese A, Tolvanen M, Söderling E. Effect of Lactobacillus rhamnosus and Bifidobacterium lactis on gingival health, dental plaque, and periodontopathogens in adolescents: A randomised placebo‑controlled clinical trial.\\nBenef Microbes 2018;9:593‑602.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='f4e18e5a-3d27-4cb1-a45a-ad61cb2fdd7e', embedding=None, metadata={'metadata': ['REFERENCES', '32. Caglar E']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='40.\\nInvernici MM, Furlaneto FA, Salvador SL, Ouwehand AC, Salminen S, Mantziari A, et al.\\nBifidobacterium animalis subsp lactis HN019 presents antimicrobial potential against periodontopathogens and modulates the immunological response of oral mucosa in periodontitis patients.\\nPLoS One 2020;15:e0238425.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='ae6905b6-5ae1-4a59-b05b-62a3dfa52fee', embedding=None, metadata={'metadata': ['REFERENCES', '32. Caglar E']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='41.\\nGueimonde L, Vesterlund S, García‑Pola MJ, Gueimonde M, Söderling E, Salminen S. Supplementation of xylitol‑containing chewing gum with probiotics: A double blind, randomised pilot study focusing on saliva flow and saliva properties.\\nFood Funct 2016;7:1601‑9.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='3ec39b88-cc3c-45bf-bce5-7e8096e0362f', embedding=None, metadata={'metadata': ['REFERENCES', '32. Caglar E']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='42.\\nIshikawa KH, Mayer MP, Miyazima TY, Matsubara VH, Silva EG, Paula CR, et al.\\nA multispecies probiotic reduces oral Candida colonization in denture wearers.\\nJ Prosthodont 2015;24:194‑9.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='5266579d-cdc6-42a6-a9ce-cab9fd8bfb5f', embedding=None, metadata={'metadata': ['REFERENCES', '32. Caglar E']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='43.\\nTehrani MH, Akhlaghi N, Talebian L, Emami J, Keyhani SE.\\nEffects of probiotic drop containing Lactobacillus rhamnosus, Bifidobacterium infantis, and Lactobacillus reuteri on salivary Streptococcus mutans and Lactobacillus levels.\\nContemp Clin Dent 2016;7:469‑74.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='60706919-9a3f-452f-9e6f-855393f1c623', embedding=None, metadata={'metadata': ['REFERENCES', '32. Caglar E']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='44.\\nJindal G, Pandey RK, Agarwal J, Singh M. A comparative evaluation of probiotics on salivary mutans streptococci counts in Indian children.\\nEur Arch Paediatr Dent 2011;12:211‑5.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='4b572e1d-c44a-4bfa-bd16-9fac872ad78e', embedding=None, metadata={'metadata': ['REFERENCES', '32. Caglar E']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='45.\\nYousuf A, Sidiq M, Ganta S, Nagaraj A, Vishnani P, Jan I. Effect', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='62680785-f15d-4c62-8ca4-a10d1d49097a', embedding=None, metadata={'metadata': ['REFERENCES', '32. Caglar E']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='11Dental Research Journal', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='10de5cd5-3f1b-4739-bbbc-711d21c9b653', embedding=None, metadata={'metadata': ['REFERENCES', '32. Caglar E']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='of freeze dried powdered probiotics on gingival status and plaque inhibition: A randomized, double‑blind, parallel study.\\nContemp Clin Dent 2017;8:116‑21.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='bdbce452-a6ec-4483-b3d0-0875f3a4908b', embedding=None, metadata={'metadata': ['REFERENCES', '48. Ryan, R']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='and Hill, S. How to GRADE the Quality of the Evidence.\\nCochrane Consumers and Communication Group.\\n2016.\\nAvailable from: http://cccrg.cochrane.org/author‑resources.\\nVersion 3.0.\\n[Last accessed on 2022 Jan 02].', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='a5ae4e24-b92d-4cfd-a38d-0ad7689ad47f', embedding=None, metadata={'metadata': ['Systemic corticosteroids in treatment of chronic rhinosinusitis—A systematic review']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Sarah Tamenea, Kim Dalhoff b, Peter Schwarzc, Vibeke Backera,d and Kasper Aanaesa aDepartment of Otorhinolaryngology, Head & Neck Surgery and Audiology, Rigshospitalet and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; bDepartment of Clinical Pharmacology, Bispebjerg and Frederiksberg University Hospital, Copenhagen, Denmark; cDepartment of Endocrinology, Rigshospitalet and Faculty of Health Sciences, University of Copenhagen, Denmark, Copenhagen; dCenter of Physical Activity Research (CFAS), Rigshospitalet, University Hospital, Copenhagen, Denmark', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='187bcb32-bb18-44ae-8b75-84b81d538df3', embedding=None, metadata={'metadata': ['Systemic corticosteroids in treatment of chronic rhinosinusitis—A systematic review', 'ABSTRACT']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Purpose: When first-line chronic rhinosinusitis (CRS) treatment fails, patients can either be treated with oral or injected systemic corticosteroids.\\nAlthough the EPOS and international guidelines for CRS do not mention injected corticosteroids, it is commonly used by ear, nose, and throat specialists.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='29746944-eb60-4dae-91c5-61706690d0db', embedding=None, metadata={'metadata': ['Systemic corticosteroids in treatment of chronic rhinosinusitis—A systematic review', 'ABSTRACT']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='While the risks of systemic corticosteroids, in general, are known, the pros and cons of injected and oral corticosteroids (OCS) in CRS treatment are unclear.\\nMethods: A systematic review of studies that report the effects and/or side effects of injected and oral corticosteroids in the treatment of CRS was made according to the PRISMA guidelines.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='f7a173a0-8a0e-4a00-832b-8a05b8f710fd', embedding=None, metadata={'metadata': ['Systemic corticosteroids in treatment of chronic rhinosinusitis—A systematic review', 'ABSTRACT']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Results: Altogether, 48 studies were included, only five studies reported on injected corticosteroids, and five attended with side effects.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='1c9dc777-258f-4499-94ba-c09f9bd2ce32', embedding=None, metadata={'metadata': ['Systemic corticosteroids in treatment of chronic rhinosinusitis—A systematic review', 'ABSTRACT']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Three studies found beneficial effects of OCS perioperatively on sinus surgery, while four articles found no effect.\\nNineteen articles reported that OCS resulted in an improvement in symptoms.\\nTwo articles presented a longer-lasting effect of injected corticosteroids than OCS.\\nThree studies reported adverse side effects of systemic corticosteroids, while two studies showed no adverse side effects.\\nOne study showed less adrenal suppression after injected corticosteroids compared to OCS.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='f6d6ee34-9709-494e-8080-d8257240b2cf', embedding=None, metadata={'metadata': ['Systemic corticosteroids in treatment of chronic rhinosinusitis—A systematic review', 'ABSTRACT']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='The evidence is not strong but shows a positive effect of systemic corticosteroids that lasts longer with injections.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='17208e0f-210a-4e40-9217-d0bf7f5765c3', embedding=None, metadata={'metadata': ['Systemic corticosteroids in treatment of chronic rhinosinusitis—A systematic review', 'ABSTRACT']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Conclusion: Although systemic corticosteroids are widely used to treat CRS, there is a lack of studies comparing the OCS and injected corticosteroids.\\nThe evidence is sparse, however, injected steroids show longer effects with fewer side effects.\\nAn RCT study is needed to compare OCS and injected corticosteroids.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='618d436c-867a-46b1-9621-6d2768208630', embedding=None, metadata={'metadata': ['Systemic corticosteroids in treatment of chronic rhinosinusitis—A systematic review', 'ABSTRACT', 'ARTICLE HISTORY', 'Received 19 March 2023 Accepted 20 July 2023']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='KEYWORDS', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='1b6c1add-f2fd-4551-af7d-4095baa349f1', embedding=None, metadata={'metadata': ['Introduction']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Chronic rhinosinusitis (CRS) is a highly prevalent inflammatory disease of the upper airways.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='164f454c-22a1-473c-9ed4-43c25c0007ae', embedding=None, metadata={'metadata': ['Introduction']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='CRS can be challenging to treat, and appropriate use of medical treatments is required to optimize patients’ daily functions and their quality of life (QoL).\\nWhen patients have tried and failed standard local treatment or still have severe symptoms (VAS ≥5), treatment with a short course of systemic steroids may be used [3–5].\\nTreatment with systemic corticosteroids almost always results in an improvement of symptoms, by reducing the inflammatory response, reducing polyp size, re-establishing normal mucosal function, and thereby improving sinus drainage and improving nasal airflow and reducing obstruction of the olfactory area; however, often the effect is transient [3].\\nWhen corticosteroid injections are chosen as the treatment plan for CRS 14 mg of Betamethasone (Diprofos ®) is used as a single injection in Denmark, which compares to 88 mg equivalent dose of prednisolone (Table 1).\\nWhen OCS is used, a 14-day treatment plan with 50 mg prednisolone daily (700 mg in total) could be cho- sen [7].\\nNew treatment options with monoclonal anti- bodies (biologicals) may in some countries be offered to CRS with nasal polyps (CRSwNP) to avoid the use of systemic corticosteroids or revision sinus surgery.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='fda38847-5bc2-4b1a-9b5e-7dd5cf181aba', embedding=None, metadata={'metadata': ['Introduction']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='The risks of adverse side effects heighten with increasing cumulative exposure and increasing mean daily exposure to systemic corticosteroids [9].\\nThe short- and long-term risks are summarized in CONTACT Sarah Tamene sarah.tamene@yahoo.dk Department of Otolaryngology, Head & Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, Inge Lehmannsvej 7, Copenhagen DK-2100, Denmark EUROPEAN CLINICAL RESPIRATORY JOURNAL 2023, VOL.\\n10, 2240511 https://doi.org/10.1080/20018525.2023.2240511 © 2023 The Author(s).\\nPublished by Informa UK Limited, trading as Taylor & Francis Group.\\nThis is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.\\nThe terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='4038172a-4eda-4582-9d94-445ae7f4a597', embedding=None, metadata={'metadata': ['Introduction']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text=' | Table 2. Even though systemic corticosteroids are recommended as standard treatment for CRS, there seems to be a lack of recommendations concerning the choice of drug, choice of treatment method (injec- tion or oral corticosteroids (OCS)), dose, and duration of treatment. OCS is only sparsely mentioned in the 2020 edition of the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) and corticos- teroid injections are not mentioned at all [3]. Therefore, this review was made in an attempt to enhance the EPOS guidelines with a focus on the current evidence of effects and side effects of treating CRS with systemic corticosteroids and especially injected corticosteroids. | In Denmark, you need a prescription for buying systemic steroids.\\nAccording to Amgros, who secure supplies of medicines for public hospitals, a total amount of 29.073 doses of 2 mL Diprofos was bought for Danish hospitals and pharmacies in 2020 (Amgros).\\nWe believe that the 1 ml packages are used by rheu- matologists, orthopedists, and in sports medicine, whereas the 2 mL packages primarily are used by ENT physicians.\\nHence, we assume that corticosteroid injections have regularly been used as a treatment for allergic rhinitis, non-allergic rhinitis, and CRS.\\nFigure 1 shows that injected corticosteroids are still used in Denmark but also show a decrease after 2012.\\nThe drop in injected corticosteroids in 2013\\n', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='60e772fc-4852-4587-9d5e-b1c89e93feab', embedding=None, metadata={'metadata': ['Introduction']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Table 1.\\nCharacteristics of various corticosteroids [8].', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='028d31c9-30cf-457d-bd42-6835e8aafe86', embedding=None, metadata={'metadata': ['Introduction']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text=' | Compound | Equivalent Dose | Anti-inflammatory potency | Mineralocorticoid Potency | Biological Half-life\\n | --- | --- | --- | --- | ---\\n | Hydrocortisone (Cortisol) | 350 mg | 1 | 1 | Short\\n | Cortisone | 438 mg | 0.8 | 0.8 | Short\\n | Prednisone | 88 mg | 4 | 0.6 | Intermediate\\n | Prednisolone | 88 mg | 4 | 0.6 | Intermediate\\n | Triamcinolone | 70 mg | 5 | 0 | Intermediate\\n | Methylprednisolone | 70 mg | 5 | 0.25 | Intermediate\\n | Betamethasone | 14 mg | 25 | 0 | Long\\n | Dexamethasone | 14 mg | 25 | 0 | Long\\n | Fludrocortisone | N/A | 0 | 125 | Intermediate\\n | Deflazacort [6] | 132 mg | N/A | N/A | N/A\\n', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='15b87ddd-d31c-4508-bcf2-29437896e77f', embedding=None, metadata={'metadata': ['Introduction']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Table 2.\\nSide effects to systemic corticosteroids [15,17,20].', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='d7018925-1c1c-40f3-85a0-bbd756ae4336', embedding=None, metadata={'metadata': ['Introduction']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text=' | Short term use | Long term use\\n | Psychiatric manifestations [10]. Hypertension [11] Corticosteroid induced diabetes/poorer treatment decreases of existing diabetes [12] Infection [13] Dermatological adverse effects [14] Subcutaneous atrophy at the insertion site of injected corticosteroids [15] | Reduced sex hormones [16] Osteoporosis [17] Avascular bone necrosis [17] Subcapsular cataract [17] Glaucoma [17] Peptic ulcer disease [17] Adrenal suppression [18] Corticosteroid induced lipodystrophy [19]. Dermatological adverse effects [14]\\n', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='22d3c23d-dca6-4d63-92eb-23d90dd4e48d', embedding=None, metadata={'metadata': ['Introduction']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Figure 1.\\nThe development of the total sold Betamethasone, 7 mg/ml, 2 ml from 2011 to 2021 in Denmark to the pharmacies and hospitals*.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='86603623-475a-4f53-9c6d-85c1b4a48767', embedding=None, metadata={'metadata': ['Introduction']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='*Numbers and figure obtained from Amgros.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='a6a3a2d2-23bb-491f-94ed-8a19720991d5', embedding=None, metadata={'metadata': ['Introduction']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='corresponds to an increase in nonsystemic corticosteroid symptomatic treatment [21].\\nOur general experience (jet unpublished data) is that patients also report a longer lasting and better effectof injections than oral corticosteroids.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='610cb277-dc56-418b-aef2-de3f807ef0ae', embedding=None, metadata={'metadata': ['Materials and methods', 'Data sources and search strategy']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='We performed a systematic search on the PUBMED and EMBASE databases.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='63b12bfc-83f4-47b8-849f-db4a0402c0b3', embedding=None, metadata={'metadata': ['Materials and methods', 'Data sources and search strategy']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='A search strategy was designed and used for each database to detect all articles concerning CRS and systemic corticosteroid treatment (Appendix 1 and 2).\\nWe conducted a broad search including allergic rhinitis to obtain all articles dealing with systemic corticosteroid treatment and/or side effects.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='6992c6ff-cfe1-4330-ae6e-477fc57e5421', embedding=None, metadata={'metadata': ['Materials and methods', 'Data sources and search strategy']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='A systematic review was performed to identify all studies that reported the use of systematic corticosteroids and either the effects or side effects of the used medical therapy.\\nThis review was done accordingly to the elements in the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) by using the 27-item checklist for items to include in a systematic review and a four-phase diagram illustrating the flow of information [23].', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='4e345729-9cd1-4576-b2e7-fea05fbbdb17', embedding=None, metadata={'metadata': ['Study selection']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='The studies were reviewed by two independent authors (STA and KA) and were selected by the inclusion and exclusion criteria.\\nTitles and abstracts were screened using the web-based Covidence program for systematic review management.\\nAll our search results were uploaded to the program and assessed individually by the two authors.\\nConflicts were solved by full-text screening with STA. A fulltext review was performed in the next phase, and the studies were analyzed and included if meeting the selection criteria.\\nFinally, missing studies were searched manually and accessed from the library paper edition if possible.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='0be2427e-4cbb-4f6c-984a-28c2da616ff8', embedding=None, metadata={'metadata': ['Eligibility criteria']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='The selected inclusion criteria were: Only papers from 1987 and forward were included.\\nPatients with diffuse primary CRS (eosinophilic chronic rhinosinusitis (eCRS)/non-eosinophilic chronic rhinosinusitis (Non-eCRS)/chronic rhinosinusitis with nasal polyps (CRSwNP)/chronic rhinosinusitis without nasal polyps (CRSsNP)/Central compartment atopic disease (CCAD)) and/or allergic rhinitis (Appendix 3) according to the EPOS [3] AND, OR', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='9c3c32b2-f5d1-41df-8608-2ec99255e475', embedding=None, metadata={'metadata': ['Eligibility criteria']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='(1) Papers reporting of effect, efficacy, and/or side effects of systemic corticosteroids AND,', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='8ae31a5a-ae27-4c98-a5fb-85e904d5ba31', embedding=None, metadata={'metadata': ['Eligibility criteria']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='(2) Papers published from 1987 and forward AND, EITHER,', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='ef500f73-89b4-4827-9a73-f5b85971cf8e', embedding=None, metadata={'metadata': ['Eligibility criteria']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='The exclusion criteria were:', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='f50c6f22-9c3a-4dbc-889c-0ccc96134ee3', embedding=None, metadata={'metadata': ['Eligibility criteria', '(1) Non-English']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='(2) Case reports < 5 patients', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='247b7c04-f0c5-44bd-812f-e357e28a49dc', embedding=None, metadata={'metadata': ['Eligibility criteria', '(4) Localized CRS']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='(5) Allergic fungal and fungal sinusitis', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='46e673ec-f712-4ee9-baa7-d7a5a6d12e3d', embedding=None, metadata={'metadata': ['Eligibility criteria', '(4) Localized CRS']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='(6) Patients <18 years of age', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='fbf9c6f6-0a4f-4737-9f9c-8ccbac6731d2', embedding=None, metadata={'metadata': ['Eligibility criteria', '(4) Localized CRS']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='(7) Only local treatment with corticosteroids', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='6eef9b31-56a0-4c98-b048-b6d02394b0b1', embedding=None, metadata={'metadata': ['Eligibility criteria', '(4) Localized CRS']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='(8) Only local injection with corticosteroids in nasal polyps', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='374e0967-254a-4075-9a16-e7b18df813cd', embedding=None, metadata={'metadata': ['Eligibility criteria', '(4) Localized CRS']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='(9) Papers where both drug name and dosage/ treatment length are not given', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='a5ee290b-7ebd-4ad6-b351-7909b3b71db5', embedding=None, metadata={'metadata': ['Eligibility criteria', '(4) Localized CRS']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='(10) Letters, reviews, and animal studies', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='bde61e80-04f3-4570-afad-f8bd7d1eaa28', embedding=None, metadata={'metadata': ['Eligibility criteria', '(4) Localized CRS']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Furthermore, studies by the same authors, from the same area or possibly overlapping in time were closely reviewed to avoid any patient group overlap.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='15ebf962-cda9-4133-93f6-9d9d0fabb0e4', embedding=None, metadata={'metadata': ['Data extraction']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='A data sheet was made to extract relevant data, and the following was entered into tables: author name, publication year, study design, studied drug/treatment plan, side effects, conclusions and quality of evidence.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='8f5287b9-a2a1-4f48-b000-4a1311bb2214', embedding=None, metadata={'metadata': ['Data extraction']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='For the data to be considered complete, it required a profound description of the treatment plan, its effects, or side effects.\\nWhen the initial selection was done, the references cited in the authors’ articles were assessed to examine each article.\\nA final data set was made once the articles were assessed for eligibility.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='e392374e-80e8-4b61-9d70-7d254264dda3', embedding=None, metadata={'metadata': ['Data extraction']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Details of the data and characteristics of the studies are summarized in tables.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='bbf2b854-dcb8-41e8-92dd-cac11f72c970', embedding=None, metadata={'metadata': ['Data extraction']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='A flow chart of our study retrieval and selection process is provided in Figure 2.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='03b2d751-bc6e-4ba9-a20c-2d806ef40cdb', embedding=None, metadata={'metadata': ['Results']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Of the 1,177 identified articles 48 were selected for further review.\\nThe included studies have been divided and summarized into five tables:1) systemic corticosteroids perioperatively (n = 7; Table 3), 2) the effect of oral corticosteroids (n = 20; Table 4), 3) the effect of injected corticosteroids (n = 5; Table 5), 4) side effects to systemic corticosteroids (n = 5; Table 6), 5) other effects of corticosteroids (n = 11; Table 7).', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='9ca4c958-2301-4bbd-ac5d-05c9b5deec11', embedding=None, metadata={'metadata': ['Results', 'Identification of studies via databases']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Records identified from: PubMed (n = 1064) Embase (n = 113) Total (n = 1177)', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='cd34e1cc-4864-490b-a0cb-8e3607f50b01', embedding=None, metadata={'metadata': ['Results', 'Identification of studies via databases']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Records screened (n = 1087) Records removed before screening:', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='d820dced-4138-477a-b103-afb340d90dd3', embedding=None, metadata={'metadata': ['Results', 'Identification of studies via databases']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Duplicate records removed (n = 90) Records marked as ineligible by automation tools (n = 0)', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='c98fea14-c29c-45e8-94d0-abac2dfbbaab', embedding=None, metadata={'metadata': ['Results', 'Identification of studies via databases']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Records excluded; criteria applied (n = 989)', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='8ecbd0f5-99e1-4dc6-a7ef-82c8188bae9e', embedding=None, metadata={'metadata': ['Results', 'Identification of studies via databases']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Reports not retrieved (n = 2)[1, 2] Reports sought for retrieval (n = 98)', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='f7f7b8a9-1beb-42f9-9104-63cbe772cf7c', embedding=None, metadata={'metadata': ['Results', 'Identification of studies via databases']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Reports assessed for eligibility (n = 96) Reports excluded, with reasons (n = 48)', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='997a0167-7281-445d-b955-249236dd264b', embedding=None, metadata={'metadata': ['Results', 'Identification of studies via databases']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Table 3.\\nSystemic corticosteroids perioperatively (n = 7)', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='e93a6ba0-3944-4dc4-a0c2-dfbdec0cd00e', embedding=None, metadata={'metadata': ['Results', 'Identification of studies via databases']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Table 4.\\nEffect of oral systemic corticosteroids (n = 20)', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='985f0bd9-49b8-41f0-bbf0-9f34add84095', embedding=None, metadata={'metadata': ['Results', 'Identification of studies via databases']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Table 5.\\nEffect of injected systemic corticosteroids (n = 5)', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='8d1eb413-83c2-4878-8fac-feb60a6b3ca4', embedding=None, metadata={'metadata': ['Results', 'Identification of studies via databases']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Table 6.\\nSide effects to systemic corticosteroids (n = 5)', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='5b1d3759-85fc-4af3-be72-ffa76ce1d6f7', embedding=None, metadata={'metadata': ['Results', 'Identification of studies via databases']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Table 7.\\nOther effects of systemic corticosteroids (n = 11) Studies included in review (n = 48) Figure 2.\\nPreferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram.\\nPRISMA flowchart depicting the selection process in this study [1,2,24].', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='109c615f-84b4-4186-bdf9-bf560bfbea5f', embedding=None, metadata={'metadata': ['Discussion']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Although the use of systemic corticosteroids is a recommended treatment for CRS, there is a lack of a standardized prescribing regimen for oral and injected corticosteroids.\\nIn our study, we found 20 studies reporting the effects of OCS, but we only found five studies concerning injected corticosteroids although injected corticosteroids are frequently used [21] (Figure 1).', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='e5ce7b90-9a8e-4ab9-aafe-e1424e2301de', embedding=None, metadata={'metadata': ['Discussion']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='It is noteworthy that the choice of OCS dosage and length of treatment seems to reflect personal experience, as we found that very different dosages have been', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='dc6599be-a538-41bb-8fd9-0cc795c41cd9', embedding=None, metadata={'metadata': ['Discussion']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='3. Summary of results: systemic corticosteroids perioperatively.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='0eda41f8-4e14-4d88-971d-379df292107a', embedding=None, metadata={'metadata': ['Discussion', 'Impact of Preoperative Systemic Corticosteroids on the Histology and Diagnosis of Eosinophilic Chronic Rhinosinusitis [25]', 'Akiyama 2019']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Type of study', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='ccd6b04f-8da9-444a-80af-ddc0e038684a', embedding=None, metadata={'metadata': ['Discussion', 'Impact of Preoperative Systemic Corticosteroids on the Histology and Diagnosis of Eosinophilic Chronic Rhinosinusitis [25]', 'Akiyama 2019']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text=' | Case series | 44 | Preoperative oral |  |  | \\n | --- | --- | --- | --- | --- | ---\\n |  | Number of patients Investigated drug |  | Side effects | Conclusions | Quality of evidence\\n | 100 Oral prednisolone (30 mg/day) for 2 weeks after surgery.\\n |  |  |  | Not mentioned. | Oral prednisolone did | \\n |  |  |  | Not mentioned. | Olfactory recovery | \\n', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='58b1923e-7e4a-488d-a8fc-3a63f99f200f', embedding=None, metadata={'metadata': ['Discussion', 'Low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='prednisolone (0.3 mg/kg as a guide).\\nnot appear to markedly affect the tissue eosinophil count.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='7681dcb8-5ec3-4d86-a61a-2470439a41a1', embedding=None, metadata={'metadata': ['Discussion', 'Low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='greater than 50% after a course of OCS therapy may be a predictor of better subjective postoperative recovery.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='387da7ae-9586-4cea-b842-037d31e2fab1', embedding=None, metadata={'metadata': ['Discussion', 'Low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Prospective evaluation of oral corticosteroid as a predictor of postoperative olfactory recovery after functional endoscopic surgery for nasal polyposis [26] Differential effects of postoperative oral corticosteroid on eosinophilic vs. noneosinophilic CRSwNP subtypes [27] Rives 2019 Prospective 119 Oral prednisolone Shen 2019 Randomized controlled trial 1 mg/kg/day for 5 days preoperatively.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='2bc68f1f-ad30-48ab-ba8c-47b813d32c6d', embedding=None, metadata={'metadata': ['Discussion', 'Low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='prednisolone and 90 mg lactose for 7 days, reduced to one pill taken every other day preoperatively.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='5c7dadf7-6658-4955-ab80-71ebafdac1cd', embedding=None, metadata={'metadata': ['Discussion', 'Low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text=' |  |  | No severe side effects. | \\n | --- | --- | --- | ---\\n |  |  | Not mentioned. | \\n | Moderate\\n | Effect of steroids for nasal polyposis surgery: A placebo- controlled, randomized, double- blind study [28] |  |  | \\n | Impact of perioperative systemic steroids on surgical outcomes in patients with chronic rhinosinusitis with polyposis: evaluation with the novel Perioperative Sinus Endoscopy (POSE) scoring system [29]\\n | Ecevit 2015 Randomized controlled trial\\n | Wright 2007\\n |  |  | 22 Six pills of 10 mg | \\n |  |  | 26 30 mg of | \\n', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='9bc0aea8-183b-4fbd-8fe7-a3565b61b499', embedding=None, metadata={'metadata': ['Discussion', 'Low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='administration of systemic corticosteroids improves the perioperative visibility by reducing blood loss and shortens the operation time.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='a07a28cd-f1d9-43ed-b654-5dcc0cba269e', embedding=None, metadata={'metadata': ['Discussion', 'Low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='systemic corticosteroids appears to confer the advantages of facilitating surgery and results in endoscopically healthier sinus cavities in the short term.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='ed8426ca-13b4-4cd0-a65e-946abb0ea980', embedding=None, metadata={'metadata': ['Discussion', 'Low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Randomized controlled trial', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='c14a20bc-fefc-42e8-a698-ba0d5ac22e42', embedding=None, metadata={'metadata': ['Discussion', 'Low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Randomized controlled trial', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='af146793-5652-441e-bb5e-6e01a34facde', embedding=None, metadata={'metadata': ['Discussion', 'Low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text=' | Not mentioned. | Pretreatment with\\n | Not mentioned. | Oral prednisone\\n | Moderate\\n | Moderate\\n', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='ec7b5c5a-b582-41dc-8a99-45890dfa7377', embedding=None, metadata={'metadata': ['Discussion', 'Low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='prednisone for 5 days preoperatively and 9 days postoperatively.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='19b746a7-a672-4489-9417-5f2d2a9aca69', embedding=None, metadata={'metadata': ['Discussion', 'Clinical Trial [30]']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Lack of additive benefit of oral steroids on short-term postoperative outcomes in nasal polyposis [31] Chang 2021 Randomized controlled trial', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='3a63d9d3-cb94-4c8d-8140-172a9ca8c159', embedding=None, metadata={'metadata': ['Discussion', 'Clinical Trial [30]', 'Arancibia 2020']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text=' | 72 | 12-day\\n | 70 | Postoperative 30 mg of oral postoperative\\n', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='3f9bb837-5077-46a6-b89c-1b1b46e680e8', embedding=None, metadata={'metadata': ['Discussion', 'Clinical Trial [30]', 'Arancibia 2020']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='taper of oral prednisone: 30 mg, 4 days; 20 mg, 4 days; and 10 mg 4 days.\\nfollowing endoscopic sinus surgery conferred no additional benefit over placebo.\\nThese results suggest that the risks of oral corticosteroids may outweigh the benefits.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='82b524a0-52bb-4735-a546-e03a03ff1305', embedding=None, metadata={'metadata': ['Discussion', 'Clinical Trial [30]', 'Arancibia 2020']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='add-on treatment for CRSwNP patients does not improve sinonasal and QoL outcomes;', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='7c4a874a-ae5c-4301-8178-0341486f4d23', embedding=None, metadata={'metadata': ['Discussion', 'Clinical Trial [30]', 'Arancibia 2020']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Not mentioned.\\nPostoperative OCS as an', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='762b21c9-b14b-4085-a6ee-945be223458b', embedding=None, metadata={'metadata': ['Discussion', 'Clinical Trial [30]', 'Arancibia 2020']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='prednisone for 1 week, 20 mg for 1 week, 10 mg for 1 week, and finally 5 mg for 1 week.\\nthus, they should not be routinely recommended.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='7644f46a-069e-4208-976a-c05cf936c344', embedding=None, metadata={'metadata': ['Discussion', 'Clinical Trial [30]', 'Moderate']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='5. Summary of results: effect of systemic injected corticosteroids.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='4af8f296-04de-4cdc-a27a-0a4152febcfb', embedding=None, metadata={'metadata': ['Discussion', 'Name']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Expression of genes that encode the annexin-1 and galectin-1 proteins in nasal polyposis and their modulation by glucocorticoid [51] Author and publication date', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='d7f6eb4b-80f4-465c-8611-ab7ad0aa600f', embedding=None, metadata={'metadata': ['Discussion', 'Fernandes 2010']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Type of study', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='64b618ae-28b0-483d-be3e-e058e2788e6a', embedding=None, metadata={'metadata': ['Discussion', 'Fernandes 2010']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text=' | Prospective | 11 | A 1 ml ampoule of\\n | --- | --- | ---\\n | Number of patients | Investigated drug | Side effects | Conclusions | Quality of evidence\\n | --- | --- | --- | --- | ---\\n | 36 Oral prednisolone\\n |  |  | Not mentioned. | When subjects were given | \\n |  |  | Not mentioned. | Specific immunotherapy | \\n', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='b79c0851-6aed-4714-880a-ea5c94e051f2', embedding=None, metadata={'metadata': ['Discussion', 'Moderate']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='betamethasone acetate/ betamethasone sodium phosphate administered intramuscularly five days before surgery.\\nsystemic corticosteroids, the mean gene expression of the anti- inflammatory protein annexin-1 decreased significantly.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='19fede33-62b3-43e4-bf7f-7c105057954d', embedding=None, metadata={'metadata': ['Discussion', 'Moderate']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='can greatly reduce the need for corticosteroids.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='1b4706ea-fcf9-4bae-ad4e-d94b41ad0f47', embedding=None, metadata={'metadata': ['Discussion', 'Moderate']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Specific immunotherapy can greatly reduce the need for systemic steroids in allergic rhinitis [21]', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='bce4b880-8c7e-407e-9214-9fb5fbd440d0', embedding=None, metadata={'metadata': ['Discussion', 'Moderate']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Evolution of symptoms associated to nasal polyposis following oral steroid treatment and nasalization of the ethmoid–radical ethmoidectomy is functional surgery for NPS [52]', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='665737f5-5141-497b-8a24-3ba5568d191c', embedding=None, metadata={'metadata': ['Discussion', 'Jankowski 2003']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Retrospective 39 173 93.1% received only injected Depomedrol, Diprospan or Lederspan and 6.9% received subcutaneous immunotherapy and/ or corticosteroids.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='a5bc3296-65b7-4799-8e67-13a7a0dce6b8', embedding=None, metadata={'metadata': ['Discussion', 'Jankowski 2003']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Case series 24 Prednisolone 60 mg/ Low', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='f13c3a1a-3ebd-4858-8ab8-0201f2ed10dd', embedding=None, metadata={'metadata': ['Discussion', 'Low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='day for 7 days + the day before surgery and triamcinolone 80 mg depot injection the day after surgery.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='a2f02c17-ec3e-4a4a-a13d-b3d3d129e4b0', embedding=None, metadata={'metadata': ['Discussion', 'Low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='No side effects or complications were reported.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='bb93b089-d9ee-4e4a-84c8-91cdbb5bcf16', embedding=None, metadata={'metadata': ['Discussion', 'Low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='No side effects or complications were reported.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='f7853052-fb22-430f-9fae-41c992b26419', embedding=None, metadata={'metadata': ['Discussion', 'Low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text=' |  |  | Systemic corticosteroids are highly effective to relief symptoms associated to nasal polyposis, but their efficacy disappears over time. 5/6 who poorly responded to OCS had better effect after triamcinolone depot injection and remained stable for 12 months.\\n | --- | --- | ---\\n | Olfaction in patients with nasal polyposis: effects of systemic steroids and radical ethmoidectomy with middle turbinate resection (nasalization) [22] |  | Following the 7-day treatment with systemic corticosteroids the olfactory score increased significantly but decreased in the following two months. It re-increased after the depot injection of 80 mg triamcinolone and was stable 12 months after.\\n | Intramuscular betamethasone dipropionate vs. oral prednisolone in hay fever patients [53]\\n | Jankowski 2003\\n | Laursen 1987\\n | Case series | 56 | Prednisolone 60 mg/\\n', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='239d0a00-2bff-45a4-be07-9be87925970a', embedding=None, metadata={'metadata': ['Discussion', 'Low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Randomized controlled trial day for 7 days and depot injection of 80 mg triamcinolone.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='cbf00811-3ee0-4e55-a31a-9fa110ed028a', embedding=None, metadata={'metadata': ['Discussion', 'Low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='7.5 mg/day for 3 weeks or injection with depot betamethasone dipropionate 2 ml.\\nNo severe side effects.\\nThe injection seems to be as effective as the oral treatment, and after 3 weeks treatment with depot steroids, in contrast to oral treatment, there seems to be no suppression of the hypothalamic pituitary-adrenal axis.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='8a54d6f4-6bab-4324-bc12-49ac30c03d7d', embedding=None, metadata={'metadata': ['Discussion', 'Low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='given with a dosing interval from 0.25 mg to 50 mg daily and a treatment length interval from 5 days to 4 weeks for the OCS (Table 3, 4, 5, 6, 7).\\nOne injection of 14 mg betamethasone corresponds to only 88 mg pre- dnisolone (Table 1), which is a much lower dose than the usual given oral treatment course (for example 37.5 mg/d for 10 days).\\nGiven that OCS is widely used with different doses and treatment lengths and injected cor- ticosteroids are also frequently used, it would be intui- tive to assume that systemic corticosteroids are efficacious and relatively safe to use.\\nHowever, as our results show, there is a lack of high-level evidence to support the use of systemic corticosteroids.\\nNo study has studied the efficacy and side effects of OCS com- pared to injected corticosteroid use in CRS patients or any of the subgroups from our inclusions.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='92b99134-94eb-4d6a-ab11-b8a47a3a0861', embedding=None, metadata={'metadata': ['Discussion', 'Low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Of the 20 studies regarding the effect of OCS, 19 reported beneficial effects and/or symptom improvements and one concluded that the effect of OCS was similar to topical corticosteroids (Table 4).\\nHowever, in the study by Karaki et.\\nal, the dose of OCS for seasonal allergic rhinitis was very low (0.25 mg twice daily), and corticosteroids, but the period for this effect is also addressed in some studies.\\nTwo studies have reported symptom relief from OCS use [36,52].\\nHowever, Jankowski et al.\\naddressed a longer-lasting effect from administrating patients with depot injection of triamcinolone 80 mg than oral prednisolone as the VAS score decreased from 6.4 to 2.0 (mean values) after the injection and stayed stable between 2.0 and 2.6 (mean values) in the next 12 months compared to the re-increase of VAS from 3.2 to 6.4 (mean values) 2 months after the oral treatment [52].', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='b369b384-e03e-46bc-ada5-99ebad458f3c', embedding=None, metadata={'metadata': ['Discussion', 'Low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='6. Summary of results: side effects of systemic corticosteroids.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='60f8e088-7c18-48fe-85b2-935bdcf73a29', embedding=None, metadata={'metadata': ['Discussion', 'Long-Term Therapy with Corticosteroids in Nasal Polyposis: A Bone Metabolism Assessment [54]']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Author and publication date', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='505f4ae3-4af9-4f51-a50a-23b740b9f4c7', embedding=None, metadata={'metadata': ['Discussion', 'Long-Term Therapy with Corticosteroids in Nasal Polyposis: A Bone Metabolism Assessment [54]']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text=' | Gelardi 2019 Case control | 40 | Prednisone. Dose unknown. | No complications occurred after chronic treatment |  | \\n | --- | --- | --- | --- | --- | ---\\n | Type of study\\n | Case series | 51 | A history of at least two |  |  | \\n |  | Number of patients | Investigated drug | Side effects | Conclusions | Quality of evidence\\n', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='fabd0443-db6b-455d-889e-5f0df8b49a99', embedding=None, metadata={'metadata': ['Discussion', 'Long-Term Therapy with Corticosteroids in Nasal Polyposis: A Bone Metabolism Assessment [54]']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='with OCS(hypertension, type 2 diabetes mellitus, gastric ulcer, cataracts and glaucoma).\\nNo increased risk of osteoporosis or osteopenia.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='124497b4-7d0e-44e6-a48c-07c835d9d25d', embedding=None, metadata={'metadata': ['Discussion', 'Long-Term Therapy with Corticosteroids in Nasal Polyposis: A Bone Metabolism Assessment [54]']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='No high risk of osteoporosis or osteopenia.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='658a14bb-a78c-482c-b9fe-fd885ee91095', embedding=None, metadata={'metadata': ['Discussion', 'Long-Term Therapy with Corticosteroids in Nasal Polyposis: A Bone Metabolism Assessment [54]']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Treatment with corticosteroids did not increase the likelihood of being affected by osteopenia or osteoporosis.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='92b74132-e0ec-443f-9dd2-95195c8cd960', embedding=None, metadata={'metadata': ['Discussion', 'Long-Term Therapy with Corticosteroids in Nasal Polyposis: A Bone Metabolism Assessment [54]']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='2–3 moderate courses of OCS annually may be used without high risk of causing osteopenia/ osteoporosis in patients with CRSwNP.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='ebd50534-f1b9-4e35-b080-8a590c225c3c', embedding=None, metadata={'metadata': ['Discussion', 'Very low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Very low Does the oral steroid treatment of patients with nasal polyposis cause osteopenia or osteoporosis?\\n[55] Cross-reactions to systemic corticosteroids in patients contact sensitized to budesonide [56]', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='0567955a-ea17-4265-a2ec-64a0e4dbc68c', embedding=None, metadata={'metadata': ['Discussion', 'Sahlstrand- Johnson 2019']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text=' | Hansel 2020 | Prospective | 23 | Systemic |  | \\n | --- | --- | --- | --- | --- | ---\\n | courses of Prednisone equivalents during\\n | the last year.\\n | Mean intake =\\n | 891 mg.\\n |  |  |  |  |  | \\n', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='25c1ec26-e02e-4b20-87a6-8ff7ade26f0a', embedding=None, metadata={'metadata': ['Discussion', 'Sahlstrand- Johnson 2019']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Osteoporosis and adrenal insufficiency.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='9c8522b5-f302-4d6a-a086-c4b268c15436', embedding=None, metadata={'metadata': ['Discussion', 'Low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='hydrocortisone 21sodium hemisuccinate, methylprednisolone, methylprednisolone sodium succinate, prednisone, triamcinolone.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='359b17e0-92af-46d8-a9ff-ca97f94337dc', embedding=None, metadata={'metadata': ['Discussion', 'Low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='consumption during the past year was greater than three short courses of reactions to systemic corticosteroids.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='9b327866-a9c3-43ad-8f51-64972e9a2413', embedding=None, metadata={'metadata': ['Discussion', 'Low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Patients with severe nasal polyposis and a high corticosteroid consumption have a high prevalence of glucocorticoid-induced osteoporosis and secondary adrenal insufficiency.\\nAdrenal suppression and osteoporosis after treatment of nasal polyposis [18]', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='390d869a-f763-4237-8d0e-56368d936575', embedding=None, metadata={'metadata': ['Discussion', 'Very low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Prevalence of metabolic bone disease among chronic rhinosinusitis patients treated with oral glucocorticoids [57] Bonfils 2006 Prospective 46 Oral corticosteroid', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='370f90fc-6f1b-45bd-af3a-f79b872dda73', embedding=None, metadata={'metadata': ['Discussion', 'Rajasekaran 2010']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='prednisolone 1 mg/ kg/day.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='d6e43266-1de9-4c7b-b694-4219fe9c3a17', embedding=None, metadata={'metadata': ['Discussion', 'Rajasekaran 2010']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Retrospective 197 History of oral corticosteroid usage (>5 mg daily for at least 3 months).\\nOsteoporosis, osteopenia, and low bone density.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='cd075148-822d-49c9-85cb-27d6076f250e', embedding=None, metadata={'metadata': ['Discussion', 'Rajasekaran 2010']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Patients with CRS with/ without polyposis treated with oral corticosteroids were found to have a high prevalence of low bone density.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='95aaf190-c365-4f11-83b1-032a199c04fa', embedding=None, metadata={'metadata': ['Discussion', 'Rajasekaran 2010']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='this could explain their results pointing to no signifi- cant effect of OCS [34].\\nSeveral studies have presented evidence that corticosteroids are beneficial for CRS patients concerning improving symptoms and quality of life (Table 4).\\nThere seems to be support for the positive effect on olfactory function after systemic cor- ticosteroids.\\nThree studies have found an improvement in olfactory function with systemic corticosteroids [22,42,49].\\nShriver et al.\\nreported that 26.6% of 425 patients showed an improvement in smell function after treatment with oral methylprednisolone, but the effect was transient [49].\\nYet, the efficacy of injected corticosteroids is implied to be bigger and longer last- ing [22].\\nOverall, there is a lot of data reporting on the improvement of symptoms with systemic In a study by Aasbjerg et al., it is reported that on average 1.6 corticosteroid injections are prescribed each year for patients with allergic rhinitis [21].\\nThis speaks for injected corticosteroids being used', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='a5f6bd33-c5fe-47ee-af8c-75190628cb6b', embedding=None, metadata={'metadata': ['Discussion', 'Rajasekaran 2010']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text=' | 7. | Summary of results: other effects of systemic corticosteroids.\\n | --- | ---\\n | Name | Author and publication date | Type of study | Number of patients | Investigated drug | Side effects | Conclusions |  | Quality of evidence\\n | --- | --- | --- | --- | --- | --- | --- | --- | ---\\n | Increased ILC2s in the eosinophilic nasal polyp endotype are associated with corticosteroid responsiveness [58] | Walford 2014 | Case series | 25 | Prednisone dose greater than 30 mg daily for a minimum of 5 days, or equivalent methylprednisolone daily dose. | Not mentioned. There were fewer ILC2s in eosinophilic nasal polyps from patients treated with systemic corticosteroid compared with polyps from patients not treated with systemic corticosteroid. |  |  | Very low\\n | Increased neutrophilia in nasal polyps reduces the response to oral corticosteroid therapy [59] | Wen 2012 | Case series | 266 | 30 mg prednisone once daily for seven days. | Not mentioned. Patients with the neutrophilic phenotype have less response to treatment with corticosteroids based on symptom scores. |  |  | Low\\n | Increased serum amyloid A in nasal polyps is associated with systemic corticosteroid insensitivity in patients with chronic rhinosinusitis with nasal polyps: a pilot study [60] | Lu 2018 | Case series | 32 | Oral prednisolone (30 mg daily for 2 weeks). | Not mentioned. The results indicate that increased serum amyloid A (SAA) in nasal polyposis is associated with reduced response to oral corticosteroids in CRSwNP. |  |  | Very low\\n | Nasal IL-25 predicts the response to oral corticosteroids in chronic rhinosinusitis with nasal polyps [61] | Hong 2018 | Case series | 52 | 2-weeks oral prednisolone. | Not mentioned. There were 29 corticosteroid- sensitive patients with CRSwNP where IL-25 increased (tissue level and serum level). |  |  | Very low\\n | Mucin 1 downregulation associates with corticosteroid resistance in chronic rhinosinusitis with nasal polyps [62] | Milara 2015 | Case series | 73 | Oral deflazacort 1 mg/ kg/day for 8 days followed by 0.5 mg/ kg/day for 7 days. | Not mentioned. Mucin 1 expression is associated with corticosteroid efficacy in patients with CRSwNP. |  |  | Low\\n | MUC4 impairs the anti- inflammatory effects of corticosteroids in patients with chronic rhinosinusitis with nasal polyps [63] | Milara 2017 | Case series | 81 | Oral deflazacort 1 mg/ kg/day for 8 days followed by 0.5 mg/ kg/day for 7 days. | Not mentioned. 22 had nasal polyps resistant to OCS. Mucin 4 (MUC4) expression was upregulated in these patients. |  |  | \\n | MUC4 impairs the correct anti-inflammatory effects of corticosteroids.\\n | Low\\n | Short Term Pre-Operative Oral Corticosteroids-Tissue Remodeling in Chronic Rhinosinusitis with Nasal Polyps [64] | Radajewski 2021 | Prospective | 65 | Oral 40 mg prednisolone at least 7 days preoperatively. | Not mentioned. The number of eosinophil fibrosis decreased in the nasal polyp’s tissue. |  |  | Very low\\n | Systemic prednisone administration selectively alters granulocyte subsets in nasal polyps from aspirin-exacerbated respiratory disease and chronic rhinosinusitis patients [65] | Edward 2013 | Prospective | 33 | Oral prednisolone 30 mg/day 1 week prior to surgery. | Not mentioned. Granulocyte subpopulations are focally affected within NPs by systemic corticosteroid exposure. |  |  | Low\\n | Surfactant protein A and D in chronic rhinosinusitis with nasal polyposis and corticosteroid response [66] | Salman 2012 | Prospective | 36 | 3 weeks oral methylprednisolone 1 mg/kg. | Not mentioned. The surfactant protein A and D levels decreased more in patients in the CRSwNP group after methylprednisolone. |  |  | Low\\n | The effects of systemic, topical, and intralesional steroid treatments on apoptosis level of nasal polyps [67] | Kapucu 2012 | Randomized controlled trial | 48 | Oral methylprednisolone 1 mg/kg/day. | No systemic or local side effects of steroid treatment were seen in any patients. | Systemic glucocorticoids induced apoptosis in nasal polyp tissue when compared with the control group. Systemic corticosteroid treatment induced the most apoptosis. |  | Low\\n', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='0fc5149f-dafa-4c14-938c-4fa88596fadf', embedding=None, metadata={'metadata': ['Very low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='The effects of corticosteroid on tissue lactoferrin in patients with nasal polyposis [68] Acıoğlu 2012 Prospective 41 1 mg/kg/day oral methylprednisolone decreasing by 10 mg every 3rd day.\\nNot mentioned.\\nPatients with NP have a lower level of tissue lactoferrin (LF).\\nCorticosteroid treatment has no effect on tissue LF concentrations.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='d76f71f5-b905-4c12-b8d8-51c780ff7640', embedding=None, metadata={'metadata': ['Very low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='frequently and being effective.\\nEssentially, the Norwegian criteria for treatment with monoclonal antibodies for nasal polyps include having had treatment with systemic corticosteroids within the past year [69].\\nSimilarly, it is also a criterion in Denmark.\\nHaving had treatment with systemic corticosteroids in the past year gives points for treatment with monoclonal antibodies [70].', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='1b8d19df-c5a6-42b2-a83e-dc0cd91e979b', embedding=None, metadata={'metadata': ['Very low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='It has been reported that the injected and oral treatments with corticosteroids affect adrenal function differently.\\nIn a study by Laursen et al., they concluded that the adrenal gland function decreased after oral prednisolone treatment in contrast to the injected Betamethasone [53].\\nHowever, it is not mentioned whether the adrenal gland function continues to be low or returns to normal.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='b7c8e2e6-4eae-4421-ab7f-357de2fdbd7a', embedding=None, metadata={'metadata': ['Very low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='The results of our study imply a positive effect on symptom relief with systemic corticosteroids and a better and longer-lasting effect with injection.\\nYet, it is noteworthy that none of the studies have studied the efficacy of single-modality oral and injected corticosteroid use and there has been no RCT that has examined the efficacy, duration of effect, or side effects of systemic corticosteroids in CRS or allergic rhinitis patients.\\nIn addition, some further limitations were detected in the body of identified evidence stemming from a focus on surrogate outcomes rather than patient-important ones’ and trials’ size.\\nLimited studies were also discovered in our review, mostly with lowquality evidence, making it difficult to draw scientific conclusions with high levels of evidence.\\nThus, there is a lack of strong evidence to support recommendations for systemic corticosteroids, but the existing literature points to symptom relief with systemic corticosteroid use and a longer-lasting effect and lower accumulated doses with injected corticosteroids compared to OCS.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='db5a7eb9-8160-45d3-8fa0-d129f828f432', embedding=None, metadata={'metadata': ['Very low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='We found seven studies concerning the administration of systemic corticosteroids perioperatively (Table 3).\\nAll seven articles concerned OCS.\\nThree of these concluded that there were beneficial effects after OCS treatment mostly regarding the facilitation of surgery, while four articles concluded that there was no effect of the treatment.\\nKeeping in mind the limited found studies with varying levels of evidence, there seems to be no definitive recommendations in the literature regarding OCS or injected corticosteroids perioperatively.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='d3e40cea-ccaf-42b3-a43e-4c7b95353ee4', embedding=None, metadata={'metadata': ['Very low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Our results showed that 11 studies focused on other effects of systemic corticosteroids.\\nDifferent inflammatory markers have been reported to be regulated by systemic corticosteroids [32,35,43,44,48,51,68], and different factors have been addressed to have an impact on the responsiveness to systemic corticosteroids [59,60,62,63,66].\\nThis suggests there is a possibility to determine which patients are fitted for systemic corticosteroids to ensure the beneficial effects of the treatment and avoid the risks of side effects for those unresponsive to systemic corticosteroids [61].\\nHowever, studies have shown low or very low-quality evidence, making it unmanageable to make recommendations based on the scientific conclusions.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='c91daba5-934b-4978-8146-40905f270d34', embedding=None, metadata={'metadata': ['Very low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='With prolonged or short-term use of systemic corticosteroids, there are well-known side effects (Table 2).\\nCorticosteroid use can cause metabolic effects, osteoporosis, and infections, among other things.\\nIt has been reported that 15% of the patients presented with truncal adiposity, facial adiposity (moon face), and dorsocervical adiposity (buffalo hump) after prednisolone treatment (10—30 mg/day) after short-term therapy (<3 months) [19].\\nAlso, the risk of hospital admission for sepsis has been reported to be 0.05% for systemic corticosteroid users even at relatively low doses compared with 0.02% for non-corticosteroid users [71].\\nThe risks of adverse side effects heighten with increasing cumulative exposure and increasing mean daily exposure to systemic corticosteroids [9].\\nHence, it is relevant to consider the equivalent dose of OCS which is higher compared to injected corticosteroids (Table 1).', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='5c4d3586-1588-430a-acfd-16146c865f44', embedding=None, metadata={'metadata': ['Very low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='While the risks of long-term systemic corticosteroids are well known, from other diseases, there is a lack of studies concerning this in rhinitis and CRS treatment.\\nWe found five studies focusing on the side effects of systemic corticosteroids and three of these articles presented adverse side effects to OCS, while two studies concluded on no adverse side effects (Table 6).\\nAmong the severe side effects, it has been shown that there is an increased risk of bone loss and adrenal insufficiency.\\nBonfils et al.\\nreported that only 39% had normal lumbar bone mineral density (BMD) and only 56% had normal BMD of the femoral neck out of 46 patients treated with OCS [18]; their included patients had an oral corticosteroid consumption during the past year that was greater than three short courses of systemic corticosteroid treatments.\\nThis should be compared with a prevalence of osteoporosis of 18.3% in the general population [72].\\nIt is highly recommended to perform DXA evaluation if a cumulated prednisolone dosage of 350 mg is reached within 1 year i.e.\\n35 mg of prednisolone for 10 days [73].\\nAlso, guidelines in Denmark recommend performing a DXA evaluation if patients receive 5 mg of prednisolone daily for 3 months or treatment with corticosteroids equivalent to at least 5 mg daily with an accumulated dose equivalent to 450 mg in 1 year [74].\\nThe American College of Rheumatology’s (ACR) Glucocorticoid-Induced Osteoporosis Guideline (GIOP) recommends that all patients continuing corticosteroid therapy ≥2.5 mg/day for >3 months or having a high dose of OCS defined as >30 mg/d or an accumulated dose of >5 g/d should have a DXAevaluation [75].\\nAnother severe side effect has been reported to be adrenal insufficiency.\\nIn the study by Bonfils et al., 48.8% of 41 patients were found to have adrenal insufficiency after OCS intake [18], while the study by Laursen et al.\\n[53] showed adrenal suppression with OCS but not with injected steroids.\\nAmong the side effects of injected corticosteroids, subcutaneous atrophy at the insertion site has been reported [15].\\nOther side effects regarding the injected corticosteroids have also been addressed, namely avascular bone necrosis.\\nNasser et al.\\nreported that a man with severe hay fever was given at least one depot corticosteroid injection each year for 11 years, leading to avascular necrosis of both femoral heads [76].\\nThese studies outline the risks of corticosteroid injections.\\nOn the other hand, fewer injections may cause fewer complications with lower risks of side effects.\\nIt was reported by Ostergaard and colleagues in a study that included 1,362 patients that a single injection of corticosteroids have no complications and supported no concern for adrenal suppression, osteoporosis, or serious tissue atrophy [77].\\nOther authors have foreseen the actual safety of systemic corticosteroids without the reported side effects [43,54,55].', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='eef4dd0f-cfb4-4218-b333-5c5b4dbb10ff', embedding=None, metadata={'metadata': ['Very low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='In summary, there is a lack of studies that report on the prevalence of side effects of systemic corticosteroids.\\nOnly osteoporosis, adrenal insufficiency, risk of allergy, and tissue atrophy after injections are mentioned in the reviewed studies.\\nThere is especially a deficiency in the literature concerning dosage and treatment length to avoid any adverse side effects and there are no studies that report on how long it takes for side effects to arise after ending treatment with systemic corticosteroids.\\nIt can be critically discussed whether many of the studies were not citing side effects after systemic treatment with corticosteroids simply because rhinologists do not see them.\\nPatients go to their ophthalmologists to have their glaucoma treatment, others go to the emergency room if they have (pathological) fractures, GP for diabetes, etc.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='44d1d08a-ae08-4a22-b77e-fcae465cc3f7', embedding=None, metadata={'metadata': ['Very low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='10.1016/j.aorl.2009.03.005 [3] Fokkens WJ, Lund VJ, Hopkins C, et al.\\nExecutive summary of EPOS 2020 including integrated care pathways.\\nRhinology.\\n2020;58(2):82–111.\\ndoi: 10.4193/ Rhin20.601 [4] Hellings PW, Klimek L, Cingi C, et al.\\nNon-allergic rhinitis: position paper of the european academy of allergy and clinical immunology.\\nAllergy.\\n2017;72 (11):1657–1665.\\ndoi: 10.1111/all.13200 [5] Hellings PW, Scadding G, Bachert C, et al.\\nEUFOREA treatment algorithm for allergic rhinitis.\\nRhinology.\\n2020;58(6):618–622.\\ndoi: 10.4193/Rhin20.376 Parente L. Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids.\\nBMC Pharmacol Toxicol.\\n2017;18(1):1. doi: 10.1186/s40360-016-0111-8 [7] Kirtsreesakul V, Wongsritrang K, Ruttanaphol S. Clinical efficacy of a short course of systemic steroids in nasal polyposis.\\nRhinology.\\n2011;49(5):525–532.\\ndoi:', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='e6f9bb5e-8018-4397-a413-08bc468d92c6', embedding=None, metadata={'metadata': ['Very low']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Limited studies have been discovered in our paper implicating the lack of high level of evidence of the efficacy, duration of effect, and side effects of OCS and injected corticosteroids.\\nAlso, the limited number of studies indicates no strong evidence for the scientific conclusions emphasizing the need for a well-conducted RCT regarding this topic.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='c3cfc71d-5fcc-4936-82e6-c132c2d58e5d', embedding=None, metadata={'metadata': ['Conclusions']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Oral and injected glucocorticosteroids are often effectively used in CRS treatment.\\nNevertheless, evidence of drug of choice, dosage, treatment length, number of treatment courses pr.\\nyear, side effects, and treatment methods are surprisingly poor.\\nThe only side effects reported were osteoporosis and adrenal insufficiency.\\nA careful estimate shows that the effect of OCS lasts 2 months and a little longer for injected corticosteroids.\\nAdditionally, the corticosteroid injection has a much lower dose compared to OCS with less adrenal suppression, but the effect cannot be stopped if side effects occur.\\nAltogether, the presented data indicate that an RCT study is needed to compare OCS and injected corticosteroids, focusing on their efficacy, duration of effect and side effects.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='598e0222-d1d3-446c-a7fa-862af044a141', embedding=None, metadata={'metadata': ['Acknowledgments']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='The authors would like to thank Jeppe Skou Petersen, seniorspecialist, from Amgros for providing data.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='a0746f16-4dfa-470b-8c81-da93a1270fdc', embedding=None, metadata={'metadata': ['Disclosure statement']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='No potential conflict of interest was reported by the author(s).', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='74d4e94c-4e6c-4f4d-9d4c-aa3cbce65364', embedding=None, metadata={'metadata': ['Funding']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='There has been no funding for this work.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='8d30457b-c204-4da8-a431-2656657a44e6', embedding=None, metadata={'metadata': ['Thank References']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='[1] Ho J, Li W, Grayson JW, et al.\\nSystemic medication requirement in post-surgical patients with eosinophilic chronic rhinosinusitis.\\nRhinology.\\n2021;59(1):59–65.\\ndoi: 10.4193/Rhin20.073 [2] Giordano J, Darras J, Chevalier D, et al.\\nPreoperative corticosteroid treatment and nasal polyposis.\\nAnn Otolaryngol Chir Cervicofac.\\n2009;126(3):120–124.\\ndoi:', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='68bb7e8d-24a7-4e3a-8853-afacc6d7e86b', embedding=None, metadata={'metadata': ['Thank References']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='10.4193/Rhino11.140 [8] ClinCals.\\n(2015, October 24).\\nCorticosteroid Conversion Calculator.\\nRetrieved from ClinCals: https://clincalc.\\ncom/corticosteroids/ [9] Price DB, Trudo F, Voorham J, et al.\\nAdverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study.\\nJ Asthma Allergy.\\n2018;11:193–204.\\ndoi: 10.2147/JAA.S176026 [10] Warrington TP, Bostwick JM.\\nPsychiatric adverse effects of corticosteroids.\\nMayo Clin Proc.\\n2006;81 (10):1361–1367.\\ndoi: 10.4065/81.10.1361 [11] Goodwin JE, Geller DS.\\nGlucocorticoid-induced hypertension.\\nPediatr Nephrol.\\n2012;27(7):1059–1066.\\ndoi: 10.1007/s00467-011-1928-4 [12] Hirsch IB, Paauw DS.\\nDiabetes management in special situations.\\nEndocrinol Metab Clin North Am.\\n1997;26 (3):631–645.\\ndoi: 10.1016/S0889-8529(05)70271-1 [13] Segal BH, Sneller MC.\\nInfectious complications of immunosuppressive therapy in patients with rheumatic diseases.\\nRheum Dis Clin North Am.\\n1997;23 (2):219–237.\\ndoi: 10.1016/S0889-857X(05)70327-6 [14] Da Silva JA, Jacobs JW, Kirwan JR, et al.\\nSafety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.\\nAnn Rheum Dis.\\n2006;65(3):285–293.\\ndoi: 10.1136/ard.2005.\\n038638 [15] Ameratunga R. Gluteal subcutaneous atrophy after depot steroid injection for allergic rhinitis.\\nWorld Allergy Organ J.\\n2012;5(11):168–169.\\ndoi: 10.1097/ WOX.0b013e3182758d80 [16] Stanbury RM, Graham EM.\\nSystemic corticosteroid ther- apy–side effects and their management.\\nBr J Ophthalmol.\\n1998;82(6):704–708.\\ndoi: 10.1136/bjo.82.6.704 [17] Keenan GF.\\nManagement of complications of glucocor- ticoid therapy.\\nClin Chest Med.\\n1997;18(3):507–520.\\ndoi: 10.1016/S0272-5231(05)70398-1 [18] Bonfils P, Halimi P, Malinvaud D. Adrenal suppression and osteoporosis after treatment of nasal polyposis.\\nActa Otolaryngol.\\n2006;126(11):1195–1200.\\ndoi: 10.1080/ 00016480600672667 [19] Fardet L, Kassar A, Cabane J, et al.\\nCorticosteroid- induced adverse events in adults: frequency, screening and prevention.\\nDrug Saf.\\n2007;30(10):861–881.\\ndoi: 10.\\n2165/00002018-200730100-00005 [20] Buchman AL.\\nSide effects of corticosteroid therapy.\\nJ Clin Gastroenterol.\\n2001;33(4):289–294.\\ndoi: 10.1097/ 00004836-200110000-00006 [21] Aasbjerg K, Torp-Pedersen C, Backer V. Specific immu- notherapy can greatly reduce the need for systemic steroids in allergic rhinitis.\\nAllergy.\\n2012;67 (11):1423–1429.\\ndoi: 10.1111/all.12023 [22] Jankowski R, Bodino C. Olfaction in patients with nasal polyposis: effects of systemic steroids and radical eth- moidectomy with middle turbinate resection (nasalization).\\nRhinology.\\n2003;41(4):220–230.\\nMoher D, Liberati A, Tetzlaff J, et al.\\nPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.\\nPLOS Med.\\n2009;6(7):e1000097.\\ndoi: 10.1371/journal.pmed.1000097 [24] Page MJ, Moher D, Bossuyt PM, et al.\\nPRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews.\\nBMJ.\\n2021;372:n160.\\ndoi: 10.1136/bmj.n160 [25] Akiyama K, Makihara S, Uraguchi K, et al.\\nImpact of preoperative systemic corticosteroids on the histology and diagnosis of eosinophilic chronic rhinosinusitis.\\nInt Arch Allergy Immunol.\\n2019;179(2):81–88.\\ndoi: 10.\\n1159/000496437 [26] Rives P, Espitalier F, Michel G, et al.\\nProspective evalua- tion of oral corticosteroid as a predictor of postoperative olfactory recovery after functional endoscopic surgery for nasal polyposis.\\nEur Arch Otorhinolaryngol.\\n2019;276(12):3359–3366.\\ndoi: 10.1007/s00405-019- 05537-y [27] Shen KH, Wang YH, Hsu TW, et al.\\nDifferential effects of postoperative oral corticosteroid on eosinophilic vs. non-eosinophilic CRSwNP subtypes.\\nAm J Otolaryngol.\\n2019;40(1):22–29.\\ndoi: 10.1016/j.\\namjoto.2018.09.005 [28] Ecevit MC, Erdag TK, Dogan E, et al.\\nEffect of steroids for nasal polyposis surgery: A placebo-controlled, ran- domized, double-blind study.\\nLaryngoscope.\\n2015;125 (9):2041–2045.\\ndoi: 10.1002/lary.25352 [29] Wright ED, Agrawal S. Impact of perioperative systemic steroids on surgical outcomes in patients with chronic rhinosinusitis with polyposis: evaluation with the novel Perioperative Sinus Endoscopy (POSE) scoring system.\\nLaryngoscope.\\n2007;117(11 Pt 2 Suppl 115):1–28.\\ndoi:', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='0baaa54f-da49-4ebc-9c3c-04eae508c808', embedding=None, metadata={'metadata': ['Thank References']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Indian J Otolaryngol Head Neck Surg.\\n2013;65(Suppl 2):402–405.\\ndoi: 10.1007/s12070-013-0625-y [43] Lennard CM, Mann EA, Sun LL, et al.\\nInterleukin-1 beta, interleukin-5, interleukin-6, interleukin-8, and tumor necrosis factor-alpha in chronic sinusitis:', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='0c589fc9-17ba-4c5e-93b8-112c41b24e21', embedding=None, metadata={'metadata': ['Thank References']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='response to systemic corticosteroids.\\nAm J Rhinol.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='6fa943ad-8e2c-466b-a946-6afd576ee706', embedding=None, metadata={'metadata': ['Thank References']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='2000;14(6):367–373.\\ndoi: 10.2500/105065800779 954329 [44] Bolger WE, Joshi AS, Spear S, et al.\\nGene expression analysis in sinonasal polyposis before and after oral corticosteroids: a preliminary investigation.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='c45bae6e-043c-4e4d-b600-4ffef10881e6', embedding=None, metadata={'metadata': ['Thank References']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Otolaryngol Head Neck Surg.\\n2007;137(1):27–33.\\ndoi:', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='1f5748c2-6722-4a11-a093-eee7890e829e', embedding=None, metadata={'metadata': ['Thank References']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='[47] Berkiten G, Salturk Z, Topaloğlu İ. Efficacy of systemic steroid treatment in sinonasal polyposis.\\nJ Craniofac Surg.\\n2013;24(3):e305–8.\\ndoi: 10.1097/SCS.0b013e 31828f261f [48] Woodworth BA, Joseph K, Kaplan AP, et al.\\nAlterations in eotaxin, monocyte chemoattractant protein-4, interleukin-5, and interleukin-13 after systemic steroid treatment for nasal polyps.\\nOtolaryngol Head Neck Surg.\\n2004;131(5):585–589.\\ndoi: 10.1016/j.otohns.2004.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='48a799b7-d2d5-44af-9301-8e094e4a581e', embedding=None, metadata={'metadata': ['Thank References']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='05.028', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='bc1c9915-046e-4d03-9ff1-f7c972d8d5da', embedding=None, metadata={'metadata': ['Thank References']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='[49] Schriever VA, Merkonidis C, Gupta N, et al.\\nTreatment of smell loss with systemic methylprednisolone.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='fb6d1e39-4ff3-4765-90da-9d5530405132', embedding=None, metadata={'metadata': ['Thank References']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Rhinology.\\n2012;50(3):284–289.\\ndoi: 10.4193/Rhino.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='bfadba91-bde1-4ba4-96f9-fccf3b33c7f7', embedding=None, metadata={'metadata': ['Appendices Appendix 1: Search history in PubMed']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text=' | Number | Search details | Results\\n | --- | --- | ---\\n | 1 | Chronic rhinosinusitis*[Title/Abstract] | 7,605\\n | 2 | CRS[Title/Abstract] | 12,753\\n | 3 | Nasal polyps*[Title/Abstract] | 5,258\\n | 4 | Nasal polyp*[Title/Abstract] | 7,729\\n | 5 | Allergy*[Title/Abstract] | 82,107\\n | 6 | #1 OR #2 OR #3 OR #4 OR #5 | 102,756\\n | 7 | Systemic glucocorticoids*[Title/Abstract] | 512\\n | 8 | Systemic glucocorticoid*[Title/Abstract] | 856\\n | 9 | Oral glucocorticoid*[Title/Abstract] | 858\\n | 10 | Oral glucocorticoids*[Title/Abstract] | 577\\n | 11 | inj. glucocorticoid*[Title/Abstract] | 5\\n | 12 | inj. glucocorticoids*[Title/Abstract] | 3\\n | 13 | injected glucocorticoids*[Title/Abstract] | 5\\n | 14 | injected glucocorticoid*[Title/Abstract] | 8\\n | 15 | injection glucocorticoids*[Title/Abstract] | 2,961\\n | 16 | injection glucocorticoid*[Title/Abstract] | 5,905\\n | 17 | Hay fever* [Title/Abstract] | 3,887\\n | 18 | #7 #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 | 7,458\\n | 19 | #6 AND #18 | 83\\n | 20 | Systemic corticosteroid*[Title/Abstract] | 6,481\\n | 21 | Systemic corticosteroids*[Title/Abstract] | 4,797\\n | 22 | Systemic steroids*[Title/Abstract] | 2,860\\n | 23 | Systemic steroid*[Title/Abstract] | 4,148\\n | 24 | OCS[Title/Abstract] | 7,330\\n | 25 | Oral corticosteroid*[Title/Abstract] | 5,244\\n | 26 | Oral corticosteroids*[Title/Abstract] | 3,805\\n | 27 | Oral steroids*[Title/Abstract] | 2,658\\n | 28 | Oral steroid*[Title/Abstract] | 3,815\\n | 29 | Inj. steroid*[Title/Abstract] | 30\\n | 30 | Inj. steroids*[Title/Abstract] | 12\\n | 31 | Inj. corticosteroid*[Title/Abstract] | 14\\n | 32 | Inj. corticosteroids*[Title/Abstract] | 6\\n | 33 | Injected steroid*[Title/Abstract] | 57\\n | 34 | Injected steroids*[Title/Abstract] | 40\\n | 35 | Injected corticosteroid*[Title/Abstract] | 67\\n | 36 | Injected corticosteroids*[Title/Abstract] | 50\\n | 37 | Injection steroid*[Title/Abstract] | 18\\n | 38 | Injection steroids*[Title/Abstract] | 1\\n | 39 | Injection corticosteroid*[Title/Abstract] | 1\\n | 40 | Injection corticosteroids*[Title/Abstract] | 5,238\\n | 41 | Oral prednisolone* [Title abstract] | 3,121\\n | 42 | #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 | 30,363\\n | 43 | #6 AND #42 | 1,064\\n', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='78905f94-90b4-4666-827f-a239b7fb3e68', embedding=None, metadata={'metadata': ['Appendices Appendix 1: Search history in PubMed', 'Appendix 2: Search history in Embase']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text=' | Search no. Search details |  |  | Results Limits\\n | --- | --- | --- | ---\\n | 1 | Chronic rhinosinusitis or CRS or Nasal polyps or Chronic rhinosinusit or allergy | 14857 | Exclude MEDLINE\\n | journals Human English language Abstracts\\n | 2 systemic glucocorticoid or systemic glucocorticoids or oral glucocorticoid or oral glucocorticoids or inj |  |  | \\n | glucocorticoid or inj glucocorticoids or injected glucocorticoid or injected glucocorticoids or injection glucocorticoid or injection glucocorticoids or systemic corticosteroid or systemic corticosteroids or oral corticosteroid or oral corticosteroids or inj corticosteroid or inj corticosteroids or injected corticosteroid or injected corticosteroids or injection corticosteroid or injection corticosteroid or systemic steroid or systemic steroids or oral steroid or oral steroids or inj steroid or inj steroids or incected steroid or injected steroids or injection steroid or injection steroids or OCS\\n | 3573\\n | 3 1 and 2 |  |  | 238\\n | 4 Filters: Adult, 1990–2023, articles |  |  | 113\\n', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='b4989dc2-6311-49fe-bb15-405548d6efcc', embedding=None, metadata={'metadata': ['Appendices Appendix 1: Search history in PubMed', 'Appendix 3. ICD 10.diagnosis codes']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text=' | Allergic rhinitis | CRS | CRSwNP:\\n | --- | --- | ---\\n | J30, J301, J302, J303, J304 | J320, J321, J322, J323, J324 | J330, J331, J338, J339\\n', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='2d126d9b-7763-4ae1-aa85-f9af4b7e3314', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Danielle Cristina Guimarães da Silvaa,*, Marcela de Sá Barreto da Cunhaa, Amanda de Oliveira Santanaa, Augusto Matheus dos Santos Alvesa, Marcos Pereira Santosa', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='a00a2ef4-8706-4e8d-8cfe-9fba9445f68f', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'ABSTRACT']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Objective: To systematically review the literature in search of the most suitable and effective nutritional interventions and indications for the nutritional treatment of children and adolescents with cerebral palsy (CP).', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='ea5d7311-2dc6-4298-9ce4-178f6921758a', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'ABSTRACT', 'RESUMO']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Objetivo: Revisar sistematicamente a literatura em busca das intervenções e indicações nutricionais mais adequadas e eficazes para o tratamento nutricional de crianças e adolescentes com paralisia cerebral (PC).', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='977635c3-b0cf-4d66-9a52-6beb4fa6f2a2', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'ABSTRACT', 'RESUMO']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Data source: This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta- Analyses (PRISMA) guidelines.\\nThe articles were selected from seven databases (Cochrane, Literatura Latino-Americana e do Caribe em Ciências da Saúde — Lilacs, Embase, United States National Library of Medicine — PubMed, Scientific Electronic Library Online — SciELO, Scopus, and Web of Science).\\nStudies from a pediatric group (0 to 18 years old) diagnosed with CP were included and the search strategy included the descriptors: “children” OR “childhood” AND “nutritional therapy” OR “nutritional intervention” OR “nutrition” OR “nutritional support” OR “diet” AND “cerebral palsy” OR “cerebral injury”.\\nMethodological quality was assessed using the checklist for cross-sectional analytical studies, the Newcastle-Ottawa scale or the Cochrane Collaboration tool for clinical trials.\\nData synthesis: Fifteen studies (n=658) published from 1990 to 2020 met the inclusion criteria.\\nAll of them had a low risk of bias.\\nThe data showed that children and adolescents with CP have worse nutritional status than those normally developed.\\nThose who received hypercaloric and hyperprotein nutritional supplementation benefited from its use.\\nStudies indicate that enteral nutrition should be considered when nutritional needs are not met by the oral diet, especially in cases where oral motor functions are impaired.\\nIn addition, there was a direct relationship between the consistency of food, the level of motor function and nutritional status.\\nFontes de dados: Esta revisão foi conduzida de acordo com as diretrizes Preferred Reporting Items for Systematic Reviews and Meta-Analyses — PRISMA.\\nOs artigos foram selecionados em sete bases de dados (Cochrane, Literatura Latino-Americana e do Caribe em Ciências da Saúde — Lilacs, Embase, United States National Library of Medicine — PubMed, Scientific Electronic Library Online — SciELO, Scopus, and Web of Science).\\nForam incluídos estudos de um grupo pediátrico (zero a 18 anos) com diagnóstico de PC e a estratégia de busca incluiu os descritores: “children” OR “childhood” AND “nutritional therapy” OR “nutritional intervention” OR “nutrition” OR “nutritional support” OR “diet” AND “cerebral palsy” OR “cerebral injury”.\\nA qualidade metodológica foi avaliada utilizando a lista de verificação para estudos transversais analíticos, escala Newcastle- Ottawa ou ferramenta da Cochrane Collaboration, para ensaios clínicos.\\nSíntese dos dados: Quinze estudos (n=658) publicados de 1990 a 2020 preencheram os critérios de inclusão.\\nTodos tiveram baixo risco de viés.\\nOs dados mostraram que crianças e adolescentes com PC apresentam pior estado nutricional do que os normalmente desenvolvidos.\\nAqueles que receberam suplementação nutricional hipercalórica e hiperproteica beneficiaram-se de seu uso.\\nEstudos demonstram que a nutrição enteral deve ser considerada quando as necessidades nutricionais não são supridas pela dieta oral, principalmente nos casos em que as funções oromotoras estão prejudicadas.\\nAlém disso, houve relação direta entre a consistência dos alimentos, o nível de função motora e o estado nutricional.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='0c678414-a8c7-4cdd-85eb-e72084c62d31', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'ABSTRACT', 'RESUMO', 'Corresponding author. E-mail: daniellenut@hotmail.com (D. C. G. Silva).']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='aUniversidade Federal do Oeste da Bahia, Barreiras, BA, Brasil.\\nReceived on June 14, 2022; approved on February 05, 2023.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='e0e11120-7fe0-4305-b094-921327bd264f', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'ABSTRACT', 'RESUMO', 'Corresponding author. E-mail: daniellenut@hotmail.com (D. C. G. Silva).']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Conclusions: Children and adolescents with CP have a greater risk of malnutrition.\\nThe use of nutritional supplementation may help with weight gain.\\nIn addition, enteral nutrition and modification of food texture have been used to improve the nutritional status of this group.\\nKeywords: Cerebral palsy; Nutritional therapy; Malnutrition; Review.\\nConclusões: Crianças e adolescentes com PC têm maior risco de desnutrição.\\nO uso de suplementação nutricional pode auxiliar no ganho de peso desses pacientes.\\nAlém disso, a nutrição enteral e a modificação da textura dos alimentos têm sido artifícios utilizados para a melhora do estado nutricional neste grupo.\\nPalavras-chave: Paralisia cerebral; Terapia nutricional; Desnutrição; Revisão.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='9e28f0c5-5ac4-4e90-9d26-06f02883e82a', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Nutritional interventions in children and adolescents with cere- bral palsy (CP) are an important strategy for maintaining the overall health of this group, with a view to preventing nutri- tional deficiencies and malnutrition and promoting health.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='9b0e924a-c28d-4067-9943-7bbbd5683796', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='CP was described for the first time in 1843, after a study was conducted of 47 children with a similar clinical status who suffered from seizures at birth.\\nCurrently, CP is defined as a group of postural and movement disorders that limit activities.\\nIt occurs due to non-progressive alterations in the development of the fetus’ or infant’s brain.1,2 According to World Cerebral Palsy, around 17 million people around the world have CP and the disorder affects two in every thousand live births.3-5 Generally, the diet of individuals with CP should be similar to that of healthy people, given that their needs involve main- taining adequate nutrition in terms of quantity and quality.6 However, in situations of gastroesophageal reflux or difficulties with chewing and swallowing, diet modifications are needed.7 It should be noted that the type and severity of CP can directly influence nutritional status.\\nMoreover, abnormal muscle tone can cause greater energy expenditure.8 National and international studies have shown that chil- dren and adolescents with CP have an increased risk of mal- nutrition.7-11 Thus, it is essential to identify risk factors for this clinical condition early in order to improve the progno- sis of these individuals.\\nEpidemiological investigations have presented different behaviors for the nutritional therapy of individuals with CP, ranging from recommending the use of nutritional supplements to the best route for administer- ing the diet.\\nThese indications directly influence the choice of nutritional therapy that will be used, as starting the ideal nutritional behavior early is essential to improve the progno- sis of the group in question.12-14 Despite the importance of this topic, there are a limited number of systematic review studies on the behaviors and influ- ence of nutritional interventions on nutritional outcomes, for example nutritional deficiencies and malnutrition, in cases of CP.\\nTherefore, the main objective of this review is to present the most suitable and effective nutritional interventions and indications for the nutritional treatment of children and ado- lescents with CP.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='7ef3ee90-894f-45b9-8a5f-b7b2aac2532f', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guide- lines,15 using studies that have assessed nutritional interventions, dietary characteristics, and recommended nutritional therapies for CP in infants.\\nThe protocol for this systematic review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) database (CRD 42020175068).', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='fe658f12-dfc5-4832-934c-b01dc7d7d798', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Articles, theses, and dissertations were chosen that used observational studies or clinical trials to assess the efficacy of nutritional interventions or therapies and their effect in children and adolescents (zero to 18 years old) with CP from around the world.\\nBooks, book reviews, editorials, review articles, and case reports were excluded.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='00eb68b5-d69a-4013-94d0-b011844d7b68', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Electronic searches were carried out in the Cochrane, Literatura Latino-Americana e do Caribe em Ciências da Saúde — Lilacs, Embase, United States National Library of Medicine — PubMed, Scientific Electronic Library Online — SciELO, Scopus, and Web of Science electronic databases, and in the lists of bibliographical references of the articles and other reviews on the subject, in order to identify works that were not indexed in the databases, but that would be important to include in this review (Figure 1)1.\\nPublished articles registered in the databases until October 2020 in Portuguese, English and Spanish, were included.\\nThey were identified using the descriptors (“children” OR “childhood”) AND (“nutritional therapy” OR “nutritional intervention” OR “nutrition” OR “nutritional support” OR “diet”) AND (“cerebral palsy” OR “cerebral injury”).', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='3b0cf48f-1458-40a2-ab6a-ca45b0f3865a', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Two independent reviewers identified, selected, and extracted the data from the eligible studies.\\nFirst, they screened the articles by reading the titles and abstracts.\\nThen they read the eligible ones in full, in order to make the final selection.\\nThe review- ers discussed the eligibility and exclusion criteria and defined', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='2baf2804-ad36-4249-8177-7348da939139', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Figure 1.\\nFlow diagram of literature search and selection criteria.\\nthe final selection by consensus.\\nSome relevant information (authors, year of publication, country of publication, sample size, study type, age and sex of the children, feeding route, nutritional recommendations used, and main results) were systematically organized on an Excel spreadsheet.\\nAll the ref- erences were managed using the Rayyan application, devel- oped by the Qatar Computing Research Institute (QCRI).16 The data were presented via descriptive tables containing the main results of the studies.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='12d8732d-1240-44ce-96c4-56d30918f75a', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='The risk of bias was assessed using the following proto- cols: the checklist for analytical cross-sectional studies,17 crit- ical appraisal of cohort studies, critical appraisal of case-con- trol studies, the Newcastle-Ottawa scale,18 and the Cochrane Collaboration tool for assessing risks of bias in clinical trials.19', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='a988b991-8780-4b36-9b5b-d31e8f4e0eae', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='n=178 Lilacs n=105 Embase n=437 PubMed n=519 SciELO n=01 Scopus n=847 Web of Science n=119', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='6e82078b-1839-4a71-813c-c3c125806f23', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Records identiﬁed through database searching (n=2,206)', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='43be88f4-c495-4c72-adbc-9dafe7de16d6', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Records after duplicates removed (n=1,425)', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='24666508-34ea-414d-aadf-87953085ca3d', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Records screened from databases (n=1,425)', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='3e541c09-38c6-4d3d-ab7c-f49ffdd6155e', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Full-text articles assessed for eligibility (n=33)', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='3dc29dbb-c0db-4264-a40a-bb22ba6377fc', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Additional studies identiﬁed from reference lists (n= 4)', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='8d91f02a-3af4-4faf-80f8-19c68b1326a6', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Total of full-text articles assessed for eligibility (n=37)', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='85b2de1c-3be4-47ca-9d36-566f69ce4dd0', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Reasons for exclusion after full reading – Infants without a diagnosis of CP (n=7) – Summary (n=5) – Case study (n=1) – Technical comment (n=1) – Articles without nutritional intervention (n=7) – Unavailability of access (n=1)', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='b410d58f-0dd3-48fa-96a1-c9d69cacffa0', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Studies included in qualitative synthesis (n=15) Cochrane', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='042b7c62-ddc1-4e40-a7f8-ca2ee72f828f', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'RESULTS']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='A total of 2,206 articles were identified, of which 1,425 were duplicates.\\nAfter the initial screening, 748 were excluded by reading the titles and abstracts.\\nThe researchers examined the references of the 33 articles chosen to read in full, which led to the identification of four more studies, resulting in 37 inclu- sions (Figure 1).\\nOf these publications, 15 were eligible for the study12-14,20-31 as they contained information about nutritional interventions or indications for nutritional therapies for infants with CP.\\nThe main reasons for exclusion were the following: infants with no diagnosis of CP (n=7), abstracts lacking infor- mation (n=5), case study (n=1), technical commentary (n=1), articles with no nutritional intervention (n=7), and not avail- able to access (n=1).\\nThe eligible studies were carried out in six countries: Australia,13,22,28,31 Brazil,23,24 the United States,27 Mexico,12,21,25 the United Kingdom,26,29,30 and Turkey.14,20 A predominance of cohort studies was verified, which accounted for seven publications,14,21,25-27,29,30 followed by three studies characterized as case-control,13,20,31 three cross-sectional studies,22-24 and two randomized clinical trials.12,28 There was a predominance of publications that addressed the types of spas- tic, dyskinetic and ataxic CP13,20-24,27-29,31 and five studies pre- sented information only on spastic CP.12,14,25,26,30 The studies analyzed involved a total of 658 children and adolescents, aged between zero and 18 years old, of both sexes, diagnosed with CP.\\nStudies published between 1990 and 2020 were included, with a predominance of publications between 2008 and 2020 (73%).\\nThe population was recruited through the tertiary healthcare network or through the institutions where the subjects were receiving or had received some type of care.\\nTwelve publications were identified in which the participants received their nutritional therapy at home and were monitored in hospital visits.12,13,20-24,27-30 In two studies, the participants received their nutritional therapy at home and were monitored in hospi- tal visits or home visits by the team responsible for the study,14,26 and only in one did the children and adolescents receive their nutritional therapy and monitoring at a hospital institution.25 In relation to the methodological quality of the studies, for the cross-sectional studies it was verified that all three (100%) publications clearly defined the inclusion criteria, they described the subjects and scenarios in detail, they measured exposure in a valid and reliable way, they used objective and standard criteria to measure the condition of the children, and they measured the results in a valid and reliable way.22-24 In only one publi- cation (33.3%) was it identified that strategies were used to address confounding factors22 and two studies (66.6%)22,24 used appropriate statistical analysis to address the confounding fac- tors.\\nNo study was excluded due to its methodological quality.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='6d95abe7-46df-4aa0-9052-5d4d1a632eea', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'RESULTS']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='According to the Newcastle-Ottawa scale used to assess methodological quality, the scores varied between 6 and 8, so all the articles had a low risk of bias.\\nThe main problems with the methodological quality of the cohort and case-control studies were related to category 2 (comparability between the exposed and non-exposed individuals), as 90% (n=9) of these did not address this.13,14,20,21,25-27,29-31 The risk of bias assessment of the clinical trials is summa- rized in Figure 2.32 Two clinical trials12,28 were assessed using Random sequence generation (selection bias) Allocation concealment (selection bias) Blinding of participants and personnel (performance bias) Blinding of outcome assessment (detection bias) Incomplete outcome data (attrition bias) Selective reporting (reporting bias)', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='5b120aa3-9064-4866-b7be-68a337a24e75', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'RESULTS', 'Other bias']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='100%75%50%25%0%', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='eea37ed4-c001-463e-a1e1-c1580c04250e', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'RESULTS', 'Other bias']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Low risk of bias Unclear risk of bias High risk of bias Figure 2.\\nRisk of bias for clinical trials using the Cochrane risk-of-bias tool for randomized trials (RoB 2).32', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='5a314859-54d5-4c2b-886c-af337a3e7e88', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'RESULTS', 'Other bias']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text=' | the Cochrane risk-of-bias tool for randomized trials (RoB 2).32 In the generation of a random sequence domain, only one of the studies12 described the random selection of the sample. For the concealed allocation domain, none of the studies clearly described the form of allocation concealment. For performance bias, although one of the studies28 reported being double blind, there were no details about the blinding of participants and of professionals, and it was classified as “uncertain risk of bias.” In the study of Leal-Martínez et al.,12 there was no mention of blinding of professionals or of participants, and it was classified as “high risk of bias”. Due to a sampling loss of around 15%, which could influence the statistical analyses of the outcomes, one of the studies was classified as having a high risk of attri- tion bias.28 Finally, all the studies included in this review were free of reports of selective outcomes, because this bias was one of the exclusion criteria. Figure 312,28 presents a detailed assess- ment for each domain of risk of bias in the studies. | This review identified nutritional interventions that used only the oral route in five articles12,14,20,21,26 and interventions that used only the enteral route in six publications,23,25,27-30 two of which used a nasogastric tube or gastrostomy25,27 and four of which used gastronomy. The other four publications used a combination of the oral and enteral routes.13,22,24,31 Six eligible studies proposed some type of nutritional supplementation for CP (Table 1).12-14,20-31 | With respect to the motor skills and limitations in the feeding process of the children and adolescents, nine publica- tions12-14,20,25,28-31 used the Gross Motor Function Classification System (GMFCS) criterion to analyze these and in four studies all the children’s ability to eat was severely compromised.13,25,28,31 Six publications did not mention the use of criteria to classify the motor function of children and adolescents with CP. One publication employed the Development of Care for Individuals with Serious Deficiencies (Dash-2) method,21 and four studies applied no methodologies to calculate motor func- tion, basing their assessments on brain damage and nutritional status diagnoses.23,24,27,29 Regarding the intervention based on daily elemental iron supplementation indicated by García-Contreras et al.,25 no inherent benefits of its used were demonstrated; however, there was an improvement in the nutritional status and an increase in the weight of the children and adolescents. After supplement- ing the normal diet of children with CP using a hypercaloric and hyperproteic dietary formula with a high biological value, combined with oral motor physiotherapy, Barrón-Garza et al.21 identified an increase in weight, which was significantly higher for those who carried out their physiotherapy at the clinic com- pared to those who did it at home with their parents. Kibirige26 identified greater weight gain in the infants who, besides a normal diet, received supplementation with a hyperca- loric and normoproteic formula. Vernon-Roberts et al.30 found a significant increase in body weight and other anthropometric measures after supplementing children with CP with a hypo- caloric and nutritionally complete enteral formula. Brant et al.23 found a significant increase in body weight from using a nutritionally complete normocaloric formula, maize flour, and oatmeal in combination with a normal diet or a diet composed of soybean oil, albumin, sugar, and soymilk, together with a mineral and vitamin supplement. Leal-Martínez et al.12 identified that the diet based on homemade shakes with functional foods (a large amount of vegetables, fruits, cereals, roots, and fish) was positively reflected in improved motor parameters such as walking and standing up. Two publications analyzed the textures and consistencies of the foods provided to children with CP. Arslan et al.20 note that foods with liquid or pasty textures are unable to meet the caloric and nutritional needs of children with CP. For Benfer et al.,22 children with CP are unable to eat many foods due to their textures, but such modifications guarantee a more effi- cient calorie intake, even if it is densely inferior. Although eight studies did not seek to evaluate the textures and consistencies of the foods provided using specific methods,12,13,23,27-31 general motor functions served as parameters to define them. In those cases, enteral feeding was often related to severe cases of CP in\\n | --- | --- | ---\\n | + ? | ? ? | - ? | - ? | + - | + + | ? ?\\n | --- | --- | --- | --- | --- | --- | ---\\n', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='8f8337ae-d6be-4e85-95bd-a77144db42c9', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'RESULTS', 'Other bias']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Leal-Martínez et al.12 Savage et al.28 Figure 3.\\nSummary of risk of bias.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='15298b19-36b6-40bf-9728-6fc0f7a52479', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'RESULTS', 'Other bias']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='children and adolescents, and even for those who ate orally, their care was intensified in order to avoid dysphagia and choking.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='5a1434d7-f3c7-4b11-b118-3f9262c791a3', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'DISCUSSION']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text=' | The results of this study indicate that children and adolescents with CP have a more compromised nutritional status that those who do not have the disorder. Nutritional supplementation of a normal diet leads to weight gain and improved nutritional status in this group. We observed that enteral feeding was used as the main behavior for nutritional treatment. Moreover, the modification of the texture of foods, transforming them into purees and/or semi-solids, was essential for improving the nutritional status of this infant group and for better adapting them to oral consumption. In a case-control study carried out in Turkey using 85 chil- dren with CP, Arslan et al.20 identified a greater prevalence of malnutrition and a lower height in children with CP than in the control group. The case-control study of Arrowsmith et al.33 Table 1. Results of studies. | carried out in Australia using 167 children corroborates the results of Arslan et al.,20 given that the outcome of their study showed that children with CP had a lower body weight, height, and body fat percentage than children without CP. It is sug- gested that these results are due to the difficulties with chew- ing and swallowing and the gastrointestinal problems that this population often has.7 Another point to mention is that the different feeding routes can directly influence the nutritional therapy of children with CP.34 Sullivan et al.29 reported that patients who use gas- trostomy (GTT) had a greater daily dietary intake, achieving 69% of the recommended energy value, while those fed orally achieved 57% of the recommended energy intake, with less than 10% difference being identified between the two groups. In line with the previous findings, Caselli et al.24 analyzed 54 patients with CP fed via different routes — 25 fed via GTT and 29 orally — and concluded that there was no significant difference regarding the prevalence of malnutrition in relation to weight or body mass index. Thus, it is suggested that children\\n | --- | ---\\n | Reference | Interventions (feeding route, nutritional recommendations used)\\n | Arslan et al.,20 | Oral feeding. Normal diet for the children in the control group. Differentiated consistency diet for the children in the orally fed case group.\\n | Barrón-Garza et al.,21 | Oral feeding for 3 years and 9 months. Hypercaloric diet, with 50% carrying out oral motor therapy with their parents at home and the other half doing so at a clinic.\\n | Benfer et al.,22 | Oral feeding (n=87) and enteral feeding (n=12).\\n | Brant et al.,23 | Enteral feeding via gastrostomy, with a mean monitoring period of 5.9 months.\\n | Caselli et al.,24 | Enteral feeding via gastrostomy (n=25) and oral feeding (n=29).\\n | García-Contreras et al.,25 | Enteral feeding via nasogastric tube (n=8) and gastrostomy (n=5) for 4 weeks. Use of a lactose- free infant formula (Nestlé®), adding corn syrup to the formula to increase the energy density.\\n | Kibirige26 | Oral feeding for 8 weeks. 4 children received liquid nutrition and supplementation.\\n | Leal-Martínez et al.,12 | Oral feeding. Use of 3 liquid diets, 2 administered at breakfast and 1 at dinner. Follow-up group (FG) (n=10): normal diet. Control group (CG) (n=10): vermifugated and received a nutritional therapy recommended by the WHO (2010). Intervention group (IG) (n=10): vermifugated and received the Nutritional Support System (NSS).\\n | Sanders et al.,27 | Enteral feeding via nasogastric tube (n=4) and gastrostomy (47) for 6 months. The dietary formulas used were Complete Modified Formulas (Sandoz) or lsocal (Mead Johnson), each one providing 1 kcal/mL.\\n | Savage et al.,28 | Enteral feeding by nasogastric tube (n=1) and percutaneous endoscopic gastrostomy (n=12). Standard enteral formula based on casein and another with 50% whey and 50% total casein protein for 1 week (n=7), and a formula based on partially hydrolyzed whey protein (n=6) .\\n | Schoendorfer et al.,31 | Children with CP (case group): percutaneous (n=9) and oral (12) enteral feeding.\\n | Schoendorfer et al.,13 | Enteral (n=9) and oral (n=15) feeding.\\n | Soylu et al.,14 | Oral feeding for 6 months.\\n | Sullivan et al.,29 | Enteral feeding by gastrostomy for 12 months.\\n | Vernon-Roberts et al.,30 | Enteral feeding by gastrostomy for 6 months. An enteral feeding of low caloric energy (Kcal), complete with micronutrients and rich in fiber, was administered.\\n', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='b5f75e76-bda0-4d4e-88ec-c0f67c9f5d4a', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'DISCUSSION']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='with GTT experience less energy expenditure as a result of the lower demand for energy than those fed orally.35,36 Regarding the use of supplementation, we observed an improvement in the nutritional status of the children that used nutritional supplementation, especially when the weight gain factor is analyzed.23,25,27,28 From this perspective, Vernon-Roberts et al.30 carried out a cohort study in the United Kingdom of 14 children with CP and identified body weight gain and lin- ear growth as a result of supplementation with a hypercaloric enteral formula (0.75 kcal/mL) that was nutritionally com- plete and rich in fibers.\\nThe randomized clinical trial carried out in Mexico by Leal-Martínez et al.12 found that nutritional supplementation in the form of homemade shakes with func- tional foods (a large amount of vegetables, fruits, cereals, roots and fish) significantly improved the motor function of children with CP.\\nIn a study on the nutritional management of children with CP, Bell et al.35 note that first-line treatment involves the inclusion of oral nutritional support adapted to the individual needs of each child, provided they can consume a diet orally without the risk of aspiration or greater complications.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='bf0a8420-0575-4cb5-8dd9-6290ebe4c142', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'DISCUSSION']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='The administration of nutritional support should be adapted to the physical status of the children, their capacity to consume foods, and the possibility of oral ingestion, as their diet needs to be adapted in order to maximize dietary efficiency and reduce fatigue during meals, thus leading to a greater dietary intake.10,35 For this, the use of enteral nutrition should be considered when oral feeding does not satisfy their needs and in the case of severe malnutrition and deglutination disorder.\\nThis can also be used to complement oral nutrition.29,35,37 It is important to stress that nutritional supplementation can improve the prognosis of the group studied and provide a better quality of life.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='9593ae48-7b5d-470e-87cb-492a60aea7d6', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'DISCUSSION']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='It is worth highlighting that in the absence of specific nutri- tional recommendations for children with CP, it is appropriate to use guidelines and nutritional evidence for children with neurological disorders.\\nIt also warrants mentioning that mal- nutrition and nutritional deficiencies in the population studied can be influenced by nutritional and non-nutritional factors.38 In their guide “Recommendations for Nutritional Management of Children with Neurological Impairment (NI),” the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) discusses recommendations regarding the nutri- tional needs of children with intellectual impairment and pro- vides alternative recommendations for children with CP, which can be used when there are no specific parameters for this pop- ulation.39 However, as an alternative for supplementation, foods rich in nutrients that are lacking in the patient can be added to the diet.\\nNutritional deficiency should be diagnosed via labora- tory tests and it is only after identifying a particular deficiency that some type of supplementation should be prescribed.35,40 Choosing the right nutritional formula is extremely import- ant for the effectiveness of the nutritional treatment of children with CP.\\nA variety of products is used for nutrition, including polymeric, semi-elemental, and elemental formulas adapted to every need and different life phases.\\nMost enteral foods are formulated to serve as a source of complete nutrition, provid- ing all the nutrients needed for the day-to-day maintenance of the body.41 Vernon-Roberts et al.30 note that nutritional treat- ment should be based on the provision of a diet with a standard energy density calculated based on the patient’s age.\\nThis should evolve to a high-density formula when the child does not tol- erate large quantities of a food.\\nFinally, a lower energy density formula can be used in those who present more rapid weight gain.\\nThus, it is stressed that the nutritional behavior should be individualized and prescribed according to the particular- ities of each child.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='7034273a-6fcc-482a-b307-4cb72e67125c', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'DISCUSSION']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Some nutritional interventions for CP can be carried out by modifying the textures/consistencies of foods.\\nSuch alter- ations may be recommended to provide safety and efficiency during meals or to stimulate the development of motor oral skills in this population.42 In a study of 99 children with CP, Benfer et al.22 identified that modifying the texture of foods/ fluids in 39% of the population studied led to an improvement in energy and nutritional intake and more autonomy among the children.\\nThe authors also showed that the children with modified diets had greater gross motor limitations and were therefore unable to feed themselves with foods in their normal textures.\\nSimilarly, Arslan et al.20 identified that children with CP who consumed liquid, pasty, or minced diets achieved greater growth and nutritional status, as well as having fewer dietary problems.\\nThus, exploring the textures of the foods consumed by children with CP will support better management decisions regarding the nutritional therapy and recovery of these patients.\\nThis review study has some limitations.\\nThe summary of the results of studies using different methodological approaches was complex and impeded a meta-analysis from being carried out.\\nOn the other hand, the age range (0–18 years old) makes it hard to compare and summarize the results.\\nThese limitations notwithstanding, we adopted consistent methodological pro- cedures performed by independent reviewers and assessed the studies that fulfilled the eligibility criteria in order to reduce the possibility of bias.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='b94390ad-a75d-4a58-aa54-86237943de16', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'DISCUSSION']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='It is concluded that children and adolescents with CP have a greater risk of malnutrition and that the use of nutritional sup- plementation may help with weight gain.\\nIn addition, enteral nutrition and modification of food texture have been used to improve the nutritional status of this group.\\nThe nutritional treatment of CP should be multi-factorial and aim to promote a better quality of life and improvement in the prognosis of these individuals, given that diet is an essential factor for the recovery and repair of these patients.\\nTo guarantee the success of interventions, nutritional status should be periodically mon- itored by a multidisciplinary team.\\nFor this, we recommend conducting more studies on nutritional interventions in chil- dren and adolescents with CP, given that more information is needed to achieve precise and adequate nutritional behavior for this target population.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='a390189f-2d83-4b4c-bce0-47b21f9c7b81', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'DISCUSSION', 'Conflict of interests']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='The authors declare there is no conflict of interests.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='b077e806-8d0f-4280-beaa-29fe35510f21', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'DISCUSSION', 'Authors’ contribuition']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Study design: Silva DCG, Cunha MSB.\\nData collection: Silva DCG, Santana AO, Alves AMS. Data analysis: Silva DCG, Cunha MSB, Santos MP.\\nManuscript writing: Silva DCG, Santana AO, Alves AMS. Manuscript revision: Silva DCG, Cunha MSB, Santos MP.\\nStudy supervision: Silva DCG, Santos MP.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='423f461f-5329-4103-ab0b-f4836498ea95', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'DISCUSSION', 'Funding']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='The survey received funding by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) — pro- cess no 443018/2019-7.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='f2eda395-2df2-49e2-81db-c81b80ae30cc', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'DISCUSSION', 'Declaration']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='The database that originated the article is available with the corresponding author.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='eca36f7e-4c9a-4d5a-bba5-8a6c0d41848b', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Ministério da Saúde.\\nSecretaria de Atenção à Saúde.\\n10.\\nMarques JM, Sá LO.\\nFeeding a child with cerebral palsy:', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='16cca17b-c9b5-4f20-a9d1-ae5f1f9ac931', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Departamento de Ações Programáticas Estratégicas.\\nDiretrizes de atenção à pessoa com paralisia cerebral.\\nBrasília: Ministério da Saúde; 2013. parents’ difficulties.\\nRev Enf Ref.\\n2016;4:11-9. http://dx.doi.\\norg/10.12707/RIV16041', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='f52f2023-e82e-4b66-815f-1763d29196c2', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '11. Kuperminc MN, Stevenson RD']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Growth and nutrition 2.\\nRosenbaum P, Paneth N, Leviton A, Goldstein M, Bax M, Damiano D, et al.\\nA report: the definition and classification of cerebral palsy April 2006.\\nDev Med Child Neurol Suppl.\\n2007;109:8-14.\\nPMID: 17370477 disorders in children with cerebral palsy.\\nDev Disabil Res Rev.\\n2008;14:137-46. https://doi.org/10.1002/ddrr.14 12.\\nLeal-Martínez F, Franco D, Peña-Ruiz A, Castro-Silva F,', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='0b8a26f4-dd90-4547-bb06-c2c0213af155', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '3. O’Shea TM']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Diagnosis, treatment, and prevention of cerebral', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='345cd6b1-346a-44e0-8cdb-b507b3bef238', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '3. O’Shea TM']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text=' | palsy. Clin Obstet Gynecol. 2008;51:816-28. https://doi. org/10.1097/GRF.0b013e3181870ba7 Christine C, Dolk H, Platt MJ, Colver A, Prasauskiene A, |  | Escudero-Espinosa AA, Rolón-Lacarrier OG, et al. Effect of a nutritional support system (diet and supplements) for improving gross motor function in cerebral palsy: an exploratory randomized controlled clinical trial. Foods. 2020;9:1449. https://doi.org/10.3390/foods9101449\\n | --- | --- | ---\\n | Krägeloh-Mann I, et al. Recommendations from the SCPE collaborative group for defining and classifying cerebral palsy. Dev Med Child Neurol Suppl. 2007;109:35-8. https:// doi.org/10.1111/j.1469-8749.2007.tb12626.x. | 13. | Schoendorfer N, Tinggi U, Sharp N, Boyd R, Vitetta L,\\n', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='4ab5b198-86cb-493d-9127-6c20e4cb74a1', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '5. World Cerebral Palsy Day [homepage on the Internet]']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='About Davies SM.\\nProtein levels in enteral feeds: do these meet requirements in children with severe cerebral palsy?\\nBr J Nutr.\\n2012;107:1476-81. https://doi.org/10.1017/ S0007114511004533 world cerebral palsy day [cited 2020 Nov 20].\\nAvailable from: https://worldcpday.org/ 14.\\nSoylu OB, Unalp A, Uran N, Dizdarer G, Ozgonul FO, Conku 6.\\nGomes V, Campos MA, Gregório MJ.\\nRelação entre função motora, competências alimentares e peso de crianças e adolescents com paralisia cerebral.\\nActa Port Nutr.\\n2016;6:20-3. https://dx.doi.org/10.21011/apn.2016.0604 A, et al.\\nEffect of nutritional support in children with spastic quadriplegia.\\nPediatr Neurol.\\n2008;39:330-4. https://doi.\\norg/10.1016/j.pediatrneurol.2008.07.020 15.\\nPage MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='7e964be8-867e-4744-a89b-15e4bcac04ba', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Feeding disorders in children with gastro-esophageal reflux disease.\\nPro Fono.\\n2007;19:59-66. https://doi.org/10.1590/s0104-56872007000100007 TC, Mulrow CD, et al.\\nThe PRISMA 2020 statement: an updated guideline for reporting systematic reviews.\\nInt J Surg.\\n2021;88:105906. https://doi.org/10.1016/j.\\nijsu.2021.105906 16.\\nOuzzani M, Hammady H, Fedorowicz Z, Elmagarmid A.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='4c88e109-24ee-45cc-8fb2-db12da1eebcf', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='8. Fung EB, Samson-Fang L, Stallings VA, Conaway M, Liptak G, Henderson RC, et al.\\nFeeding dysfunction is associated with poor growth and health status in children with cerebral palsy.\\nJ Am Diet Assoc.\\n2002;102:361-73. https://doi.org/10.1016/ s0002-8223(02)90084-2 Rayyan-a web and mobile app for systematic reviews.\\nSyst Rev.\\n2016;5:210. https://doi.org/10.1186/s13643- 016-0384-4', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='ffdb70ce-3346-463d-ac91-a5a8cf9f525b', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '17. Joanna Briggs Institute [homepage on the Internet]']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='The M, et al [homepage on the Internet].\\nThe Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses [cited 2019 Apr 20].\\nAvailable from: http://www.ohri.ca/programs/clinical_epidemiology/ oxford.asp 9.\\nAdamu AS, Sabo UA, Gwarzo GD, Belonwu RO.\\nNutritional status in cerebral palsy: a cross-sectional comparative survey of children in Kano, Nigeria.\\nNiger Postgrad Med J.\\n2018;25:156-60. https://doi.org/10.4103/npmj.npmj_67_18 Joanna Briggs Institute Critical Appraisal tools for use in JBI Systematic Reviews.\\nChecklist for qualitative research [cited 2019 Apr 20].\\nAvailable from: https://jbi.global/sites/ default/files/2019-06/JBI_Critical_Appraisal-Checklist_for_ Qualitative_Research2017.docx 18.\\nWells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos 19.\\nHiggins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ,', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='3a511116-54b5-4bfb-9dfc-87f9225d4998', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '17. Joanna Briggs Institute [homepage on the Internet]']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='et al [homepage on the Internet].\\nCochrane Handbook for Systematic Reviews of Interventions version 6.0 [cited 2019 Apr 20].\\nAvailable from: www.training.cochrane.org/handbook 20.\\nArslan SS, Ilgaz F, Demir N, Karaduman AA.\\nThe effect of', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='2df38d93-cb2e-4546-8da4-512b36928cce', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '17. Joanna Briggs Institute [homepage on the Internet]']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='the inability to intake chewable food texture on growth, dietary intake and feeding behaviors of children with cerebral palsy.\\nJ Dev Phys Disabil.\\n2018;30:205-14. https:// doi.org/10.1007/s10882-017-9580-y 21.\\nBarrón-Garza F, Robles-Montiel A, Elizondo-Vázquez JB,', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='e6c58825-c326-411a-b1f6-608eef735f63', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '17. Joanna Briggs Institute [homepage on the Internet]']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Riquelme-Heras MA, Riquelme-Heras H. Oromotortherapy and dietary supplement, improve feeding skills and nutrition of patients with cerebral palsy.\\nRev Esp Nutr Comunitária.\\n2017;23:160-5.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='e19e0993-dfa4-4042-923e-63d04da51f2b', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '17. Joanna Briggs Institute [homepage on the Internet]']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='22.\\nBenfer KA, Weir KA, Ware RS, Davies PS, Arvedson J, Boyd', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='c42f836f-207f-45bf-8e54-57f2dab7285a', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '17. Joanna Briggs Institute [homepage on the Internet]']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='RN, et al.\\nParent-reported indicators for detecting feeding and swallowing difficulties and undernutrition in preschool- aged children with cerebral palsy.\\nDev Med Child Neurol.\\n2017;59:1181-7. https://doi.org/10.1111/dmcn.13498 23.\\nBrant CQ, Stanich P, Ferrari Jr AP.\\nImprovement of children’s', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='f6888993-5064-4038-acd5-e9edb292d5ce', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '17. Joanna Briggs Institute [homepage on the Internet]']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='nutritional status after enteral feeding by PEG: an interim report.\\nGastrointest Endosc.\\n1999;50:183-8. https://doi.\\norg/10.1016/s0016-5107(99)70222-1 24.\\nCaselli TB, Lomazi EA, Montenegro MA, Bellomo-Brandão', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='43fd7e47-8a8f-44c9-b185-2e58c05e28dc', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '17. Joanna Briggs Institute [homepage on the Internet]']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='MA.\\nComparative study on gastrostomy and orally nutrition of children and adolescents with tetraparesis cerebral palsy.\\nArq Gastroenterol.\\n2017;54:292-6. https://doi.org/10.1590/ S0004-2803.201700000-48 25.\\nGarcía-Contreras AA, Vásquez-Garibay EM, Romero-Velarde', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='ed24741d-4ac7-4c58-880c-e645f9803fb1', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '17. Joanna Briggs Institute [homepage on the Internet]']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='E, Ibarra-Gutiérrez AI, Troyo-Sanromán R, Sandoval-Montes IE.\\nIntensive nutritional support improves the nutritional status and body composition in severely malnourished children with cerebral palsy.\\nNutr Hosp.\\n2014;29:838-43. https://doi.org/10.3305/nh.2014.29.4.7247', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='d3e09e2e-86c0-471d-8cb1-7c827a5b9f9e', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Kibirige MS. Weight gain and severe cerebral palsy.\\nJ Nutr Med.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='65340845-c203-4e92-ae7f-e0a1a83cffdb', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='1992;3:137-43. https://doi.org/10.3109/13590849208997971 27.\\nSanders KD, Cox K, Cannon R, Blanchard D, Pitcher J,', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='ebb32e00-c6de-4b51-bea5-154bb909e793', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Papathakis P, et al.\\nGrowth response to enteral feeding by children with cerebral palsy.\\nJPEN J Parenter Enteral Nutr.\\n1990;14:23-6. https://doi.org/10.1177/014860719001400123 28.\\nSavage K, Kritas S, Schwarzer A, Davidson G, Omari T.', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='6d4a8c6d-e573-4377-b98d-2e2ec5f4150d', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Whey- vs casein-based enteral formula and gastrointestinal function in children with cerebral palsy.\\nJPEN J Parenter Enteral Nutr.\\n2012;36(Suppl1):118S-23S.\\nhttps://doi.\\norg/10.1177/0148607111428139 29.\\nSullivan PB, Juszcczak E, Bachlet AM, Lambert B, Vernon-', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='3b1904b5-c906-4f83-84c3-a83a94a51c05', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Roberts A, Grant HW, et al.\\nGastrostomy tube feeding in children with cerebral palsy: a prospective, longitudinal study.\\nDev Med Child Neurol.\\n2005;47:77-85. https://doi.\\norg/10.1017/s0012162205000162 30.\\nVernon-Roberts A, Wells J, Grant H, Alder N, Vadamalayan', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='38001836-5cc9-4d8f-b546-942ef6a8dee9', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='B, Eltumie M, et al.\\nGastrostomy feeding in cerebral palsy: enough and no more.\\nDev Med Child Neurol.\\n2010;52:1099- 105. https://doi.org/10.1111/j.1469-8749.2010.03789.x 31.\\nSchoendorfer N, Tinggi U, Sharp N, Boyd R, Vitetta L, Davies', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='96c1f99d-14a9-4c0e-bc36-c161acf567e8', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='SM.\\nMicronutrient intakes in enterally and orally fed children with severe cerebral palsy.\\nE Spen Eur E J Clin Nutr Metab.\\n2011;6:e259-63.\\nhttps://doi.org/10.1016/j.eclnm.2011.09.003 32.\\nHiggins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='dc6863c0-d452-4d00-bbd5-67c788b2ff9b', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='AD, et al.\\nThe Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.\\nBMJ.\\n2011;343:d5928.\\nhttps://doi.org/10.1136/bmj.d5928 33.\\nArrowsmith FE, Allen JR, Gaskin KJ, Somerville H, Birdsall J,', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='1cfaf943-e6e7-42bf-98a9-404287b04f12', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Barzi F, et al.\\nNutritional rehabilitation increases the resting energy expenditure of malnourished children with severe cerebral palsy.\\nDev Med Child Neurol.\\n2012;54:170-5. https:// doi.org/10.1111/j.1469-8749.2011.04166.x 34.\\nStrauss DJ, Shavelle RM, Anderson TW.\\nLife expectancy of', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='cd2c44b5-2374-43fc-8b13-c15fe56e9044', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='children with cerebral palsy.\\nPediatr Neurol.\\n1998;18:143-9. https://doi.org/10.1016/s0887-8994(97)00172-0', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='b6b49d0a-f478-445e-9ef4-d4b9b3083847', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS', '35. Bell KL, Samson-Fang L']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Nutritional management of children with cerebral palsy.\\nEur J Clin Nutr.\\n2013;67 Suppl2:S13-6.\\nhttps://doi.org/10.1038/ejcn.2013.225 36.\\nCaselli TB, Lomazi EA, Montenegro MA, Bellomo-', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='78b880cb-60a1-49c0-973c-7d0f5b99d5b3', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS', '35. Bell KL, Samson-Fang L']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Brandão.\\nAssessment of nutritional status of children and adolescents with spastic quadriplegic cerebral palsy.\\nArq Gastroenterol.\\n2017;54:201-5. https://doi.org/10.1590/ S0004-2803.201700000-32', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='035bdb37-d16c-4540-8d17-46b1d26c11bb', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS', '37. ASPEN Board of Directors and the Clinical Guidelines Task']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Force.\\nGuidelines for the use of parenteral and enteral nutrition in adult and pediatric patients.\\nJPEN J Parenter Enteral Nutr.\\n2002;26(1 Suppl):1SA-138SA.\\nPMID: 11841046 38.\\nPenagini F, Mameli C, Fabiano V, Brunetti D, Dilillo D, Zuccotti', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='1d62d2ae-948e-465f-8cb9-4bf23edef9e5', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS', '37. ASPEN Board of Directors and the Clinical Guidelines Task']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='GV.\\nDietary intakes and nutritional issues in neurologically impaired children.\\nNutrients.\\n2015;7:9400-15. https://doi.\\norg/10.3390/nu7115469 39.\\nRomano C, van Wynckel M, Hulst J, Broekaert I, Bronsky', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='670c4b55-13a7-4565-8383-78f91a256572', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS', '37. ASPEN Board of Directors and the Clinical Guidelines Task']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='J, Dall’Oglio L, et al.\\nEuropean Society for Paediatric Gastroenterology, hepatology and nutrition guidelines for the evaluation and treatment of gastrointestinal and nutritional complications in children with neurological impairment.\\nJ Pediatr Gastroenterol Nutr.\\n2017;65:242-64. https://doi.org/10.1097/MPG.0000000000001646 40.\\nHillesund E, Skranes J, Trygg KU, Bøhmer T. Micronutrient status', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='6f2209f6-716a-4b97-b230-23ca535aa288', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS', '37. ASPEN Board of Directors and the Clinical Guidelines Task']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='in children with cerebral palsy.\\nActa Paediatr.\\n2007;96:1195-8. https://doi.org/10.1111/j.1651-2227.2007.00354.x 41.\\nBraegger C, Decsi T, Dias JA, Hartman C, Kolacek S, Koletzko', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='eccdf153-76ff-4e02-8ab0-09da55bffe93', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS', '37. ASPEN Board of Directors and the Clinical Guidelines Task']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='B, et al.\\nPractical approach to paediatric enteral nutrition: a comment by the ESPGHAN committee on nutrition.\\nJ Pediatr Gastroenterol Nutr.\\n2010;51:110-22. https://doi.\\norg/10.1097/MPG.0b013e3181d336d2', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='ca795a9d-ab90-454c-9c3b-c6eb42279fe5', embedding=None, metadata={'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS', '37. ASPEN Board of Directors and the Clinical Guidelines Task', '42. Dietitians Association of Australia']}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='The Speech Pathology Association of Australia Limited.\\nTexture-modified foods and thickened fluids as used for individuals with dysphagia: Australian standardised labels and definitions.\\nNutr Diet.\\n2007;64:S53-76.\\nhttps://doi.org/10.1111/j.1747-0080.2007.00153.x © 2023 Sociedade de Pediatria de São Paulo.\\nPublished by Zeppelini Publishers.\\nThis is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n')]"
      ]
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "documents = []\n",
    "for block in blocks:\n",
    "    metadata = []\n",
    "    \n",
    "    for item in block.parent_text().split(\">\"):\n",
    "        metadata.append(item.strip())\n",
    "    documents.append(Document(text=block.to_text(), metadata={\"metadata\": metadata}))\n",
    "documents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "---\n",
      "Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review > M.Y Jayachandra, R. Gayathiri, C.N.Aruna, Padma K. Bhat, P.M. Arumugam\n",
      "Department of Public Health Dentistry, Rajarajeswari Dental College and Hospital, Bengaluru, Karnataka, India\n",
      "---\n",
      "Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review > ABSTRACT\n",
      "Background: The burden of oral diseases is increasing, which constitute a major public health problem.\n",
      "The use of probiotics as an adjuvant, along with routine dental care practice by an individual, can produce additional benefits in the maintenance of one’s oral health.\n",
      "The study aimed to investigate the effect of Bifidobacterium as a probiotic on oral health.\n",
      "---\n",
      "Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review > ABSTRACT > Address for correspondence:\n",
      "Dr. R. Gayathiri, Rajarajeswari Dental College and Hospital, No 14, Ramohalli Cross, Mysore Road, Kumbalgodu, Bengaluru ‑ 560 074, Karnataka, India.\n",
      "E‑mail: gayuharin95@gmail.\n",
      "com\n",
      "---\n",
      "Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review > ABSTRACT > Address for correspondence:\n",
      "Material and Methods: Six databases and registers were searched from the start of the database to December 2021 without any restrictions.\n",
      "Randomized controlled trials (RCTs) evaluating the clinical effects of Bifidobacterium as a probiotic on oral health were included in the study.\n",
      "The Preferred Reporting Items for Systematic Reviews and Meta‑analyses (PRISMA) guidelines were followed to conduct this systematic review.\n",
      "The included studies were analyzed for the risk of bias using the Cochrane risk‑of‑bias tool for randomized trial (RoB 2) tool as well as quality of available evidence using GRADE criteria.\n",
      "Results: From the 22 qualified studies, four studies showed non‑significant results.\n",
      "There was a high risk of bias in 13 studies and some concerns of bias in nine studies.\n",
      "No adverse effects were reported, and the quality of available evidence was moderate.\n",
      "Conclusion: The effect of Bifidobacterium on oral health is questionable.\n",
      "Further high‑quality RCTs are required on the clinical effects of bifidobacteria and also the optimum level of probiotic needed, and ideal mode of administration to provide oral health benefits.\n",
      "Furthermore, synergistic effects of the combined use of various strains of probiotics need to be studied.\n",
      "---\n",
      "Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review > ABSTRACT > Address for correspondence:\n",
      "Keywords: Bifidobacterium, oral health, probiotics\n",
      "---\n",
      "Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review > INTRODUCTION\n",
      "Recently, there is a growing interest in the use of probiotic products for restoring dysbiotic microbiota.\n",
      "[1] The Food and Agriculture Organization FAO and the World Health Organization (WHO) in 2001 defined probiotics as “live microorganisms which when administered in adequate amounts confer a health benefit on the host.\n",
      "”[2] Because of their potential health‑promoting attributes, probiotic supplements are usually directed towards Lactobacilli and/or bifidobacteria.\n",
      "The beneficial effects may result from the suppression of harmful microorganisms or stimulation of organisms which contribute positively to the nutrition and health of human beings and animals.\n",
      "The extent to which this may be achieved can be difficult to assess.\n",
      "[3] Probiotic effects are strain specific; thus, each individual bacterial strain must be tested separately for the health This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution‑NonCommercial‑ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non‑commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.\n",
      "---\n",
      "Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review > INTRODUCTION > Access this article online\n",
      "Website: www.drj.ir www.drjjournal.net www.ncbi.nlm.nih.gov/pmc/journals/1480 How to cite this article: Jayachandra MY, Gayathiri R, Aruna CN, For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com\n",
      "---\n",
      "Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review > INTRODUCTION > Access this article online\n",
      "Bhat PK, Arumugam PM.\n",
      "Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review.\n",
      "Dent Res J 2023;20:32.\n",
      "---\n",
      "Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review > INTRODUCTION > Access this article online\n",
      "1© 2023 Dental Research Journal | Published by Wolters Kluwer - Medknow\n",
      "---\n",
      "Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review > INTRODUCTION > Access this article online\n",
      "benefit in question, and the effects described for one strain cannot be directly applied to others.\n",
      "[4] Bifidobacteria occur naturally in the oral cavity and are among the most predominant anaerobic bacteria within the intestinal lumen.\n",
      "[5] It is generally thought that bifidobacteria have combined local and systemic effects involving adhesion, co‑aggregation, competitive inhibition, production of organic acids and bacteriocin‑like compounds, and immune modulation.\n",
      "[6] A body of evidence suggests that bifidobacteria play a critical role in maintaining the equilibrium of the normal gut flora, and a number of probiotic‑induced benefits on general health have been proposed, such as reduced susceptibility to infections, reduction of allergies and lactose intolerance, as well as lowered blood pressure and serum cholesterol values.\n",
      "[7] In vitro studies using bifidobacteria have demonstrated beneficial effects against oral pathogens.\n",
      "[8‑22] Although various experimental studies support the beneficial effect of Bifidobacterium on oral pathogens and oral diseases such as dental caries, gingivitis and periodontitis other clinical trials have failed to show similar results.\n",
      "---\n",
      "Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review > Objectives\n",
      "The burden of oral diseases is increasing, which constitutes a major public health problem.\n",
      "The use of probiotics as an adjuvant, along with routine dental care practice by an individual, can produce additional benefits in the maintenance of one’s oral health.\n",
      "However, short‑term trials focusing on the clinical effects of probiotics on oral health have not been reviewed in an evidence‑based manner.\n",
      "Our aim was to systematically assess the available evidence from the randomized controlled trials (RCTs) on the benefits Bifidobacterium on oral health.\n",
      "---\n",
      "MATERIALS AND METHODS > Protocol development and registration\n",
      "Before starting the systematic review, the study protocol was registered on the PROSPERO database (http://www.crd.york.ac.uk/PROSPERO, ID: CRD42022306243).\n",
      "The preferred reporting items for systematic reviews and meta‑analyses (PRISMA 2020)[23,24] was used.\n",
      "Since it is a systematic review, ethical approval was not taken.\n",
      "---\n",
      "MATERIALS AND METHODS > Eligibility criteria\n",
      "The criteria were established using PICOS (Participants, Interventions, Comparators, Outcomes, and Study design) approach.\n",
      "Randomized clinical trials investigating the effect of Bifidobacterium as a probiotic on oral health conditions were included in the study.\n",
      "No language and publication date restrictions were imposed.\n",
      "Accepted manuscripts were also included.\n",
      "Participants without any age restrictions were included.\n",
      "Participants should receive probiotics containing Bifidobacterium in any form, such as milk, curd, yogurt, ice cream, or lozenges, in any dosage and should be compared with participants who received a placebo, control, or no interventions at all.\n",
      "The outcome parameters included Streptococcus, Lactobacillus, and Porphyromonas gingivalis count in saliva and plaque, occurrence of dental caries in deciduous and permanent teeth, occurrence of periodontitis.\n",
      "Studies without human participants, control or placebo groups, <1 week of intervention, and reviews were excluded from the study.\n",
      "---\n",
      "MATERIALS AND METHODS > Information sources and search strategy\n",
      "Clinical trials were identified and included in this study using various electronic databases and registers such as (MEDLINE, CENTRAL, Scopus, Web of Science, Cochrane library, and Clinical Trials Registry).\n",
      "The search was from the beginning of each database and registers till December 2021. No restrictions were imposed on the publication dates and foreign languages.\n",
      "Foreign language articles were translated into English.\n",
      "The list of references which was included in each study was also cross‑verified so that all the relevant trials were included.\n",
      "The various search terms used to identify the relevant clinical trials from each database were Bifidobacterium and oral health, Bifidobacterium and dentistry, Bifidobacterium and dental caries, Bifidobacterium as probiotic.\n",
      "The search strategies were peer‑reviewed as a part of the systematic review process.\n",
      "---\n",
      "MATERIALS AND METHODS > Study selection and data collection\n",
      "The list of clinical trials gathered through electronic databases was assessed by two independent researchers in an unblinded, standardized manner.\n",
      "Both the researches reviewed each included study and extracted the following details of the publication date, authors name, title, study design, randomization, study population, sample size, duration of intervention and follow‑up, number of dropouts, loss to follow‑up form, and dosage of Bifidobacterium administered, any adverse reactions and outcome of the study such as Streptococcus, Lactobacillus and P. gingivalis count in saliva and plaque, the occurrence of dental caries in deciduous and permanent teeth, the occurrence of periodontitis were included.\n",
      "Disagreements were resolved by the third researcher.\n",
      "---\n",
      "DATA ITEMS > Risk of bias in individual studies\n",
      "Two reviewers worked independently to assess the risk of bias for individual studies at the study as well as at the outcome level.\n",
      "They determined the adequacy involved in the various stages of randomization such as random allocation sequence (selection bias), allocation concealment (selection bias), blinding of the investigator, participants or outcome assessors (performance bias), loss of follow‑up, incomplete outcome data (attrition bias), and selective reporting (reporting bias)\n",
      "---\n",
      "DATA ITEMS > Summary measures > Planned methods of analysis\n",
      "Two independent reviewers checked each of the trials for risk of bias and quality of available evidence.\n",
      "The risk of bias in the selected studies was analyzed using the Cochrane risk‑of‑bias tool for randomized trial (RoB 2), which is the recommended tool for use in Cochrane Reviews, and the quality of available evidence was analyzed using GRADE criteria.\n",
      "---\n",
      "DATA ITEMS > Summary measures > Risk of bias across studies and additional analyses\n",
      "Overall, the quality of evidence from these trials was moderate.\n",
      "---\n",
      "RESULTS > Study selection\n",
      "The study selection is shown in Figure 1.\n",
      "---\n",
      "RESULTS > Study characteristics > 1) Ice cream\n",
      "Nagarajappa et al.\n",
      "[7] and Caglar et al.\n",
      "[25] assessed the effect on salivary Streptococcus mutans and lactobacilli for 18 days and 10 days, respectively.\n",
      "Ashwin et al.\n",
      "[26] assessed the effect on salivary S. mutans for 7 days, and Singh et al.\n",
      "[27] assessed the effect of Bifidobacterium and Lactobacilli‑containing probiotic on S. mutans and lactobacilli for 10 days.\n",
      "---\n",
      "RESULTS > Study characteristics > 2) Yogurt\n",
      "Caglar et al.,[28] Nozari et al.,[29] and Zare Javid et al.\n",
      "[30] assessed the effect on salivary S. mutans and lactobacilli for 14 days.\n",
      "Pinto et al.\n",
      "[31] and Caglar[32] assessed the effect on the dental plaque for 14 days.\n",
      "Kuru et al.\n",
      "[33] assessed the effect on gingival health for 28 days.\n",
      "Cildir et al.\n",
      "[34] assessed the effect on S. mutans for 14 days.\n",
      "Bafna et al.\n",
      "[35] assessed the effect of Bifidobacterium and Lactobacilli containing\n",
      "---\n",
      "RESULTS > Study characteristics > 2) Yogurt\n",
      "probiotic on S. mutans for 14 days\n",
      "---\n",
      "RESULTS > Study characteristics > 3) Tablet\n",
      "Taipale et al.\n",
      "[36] assessed the effect on oral colonization of S. mutans for 2 years.\n",
      "---\n",
      "RESULTS > Study characteristics > 4) Lozenges\n",
      "Toiviainen et al.\n",
      "[37] assessed the effect of on salivary S. mutans, amount of plaque, gingival inflammation, and oral microbiome.\n",
      "Jäsberg et al.\n",
      "[38] assessed the effect on the salivary levels of matrix metalloproteinase (MMP)‑9 and tissue inhibitors of metalloproteinases (TIMP)‑1.\n",
      "Alanzi et al.\n",
      "[39] assessed the effect on gingival health, dental plaque, and periodonto‑pathogens for 4 weeks.\n",
      "Invernici et al.\n",
      "[40] evaluated the effects on clinical periodontal parameters (plaque accumulation and gingival bleeding), on the immunocompetence of gingival tissues (expression of beta‑defensin‑3, toll‑like receptor 4, cluster of differentiation [CD]‑57 and CD‑4), and on immunological properties of saliva (immunoglobulin A [IgA] levels) in nonsurgical periodontal therapy in generalized chronic periodontitis patients\n",
      "---\n",
      "RESULTS > Study characteristics > 5) Chewing gum\n",
      "Gueimonde et al.\n",
      "[41] assessed the effect on saliva flow rate, saliva IgA levels, and saliva pH.\n",
      "---\n",
      "RESULTS > Study characteristics > 6) Capsule\n",
      "Ishikawa et al.\n",
      "[42] assessed the effect on the colonization of candida species on dentures for 5 weeks.\n",
      "---\n",
      "RESULTS > Study characteristics > 7) Probiotic drop\n",
      "Tehrani et al.\n",
      "[43] assessed the effect on salivary S. mutans and Lactobacillus for 2 weeks.\n",
      "---\n",
      "RESULTS > Study characteristics > 8) Freeze‑dried powder\n",
      "Jindal et al.\n",
      "[44] assessed the effect on salivary S. mutans for 14 days, and Yousuf et al.\n",
      "[45] assessed the effect on the gingival status and plaque inhibition for 21 days.\n",
      "---\n",
      "RESULTS > Study characteristics > Participants\n",
      "Twenty‑two included studies involved 1175 participants.\n",
      "The inclusion criteria in these studies were orally and systemically healthy non‑medicating participants having good oral health with no untreated caries lesions and daily toothbrushing habits with fluoride toothpaste.\n",
      "The exclusion criteria were habitual consumption of other forms of probiotics, systemic antibiotic medication within 6 weeks, topical 3Dental Research Journal fluoride treatments within 4 weeks, allergic to dairy products, receiving Xylitol‑containing products, use of antibiotics, antimicrobials, cavitated or active carious lesions, and lactose intolerance.\n",
      "---\n",
      "RESULTS > Study characteristics > Participants\n",
      "Figure 1: Flow diagram of the record through the review process.\n",
      "---\n",
      "RESULTS > Study characteristics > Intervention\n",
      "The participants received probiotic Bifidobacterium in any (ice cream, yogurt, lozenges, tablet, chewing gum, capsule, freeze‑dried powder, or probiotic drop) form or placebo minimum of once a day.\n",
      "---\n",
      "RESULTS > Study characteristics > Outcomes\n",
      "The outcomes that were assessed include changes in oral microbiota, dental plaque, gingival health, levels of MMP‑9, and TIMP‑1 at baseline and after the intervention.\n",
      "No study included mortality and costs as the outcome.\n",
      "The timing of outcome measures varied between studies\n",
      "---\n",
      "RESULTS > Study characteristics > Risk of bias within studies:\n",
      "(i) Bias arising from randomization process\n",
      "---\n",
      "RESULTS > Study characteristics > Risk of bias within studies:\n",
      "(ii) Bias due to deviations from intended interventions\n",
      "---\n",
      "RESULTS > Study characteristics > Risk of bias within studies:\n",
      "(iii) Bias due to missing outcome\n",
      "---\n",
      "RESULTS > Study characteristics > Risk of bias within studies:\n",
      "(iv) Bias in the measurement of the outcome\n",
      "---\n",
      "RESULTS > Study characteristics > Risk of bias within studies:\n",
      "(v) Bias in selection of the reported result [Table 1 and Table 2][46,47]\n",
      "---\n",
      "RESULTS > Study characteristics > Risk of bias within studies: > 1) Ice cream\n",
      "Postingestion (after 1 h) in the test group, a statistically significant reduction (P < 0.05) of salivary S. mutans was recorded, but a nonsignificant trend was seen for Lactobacilli.\n",
      "Significant results were also observed between follow‑ups.\n",
      "[7] A statistically significant (P < 0.05) reduction of salivary mutans streptococci was registered after the 10‑day consumption of probiotic ice‑cream.\n",
      "A certain decline of high mutans streptococci counts (>105) was also evident after intake of the control ice cream, but the difference compared to baseline was not statistically significant.\n",
      "During the period of test product consumption, the number of subjects with high mutans streptococci counts (105 colony‑forming unit) decreased from 56% to 0.\n",
      "[25] There was reduction of MS in the children who consumed probiotic ice‑cream when compared to baseline which was statistically significant (P < 0.001).\n",
      "The effect of which reduced over the washout period and throughout the study period, there was constant increase of MS count in the control group who consumed normal ice cream.\n",
      "There was no synergistic effect of probiotic organisms for as long as 6 months.\n",
      "[26] Probiotic ice cream brought about a statistically significant reduction (P 0.003)\n",
      "---\n",
      "RESULTS > Study characteristics > Risk of bias within studies: > 1) Ice cream > Table 1: Risk of bias within studies ‑ Parallel trials\n",
      " | Trials | Bias arising from\n",
      " | --- | ---\n",
      " |  | randomization process | Bias due to deviations from intended interventions | Bias due to missing outcome | Bias in the measurement of the outcome | Bias in selection of the reported result | Overall risk of bias judgement\n",
      " | --- | --- | --- | --- | --- | --- | ---\n",
      " | Parallel group trials\n",
      " | Nagarajappa et al., 2015[7] | Some concerns | Low risk of bias | Low risk of bias | Some concerns | Low risk of bias | Some concerns\n",
      " | Ashwin et al., 2015[26] | Some concerns | Low risk of bias | Low risk of bias | Some concerns | Low risk of bias | Some concerns\n",
      " | Nozari et al., 2021[29] | Some concerns | Some concerns | Low risk of bias | Some concerns | Low risk of bias | High risk of bias\n",
      " | Kuru et al., 2017[33] | Low risk of bias | Low risk of bias | Low risk of bias | Some concerns | Low risk of bias | Some concerns\n",
      " | Bafna et al., 2018[35] | Some concerns | Some concerns | Low risk of bias | Some concerns | Low risk of bias | High risk of bias\n",
      " | Javid et al., 2019[30] | Some concerns | Low risk of bias | Low risk of bias | Low risk of bias | Low risk of bias | Some concerns\n",
      " | Taipale et al., 2012[36] | Some concerns | Some concerns | Low risk of bias | Some concerns | Low risk of bias | High risk of bias\n",
      " | Toiviainen et al., 2014[37] | Some concerns | Some concerns | Low risk of bias | Some concerns | Low risk of bias | High risk of bias\n",
      " | Jasberg et al., 2017[38] | Some concerns | Some concerns | Low risk of bias | Some concerns | Low risk of bias | High risk of bias\n",
      " | Alanzi et al., 2018[39] | Some concerns | Low risk of bias | Low risk of bias | Some concerns | Low risk of bias | Some concerns\n",
      " | Invernici et al., 2020[40] | Low risk of bias | Low risk of bias | Low risk of bias | Some concerns | Low risk of bias | Some concerns\n",
      " | Gueimonde et al., 2016[41] | Some concerns | Some concerns | Low risk of bias | Some concerns | Low risk of bias | High risk of bias\n",
      " | Ishikawa et al., 2014[42] | Some concerns | Some concerns | Low risk of bias | Some concerns | Low risk of bias | High risk of bias\n",
      " | Tehrani et al., 2021[43] | Some concerns | Low risk of bias | Low risk of bias | Some concerns | Low risk of bias | Some concerns\n",
      " | Jindal et al., 2011[44] | Some concerns | Some concerns | Low risk of bias | Some concerns | Low risk of bias | High risk of bias\n",
      " | Yousuf et al., 2017[45] | Some concerns | Some concerns | Low risk of bias | Some concerns | Low risk of bias | High risk of bias\n",
      " | Table 2: Risk of bias within studies ‑ Crossover trials\n",
      " | Trials Bias arising from | Bias arising from period and carryover effects |  |  | Bias in the measurement of the outcome | Bias in selection of the reported result | Overall risk of bias judgement\n",
      " | Crossover trials\n",
      " |  |  | Bias due to deviations from intended interventions | Bias due to missing outcome |  |  | \n",
      " | randomization process\n",
      " | Caglar et al., 2009[25] Some concerns Some concerns Low risk of bias |  |  | Low risk of bias Some concerns Low risk of bias High risk of bias |  |  | \n",
      " | Singh et al., 2011[27] Low risk of bias | Some concerns Low risk of bias |  | Low risk of bias Some concerns Low risk of bias Some concerns |  |  | \n",
      " | Caglar et al., 2005[28] Some concerns Some concerns Low risk of bias |  |  | Low risk of bias Some concerns Low risk of bias High risk of bias |  |  | \n",
      " | Pinto et al., 2014[31] Low risk of bias | Low risk of bias | Low risk of bias | Low risk of bias Some concerns Low risk of bias Some concerns |  |  | \n",
      " | Caglar et al., 2014[32] Some concerns Some concerns Some concerns Low risk of bias Some concerns Low risk of bias High risk of bias Cildir et al., 2009[34] Some concerns Some concerns Low risk of bias |  |  | Low risk of bias Some concerns Low risk of bias High risk of bias |  |  | \n",
      "\n",
      "---\n",
      "RESULTS > Study characteristics > Risk of bias within studies: > 1) Ice cream > Table 1: Risk of bias within studies ‑ Parallel trials\n",
      "in salivary mutans streptococci levels with no significant effect on lactobacilli levels.\n",
      "[27]\n",
      "---\n",
      "RESULTS > Study characteristics > Risk of bias within studies: > 2) Yogurt\n",
      "A statistically significant reduction (P < 0.05) of salivary mutans streptococci was recorded after the probiotic yogurt consumption, which was in contrast to the controls.\n",
      "[28] In the case group, neither the S. mutans count nor the Lactobacilli count was significantly reduced.\n",
      "However, there was a reduction in S. mutans and Lactobacillus counts in the control group.\n",
      "[29] Similarly, there was no difference between the yogurt containing probiotics and the control yogurt for any of the studied variables (all P > 0.05).\n",
      "A reduction in counts of total cultivable microorganisms was observed in dental plaque samples after ingestion of either yogurts (both P 0.05 vs. baseline) but not in saliva (P < 0.05).\n",
      "[31] In addition, there were no statistically differences between transition scores of test and placebo groups regarding different dental plaque sampling sites (P > 0.05).\n",
      "[32] No intergroup differences could be detected before and after the intake of the study products.\n",
      "However, after plaque accumulation, significantly better results for all parameters could be seen in the probiotic group compared to the control group (P < 0.001): lower plaque and gingivitis scores, less bleeding on probing, less increase in GCF volume, and lower total interleukin‑1 β amount/concentration.\n",
      "---\n",
      "RESULTS > Study characteristics > Risk of bias within studies: > 2) Yogurt\n",
      "[33] Daily consumption of probiotic yogurt for 2 weeks decreased the mutans streptococci counts in saliva (P < 0.05), which was in contrast to the control yogurt.\n",
      "No significant alterations in the salivary lactobacilli counts were observed.\n",
      "[34] A statistically 5Dental Research Journal significant reduction (P < 0.05) of salivary S. mutans was recorded after probiotic yogurt consumption with minimal residual effect in case group, which was in contrast to the controls.\n",
      "[35] A significant reduction in salivary S. mutans (P = 0.001) and Lactobacillus counts (P = 0.001) was observed in the intervention group as compared to their baseline and compared to the control group.\n",
      "While the reduction in S. mutans (P = 0.594) and lactobacilli (P = 0.071) was not significant in the control group after the intervention.\n",
      "[30]\n",
      "---\n",
      "RESULTS > Study characteristics > Risk of bias within studies: > 3) Tablet\n",
      "In the Bifidobacterium animalis subsp.\n",
      "lactis BB‑12 (BB‑12) group, only 6.3% of the children harbored mutans streptococci at the age of 2 years.\n",
      "This percentage was lower as compared to the xylitol control group (31.4%; P = 0.009) but did not differ from the sorbitol control group (10.3%; P = 0.56).\n",
      "[36]\n",
      "---\n",
      "RESULTS > Study characteristics > Risk of bias within studies: > 4) Lozenges\n",
      "The probiotic lozenge decreased both PI and GI (P < 0.05), while no changes were observed in the control group.\n",
      "However, no probiotic‑induced changes were found in the microbial compositions of saliva in either group.\n",
      "No study‑induced changes in the MS counts were detected either in the probiotic or the control group.\n",
      "[37] In the probiotic group (n = 29), salivary MMP‑9 levels increased (P < 0.01) and TIMP‑1 levels decreased (P < 0.01) significantly during the intervention.\n",
      "Furthermore, MMP‑9/ TIMP‑1 ratio differed significantly from the baseline level (P < 0.01).\n",
      "Probiotic consumption did not affect the saliva flow rate.\n",
      "Probiotic intervention did not affect the salivary levels of MMP‑8.\n",
      "[38] A reduction in plaque index was found for both groups, with no difference observed between the groups after intervention (P = 0.819).\n",
      "Probiotic lozenges significantly reduced the levels of Aggregatibacter actinomycetemcomitans and Fusobacterium nucleatum in saliva and plaque (P < 0.05) and levels of P. gingivalis in plaque (P < 0.05), while no significant changes were found in the control group.\n",
      "A significant reduction (P < 0.001) was also noted in the total salivary bacterial counts of the test group.\n",
      "The short‑term daily consumption of LGG and BB‑12 probiotic lozenges improved the gingival health in adolescents and decreased the microbial counts of\n",
      "A. actinomycetemcomitans and P. gingivalis.\n",
      "[39] The test group presented a decrease in probing pocket depth and a clinical attachment gain significantly higher than those of the control group at 90 days.\n",
      "---\n",
      "RESULTS > Study characteristics > Risk of bias within studies: > 4) Lozenges\n",
      "The test group also demonstrated significantly fewer periodontal pathogens of red and orange complexes, as well as lower proinflammatory cytokine levels when compared to the control group.\n",
      "Only the test group showed an increase in the number of Bifidobacterium animalis subsp.\n",
      "lactis HN019 DNA copies on subgingival biofilm at 30 and 90 days.\n",
      "The control group presented higher levels of IL‑1 β (30 and 90 days) and of IL‑8 (30 days) when compared with the test group.\n",
      "[40]\n",
      "---\n",
      "RESULTS > Study characteristics > Risk of bias within studies: > 5) Chewing gum\n",
      "However, no statistically significant differences were found between probiotic and placebo groups for any of the parameters analyzed.\n",
      "[41]\n",
      "---\n",
      "RESULTS > Study characteristics > Risk of bias within studies: > 6) Capsule\n",
      "The detection rate of Candida spp.\n",
      "was 92.0% in the placebo group after the experimental period, whereas it was reduced to 16.7% in the probiotic group.\n",
      "[42]\n",
      "---\n",
      "RESULTS > Study characteristics > Risk of bias within studies: > 7) Probiotic drop\n",
      "S. mutans level decreased significantly in the probiotic group after intervention (P = 0.045), and there were significant differences in salivary SM counts after intervention between the two groups (P = 0.04).\n",
      "In the probiotic group, LB counts decreased significantly after intervention (P = 0.048); however, there were no significant differences between the two groups (P = 0.216).\n",
      "[43]\n",
      "---\n",
      "RESULTS > Study characteristics > Risk of bias within studies: > 8) Freeze dried powder\n",
      "A statistically significant postintervention change was observed in the study groups (P < 0.001).\n",
      "A significant reduction in MS counts was observed after the administration of probiotics (Group B and Group C) for 14 days.\n",
      "[44] For both the probiotic groups, a statistically significant reduction (P < 0.05) in gingival status and plaque inhibition was recorded up to the 2nd week of probiotic ingestion.\n",
      "However, no significant difference was observed in the placebo group.\n",
      "[45]\n",
      "---\n",
      "RESULTS > Study characteristics > Risk of bias within studies: > Risk of bias across studies and additional analyses\n",
      "The confidence obtained from the trials included in this study is moderate [Table 3].\n",
      "[48]\n",
      "---\n",
      "DISCUSSION > Summary of evidence\n",
      "Probiotic technology represents a breakthrough approach to maintaining oral health by utilizing natural beneficial bacteria commonly found in healthy mouths to provide a natural defense against those bacteria thought to be harmful to teeth and gums.\n",
      "[7] Bifidobacteria have a wide commercial use and are Generally Regarded As Safe (GRAS) for use as ingredients in milk‑based infant formulas.\n",
      "---\n",
      "DISCUSSION > Summary of evidence\n",
      "[25] Bifidobacteria are the predominant anaerobic bacteria naturally occurring within the intestinal lumen and play a critical role in maintaining the equilibrium among normal intestinal flora.\n",
      "[28] Acidogenic and aciduric species of dairy products can inhibit other competing organisms and make their local environment, for example, the dental plaque, even more acidic.\n",
      "However, some species of Bifidobacterium may also have a role in maintaining health by promoting a microbiological balance in the oral cavity and oral defense factors, such as the peroxidase system, which may inhibit the acidogenicity of bacteria.\n",
      "[33] Various clinical trials have been performed on the different forms of probiotics to check its effectiveness and substantivity in the oral cavity so that it can be used as an adjuvant in oral care measures as well as a preventive aid in the occurrence of various dental diseases.\n",
      "To the best of our knowledge, studies solely focusing on the clinical effects of Bifidobacterium have not been previously summarized in an evidence‑based manner.\n",
      "---\n",
      "DISCUSSION > Summary of evidence\n",
      "Studies investigating the effect of probiotics on various microbiological parameters during the consumption of probiotics have been conflicting.\n",
      "Apart from specific strains of Bifidobacterium or the mode/duration of administration, patients’ compliance could also affect the results.\n",
      "Although compliance was found to be good, they were self‑reported by the participants which cannot be completely relied on.\n",
      "Other factors that could have affected the reported results were dietary habits, use of antibacterial agents, cleansing the mouth after consumption of probiotic, thus washing‑out the probiotic from the mouth.\n",
      "---\n",
      "DISCUSSION > Summary of evidence\n",
      "Probiotic icecream‑containing Bifidobacterium reduced the levels of salivary mutans streptococci and a non‑significant trend was observed for Lactobacillus count.\n",
      "[7,27] However, the study conducted by Caglar et al.\n",
      "[25] showed the high risk of bias due to selection and performance bias.\n",
      "Hence the results from that study are not reliable.\n",
      "All the studies using ice cream as a vehicle of probiotic delivery showed the moderate quality of evidence.\n",
      "[7‑27] In yogurt containing Bifidobacterium, there was a significant reduction of salivary mutans streptococci.\n",
      "However, there was selection and performance bias.\n",
      "[28] On contrary, S. mutans and Lactobacillus count did not reduce in the case group; however, there was a significant reduction in the control group.\n",
      "This study had inadequate information regarding randomization process and blinding, leading to selection bias.\n",
      "Performance bias was also encountered.\n",
      "[29] Both the studies showed high risk of bias.\n",
      "Furthermore, the study conducted by Pinto et al.\n",
      "[31] showed a reduction in the counts of total cultivable microorganisms in the dental plaque in both the control and the case groups, which implied that daily ingestion of yogurt with or without Bifidobacterium reduced the total microbial count, and this study showed some concerns of bias.\n",
      "Similar study conducted by Caglar.\n",
      "[32] showed no statistical significance in the reduction of salivary mutans streptococci in the dental plaque sample.\n",
      "This study also had inadequate information regarding the\n",
      "---\n",
      "DISCUSSION > Summary of evidence > Table 3: Quality of available evidence\n",
      " | Study | Risk of bias | Inconsistency Indirectness | Imprecision Others | No of patients Probiotic control | Effect | Quality\n",
      " | --- | --- | --- | --- | --- | --- | ---\n",
      " | Ice cream | Serious | Not serious | Not serious | Serious | None | 107 107 | No difference | Moderate\n",
      " | --- | --- | --- | --- | --- | --- | --- | --- | ---\n",
      " | Yogurt | Serious | Not serious | Not serious | Serious | None | 241 238 | Difference present | Moderate\n",
      " | Tablet | Serious | No serious | Not serious | Serious | None | 32 64 | No difference | Moderate\n",
      " | Lozenges | Serious | Not serious | Not serious | Serious | None | 127 111 | No difference | Moderate\n",
      " | Chewing gum | Serious | Not serious | Not serious | Serious | None | 17 19 | No difference | Moderate\n",
      " | Capsule | Serious | Not serious | Not serious | Serious | None | 30 29 | No difference | Moderate\n",
      " | Drop | Serious | Not serious | Not serious | Serious | None | 30 | No difference | Moderate\n",
      "\n",
      "---\n",
      "DISCUSSION > Summary of evidence > Table 3: Quality of available evidence\n",
      "7Dental Research Journal\n",
      "---\n",
      "DISCUSSION > Summary of evidence > Table 3: Quality of available evidence\n",
      "randomization process and blinding.\n",
      "Performance bias was encountered giving rise to a high risk of bias.\n",
      "A study conducted by Kuru et al.\n",
      "[33] showed lower plaque and gingivitis scores, less bleeding on probing, less increase in GCF volume and lower total interleukin‑1B amount/concentration with some concerns of bias.\n",
      "Similar to ice cream‑containing probiotic, a study conducted by Cildir et al.\n",
      "[34] showed a reduction in the levels of salivary mutans streptocooci and not Lactobacillus.\n",
      "However, there was the selection and performance bias giving rise to a high risk of bias in this study.\n",
      "A study conducted by Bafna et al.\n",
      "[35] showed a reduction in mutans streptococci with minimal residual effect and the result had some concerns of bias.\n",
      "A study conducted by Zare Javid et al.\n",
      "[30] showed a significant reduction in both S. mutans and Lactobacillus count.\n",
      "However, participants were aware of their assigned intervention during the trial, and hence, high risk of bias is anticipated.\n",
      "All the studies using yogurt as a vehicle of probiotic delivery showed either high risk or some concerns of bias and hence the results obtained from these studies are either not reliable or questionable.\n",
      "---\n",
      "DISCUSSION > Summary of evidence > Table 3: Quality of available evidence\n",
      "A study conducted by Taipale et al.\n",
      "[36] concluded that when Bifidobacterium administered in the form of a tablet in newborns, it did not result in permanent colonization of this probiotic or significantly affect the levels of mutans streptococci colonization.\n",
      "Only one study was conducted using probiotic tablet.\n",
      "This study had inadequate information regarding the blinding of the participants and outcome assessors, and thus, the result obtained is questionable, giving rise to high risk of bias and moderate quality of available evidence.\n",
      "---\n",
      "DISCUSSION > Summary of evidence > Table 3: Quality of available evidence\n",
      "The use of probiotic lozenge by Toiviainen et al.\n",
      "[37] showed improved periodontal status without affecting the oral microbiota and adhesion properties of plaque.\n",
      "Another study conducted by Jäsberg et al.\n",
      "[38] showed increased MMP‑9 and decreased TIMP‑1 levels in saliva, suggesting immunomodulatory effects in the oral cavity.\n",
      "However, both the studies had some concerns of bias arising from the randomization process as well has inadequate information on blinding of the study participants and outcome assessors, giving rise to a high risk of bias.\n",
      "Hence, the results are questionable.\n",
      "Alanzi et al.\n",
      "[39] suggested the use of lozenges as a simple adjunct to standard oral care, but the results had some concerns of bias.\n",
      "The overall quality of available evidence is moderate.\n",
      "Invernici et al.\n",
      "[40] suggested the use of B. lactis HN019 as an adjunct to SRP for promoting additional clinical, microbiological, and immunological benefits in the treatment of chronic periodontitis Only one study was conducted using probiotic chewing gums by Gueimonde et al.\n",
      "[41] which concluded a positive impact on the salivary flow rate, salivary pH, and IgA levels with or without the use of Bifidobacterium probiotic.\n",
      "This result is questionable because of inadequate information regarding the blinding of the participants and outcome assessors.\n",
      "Hence, this study had a high risk of bias as well as the moderate quality of available evidence.\n",
      "---\n",
      "DISCUSSION > Summary of evidence > Table 3: Quality of available evidence\n",
      "A study conducted by Ishikawa et al.\n",
      "[42] using probiotic capsules, concluded that there was the reduction in the colonization of Candida species, suggesting the use of probiotics as an alternative treatment in elderly denture wearers.\n",
      "This result is also questionable because of the high risk of bias due to inadequate information on the awareness of participants and outcome assessors of their assigned intervention during the trial and moderate quality of available evidence.\n",
      "---\n",
      "DISCUSSION > Summary of evidence > Table 3: Quality of available evidence\n",
      "A study conducted by Tehrani et al.\n",
      "[43] on probiotic drop decreased salivary counts of mutans streptococci and Lactobacillus in children with higher salivary counts.\n",
      "There were some concerns of bias and moderate quality of available evidence in this study, so the results obtained are questionable.\n",
      "---\n",
      "DISCUSSION > Summary of evidence > Table 3: Quality of available evidence\n",
      "Studies done by Jindal et al.\n",
      "[44] and Yousuf et al.\n",
      "[45] showed that freeze‑dried probiotic powder reduced Mutans streptococci count and improved gingival status and plaque inhibition, respectively.\n",
      "Both the studies have not mentioned whether the participants, as well as carers and people delivering the interventions, were aware of the assigned intervention during the trial or not, giving rise to high risk of bias and moderate quality of available evidence.\n",
      "Hence, the reliability of these studies is questionable.\n",
      "---\n",
      "DISCUSSION > Summary of evidence > Table 3: Quality of available evidence\n",
      "Overall, the risk of bias for all the studies included in this review ranged from some concerns to high risk and the quality of available evidence was also moderate.\n",
      "---\n",
      "DISCUSSION > Strengths and limitations\n",
      "RCTs represent the highest level of evidence in health care interventions, and we adhered to the well‑established guidelines in this review.\n",
      "As to our knowledge, there has been no systematic review done so far to evaluate the clinical effectiveness of Bifidobacterium as a probiotic in oral health care.\n",
      "The search did not have any restrictions on languages or publication date and was extensive.\n",
      "The studies that were included in this review did pose some limitations.\n",
      "The strains of Bifidobacterium used, its dosage, duration, mode of administration differed among studies.\n",
      "Majority of the studies had recruited less participants, which can pose a threat to the precision as well as reduce the generalizability of the results retrieved.\n",
      "---\n",
      "DISCUSSION > Recommendations for future research\n",
      "The proven effects of probiotics on general health have led to more research in the oral health field.\n",
      "Its antimicrobial and immune‑modulating ability provides a new therapeutic approach for preventing infectious disease.\n",
      "[40] Although there are various studies on probiotics done so far, further researches are needed to conclude the optimum level of probiotic required and the ideal mode of administration to maximize the use of probiotic in preventing oral diseases.\n",
      "It is also essential to evaluate the effects of using a single strain as well as the synergistic effect of combining multiple species of probiotics into a single entity.\n",
      "---\n",
      "DISCUSSION > Recommendations for future research\n",
      "Future researches have to be carried out with a larger sample size so that it can be extrapolated, long duration of interventions assessing the long‑term effects of probiotic use, washout period extending more than 2 weeks in case of cross‑over trials, combinations of probiotic strains so that it provides additional benefits on oral health.\n",
      "---\n",
      "CONCLUSION\n",
      "To conclude, from the evidences available from these trials, the effect of Bifidobacterium in oral health is questionable.\n",
      "Further high‑quality RCTs are required on the clinical effects of Bifidobacteria and also the optimum level of probiotic needed, ideal mode of administration to provide oral health benefits.\n",
      "Furthermore, synergistic effects of the combined use of various strains of probiotics need to be studied.\n",
      "---\n",
      "CONCLUSION > Financial support and sponsorship\n",
      "Nil.\n",
      "---\n",
      "CONCLUSION > Conflicts of interest\n",
      "The authors of this manuscript declare that they have no conflicts of interest, real or perceived, financial or nonfinancial in this article.\n",
      "---\n",
      "REFERENCES > 1. FAO/WHO\n",
      "Report of a Joint FAO/WHO Expert consultation on evaluation of Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria.\n",
      "---\n",
      "REFERENCES > 1. FAO/WHO\n",
      "Cordoba, Argentina.\n",
      "2001.\n",
      "October 1‑4.\n",
      "Accessed from:http:// who.int/foodsafety/fs_management/ en/probiotic_guidelines.\n",
      "pdf.\n",
      "[Last accessed on 2022 Jan 01].\n",
      "---\n",
      "REFERENCES > 2. FAO/WHO\n",
      "Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food.\n",
      "London, Ontario, Canada.\n",
      "2002.\n",
      "April 30 and May 1.\n",
      "Available from: http://www.who.int/foodsafety/publications/fs_management/ probiotics2/en/ [Last accessed on 2022 Jan 01].\n",
      "---\n",
      "REFERENCES > 3. Fuller R, Gibson GR\n",
      "Modification of the intestinal microflora using probiotics and prebiotics.\n",
      "Scand J Gastroenterol Suppl 1997;222:28‑31.\n",
      "---\n",
      "REFERENCES > 4. Haukioja A\n",
      "Probiotics and oral health.\n",
      "Eur J Dent 2010;4:348‑55.\n",
      "---\n",
      "REFERENCES > 4. Haukioja A\n",
      "5. Teughels W, Van Essche M, Sliepen I, Quirynen M. Probiotics and oral healthcare.\n",
      "Periodontol 2000 2008;48:111‑47.\n",
      "---\n",
      "REFERENCES > 4. Haukioja A\n",
      "6. Reid G, Jass J, Sebulsky MT, McCormick JK.\n",
      "Potential uses of probiotics in clinical practice.\n",
      "Clin Microbiol Rev 2003;16:658‑72.\n",
      "---\n",
      "REFERENCES > 4. Haukioja A\n",
      "7. Nagarajappa R, Daryani H, Sharda AJ, Asawa K, Batra M, Sanadhya S, et al.\n",
      "Effect of Chocobar ice cream containing Bifidobacterium on salivary Streptococcus mutans and lactobacilli: A randomised controlled trial.\n",
      "Oral Health Prev Dent 2015;13:213‑8.\n",
      "---\n",
      "REFERENCES > 4. Haukioja A\n",
      "8. Haukioja A, Loimaranta V, Tenovuo J. Probiotic bacteria affect the composition of salivary pellicle and streptococcal adhesion in vitro.\n",
      "Oral Microbiol Immunol 2008;23:336‑43.\n",
      "---\n",
      "REFERENCES > 4. Haukioja A\n",
      "9. Chen YT, Hsieh PS, Ho HH, Hsieh SH, Kuo YW, Yang SF, et al.\n",
      "---\n",
      "REFERENCES > 4. Haukioja A\n",
      "Antibacterial activity of viable and heat‑killed probiotic strains against oral pathogens.\n",
      "Lett Appl Microbiol 2020;70:310‑7.\n",
      "---\n",
      "REFERENCES > 4. Haukioja A\n",
      "10.\n",
      "Wang L, Vuletic I, Deng D, Crielaard W, Xie Z, Zhou K, et al.\n",
      "Bifidobacterium breve as a delivery vector of IL‑24 gene therapy for head and neck squamous cell carcinoma in vivo.\n",
      "Gene Ther 2017;24:699‑705.\n",
      "---\n",
      "REFERENCES > 4. Haukioja A\n",
      "11.\n",
      "Shimabukuro N, Cataruci AC, Ishikawa KH, de Oliveira BE, Kawamoto D, Ando‑Suguimoto ES, et al.\n",
      "Bifidobacterium strains present distinct effects on the control of alveolar bone loss in a periodontitis experimental model.\n",
      "Front Pharmacol 2021;12:713595.\n",
      "---\n",
      "REFERENCES > 4. Haukioja A\n",
      "12.\n",
      "Silva GA, Moreira AL, Silva PH, Salvador SL, Casarin RC, Vicente RM, et al.\n",
      "The use of probiotics can reduce the severity of experimental periodontitis in rats with metabolic syndrome: An immunoenzymatic and microtomographic study.\n",
      "J Periodontol 2022;93:e1‑12.\n",
      "---\n",
      "REFERENCES > 4. Haukioja A\n",
      "13.\n",
      "Schwendicke F, Horb K, Kneist S, Dörfer C, Paris S. Effects of heat‑inactivated Bifidobacterium BB12 on cariogenicity of Streptococcus mutans in vitro.\n",
      "Arch Oral Biol 2014;59:1384‑90.\n",
      "---\n",
      "REFERENCES > 4. Haukioja A\n",
      "14.\n",
      "Jäsberg H, Söderling E, Endo A, Beighton D, Haukioja A. Bifidobacteria inhibit the growth of Porphyromonas gingivalis but not of Streptococcus mutans in an in vitro biofilm model.\n",
      "Eur J Oral Sci 2016;124:251‑8.\n",
      "---\n",
      "REFERENCES > 4. Haukioja A\n",
      "15.\n",
      "Ricoldi MS, Furlaneto FA, Oliveira LF, Teixeira GC, Pischiotini JP, Moreira AL, et al.\n",
      "Effects of the probiotic Bifidobacterium animalis subsp.\n",
      "lactis on the non‑surgical treatment of periodontitis.\n",
      "A histomorphometric, microtomographic and immunohistochemical study in rats.\n",
      "PLoS One 2017;12:e0179946.\n",
      "---\n",
      "REFERENCES > 4. Haukioja A\n",
      "16.\n",
      "Haukioja A, Yli‑Knuuttila H, Loimaranta V, Kari K, Ouwehand AC, Meurman JH, et al.\n",
      "Oral adhesion and survival of probiotic and other lactobacilli and bifidobacteria in vitro.\n",
      "---\n",
      "REFERENCES > 4. Haukioja A\n",
      "9Dental Research Journal\n",
      "---\n",
      "REFERENCES > 4. Haukioja A\n",
      "Oral Microbiol Immunol 2006;21:326‑32.\n",
      "17.\n",
      "Argandoña Valdez RM, Ximenez‑Fyvie LA, Caiaffa KS, Rodrigues Dos Santos V, Gonzales Cervantes RM, Almaguer‑Flores A, et al.\n",
      "Antagonist effect of probiotic bifidobacteria on biofilms of pathogens associated with periodontal disease.\n",
      "Microb Pathog 2021;150:104657.\n",
      "18.\n",
      "Bohora AA, Kokate SR, Khedkar S, Vankudre A. Antimicrobial activity of probiotics against endodontic pathogens: A preliminary study.\n",
      "Indian J Med Microbiol 2019;37:5‑11.\n",
      "---\n",
      "REFERENCES > 19. Mendi A, Aslım B\n",
      "Antioxidant lactobacilli could protect gingival fibroblasts against hydrogen peroxide: A preliminary in vitro study.\n",
      "Probiotics Antimicrob Proteins 2014;6:157‑64.\n",
      "---\n",
      "REFERENCES > 19. Mendi A, Aslım B\n",
      "20.\n",
      "Albuquerque‑Souza E, Balzarini D, Ando‑Suguimoto ES, Ishikawa KH, Simionato MR, Holzhausen M, et al.\n",
      "Probiotics alter the immune response of gingival epithelial cells challenged by Porphyromonas gingivalis.\n",
      "J Periodontal Res 2019;54:115‑27.\n",
      "---\n",
      "REFERENCES > 21. Bohora A, Kokate S\n",
      "Evaluation of the role of probiotics in endodontic treatment: A preliminary study.\n",
      "J Int Soc Prev Community Dent 2017;7:46‑51.\n",
      "---\n",
      "REFERENCES > 21. Bohora A, Kokate S\n",
      "22.\n",
      "Cardoso RS, Messora MR, Silva PH, Oliveira LF, Leite‑Panissi C, Salvador S, et al.\n",
      "Effects of Bifidobacterium animalis subsp.\n",
      "lactis HN019 on ligature‑induced periodontitis in rats with experimental rheumatoid arthritis.\n",
      "Benef Microbes 2020;11:33‑46.\n",
      "---\n",
      "REFERENCES > 21. Bohora A, Kokate S\n",
      "23.\n",
      "Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group.\n",
      "Preferred reporting items for systematic reviews and meta‑analyses: The PRISMA statement.\n",
      "J Clin Epidemiol 2009;62:1006‑12.\n",
      "---\n",
      "REFERENCES > 21. Bohora A, Kokate S\n",
      "24.\n",
      "Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al.\n",
      "The PRISMA statement for reporting systematic reviews and meta‑analyses of studies that evaluate health care interventions: Explanation and elaboration.\n",
      "J Clin Epidemiol 2009;62:e1‑34.\n",
      "---\n",
      "REFERENCES > 21. Bohora A, Kokate S\n",
      "25.\n",
      "Caglar E, Kuscu OO, Selvi Kuvvetli S, Kavaloglu Cildir S, Sandalli N, Twetman S. Short‑term effect of ice‑cream containing Bifidobacterium lactis Bb‑12 on the number of salivary mutans streptococci and lactobacilli.\n",
      "Acta Odontol Scand 2008;66:154‑8.\n",
      "---\n",
      "REFERENCES > 21. Bohora A, Kokate S\n",
      "26.\n",
      "Ashwin D, Ke V, Taranath M, Ramagoni NK, Nara A, Sarpangala M. Effect of probiotic containing ice‑cream on salivary mutans streptococci (SMS) levels in children of 6‑12 years of age: A randomized controlled double blind study with six‑months follow up.\n",
      "J Clin Diagn Res 2015;9:ZC06‑9.\n",
      "---\n",
      "REFERENCES > 21. Bohora A, Kokate S\n",
      "27.\n",
      "Singh RP, Damle SG, Chawla A. Salivary mutans streptococci and lactobacilli modulations in young children on consumption of probiotic ice‑cream containing Bifidobacterium lactis Bb12 and Lactobacillus acidophilus La5.\n",
      "Acta Odontol Scand 2011;69:389‑94.\n",
      "---\n",
      "REFERENCES > 21. Bohora A, Kokate S\n",
      "28.\n",
      "Caglar E, Sandalli N, Twetman S, Kavaloglu S, Ergeneli S, Selvi S. Effect of yogurt with Bifidobacterium DN‑173 010 on salivary mutans streptococci and lactobacilli in young adults.\n",
      "Acta Odontol Scand 2005;63:317‑20.\n",
      "---\n",
      "REFERENCES > 21. Bohora A, Kokate S\n",
      "29.\n",
      "Nozari A, Motamedifar M, Seifi N, Hatamizargaran Z, Ranjbar MA.\n",
      "The effect of Iranian customary used probiotic yogurt on the children’s salivary cariogenic microflora.\n",
      "J Dent (Shiraz) 2015;16:81‑6.\n",
      "---\n",
      "REFERENCES > 21. Bohora A, Kokate S\n",
      "30.\n",
      "Zare Javid A, Amerian E, Basir L, Ekrami A, Haghighizadeh MH, Maghsoumi‑Norouzabad L. Effects of the consumption of\n",
      "---\n",
      "REFERENCES > 21. Bohora A, Kokate S\n",
      "probiotic yogurt containing Bifidobacterium lactis Bb12 on the levels of Streptococcus mutans and Lactobacilli in saliva of students with initial stages of dental caries: A double‑blind randomized controlled trial.\n",
      "Caries Res 2020;54:68‑74.\n",
      "31.\n",
      "Pinto GS, Cenci MS, Azevedo MS, Epifanio M, Jones MH.\n",
      "Effect of yogurt containing Bifidobacterium animalis subsp.\n",
      "lactis DN‑173010 probiotic on dental plaque and saliva in orthodontic patients.\n",
      "Caries Res 2014;48:63‑8.\n",
      "---\n",
      "REFERENCES > 32. Caglar E\n",
      "Effect of Bifidobacterium bifidum containing yoghurt on dental plaque bacteria in children.\n",
      "J Clin Pediatr Dent 2014;38:329‑32.\n",
      "---\n",
      "REFERENCES > 32. Caglar E\n",
      "33.\n",
      "Kuru BE, Laleman I, Yalnızoğlu T, Kuru L, Teughels W. The influence of a Bifidobacterium animalis probiotic on gingival health: A randomized controlled clinical trial.\n",
      "J Periodontol 2017;88:1115‑23.\n",
      "---\n",
      "REFERENCES > 32. Caglar E\n",
      "34.\n",
      "Cildir SK, Germec D, Sandalli N, Ozdemir FI, Arun T, Twetman S, et al.\n",
      "Reduction of salivary mutans streptococci in orthodontic patients during daily consumption of yoghurt containing probiotic bacteria.\n",
      "Eur J Orthod 2009;31:407‑11.\n",
      "---\n",
      "REFERENCES > 32. Caglar E\n",
      "35.\n",
      "Bafna HP, Ajithkrishnan CG, Kalantharakath T, Singh RP, Kalyan P, Vathar JB, et al.\n",
      "Effect of short‑term consumption of amul probiotic yogurt containing Lactobacillus acidophilus La5 and Bifidobacterium lactis Bb12 on salivary Streptococcus mutans count in high caries risk individuals.\n",
      "Int J Appl Basic Med Res 2018;8:111‑5.\n",
      "---\n",
      "REFERENCES > 32. Caglar E\n",
      "36.\n",
      "Taipale T, Pienihäkkinen K, Salminen S, Jokela J, Söderling E. Bifidobacterium animalis subsp.\n",
      "lactis BB‑12 administration in early childhood: A randomized clinical trial of effects on oral colonization by mutans streptococci and the probiotic.\n",
      "Caries Res 2012;46:69‑77.\n",
      "---\n",
      "REFERENCES > 32. Caglar E\n",
      "37.\n",
      "Toiviainen A, Jalasvuori H, Lahti E, Gursoy U, Salminen S, Fontana M, et al.\n",
      "Impact of orally administered lozenges with Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp.\n",
      "lactis BB‑12 on the number of salivary mutans streptococci, amount of plaque, gingival inflammation and the oral microbiome in healthy adults.\n",
      "Clin Oral Investig 2015;19:77‑83.\n",
      "---\n",
      "REFERENCES > 32. Caglar E\n",
      "38.\n",
      "Jäsberg H, Tervahartiala T, Sorsa T, Söderling E, Haukioja A. Probiotic intervention influences the salivary levels of Matrix Metalloproteinase (MMP)‑9 and Tissue Inhibitor of metalloproteinases (TIMP)‑1 in healthy adults.\n",
      "Arch Oral Biol 2018;85:58‑63.\n",
      "---\n",
      "REFERENCES > 32. Caglar E\n",
      "39.\n",
      "Alanzi A, Honkala S, Honkala E, Varghese A, Tolvanen M, Söderling E. Effect of Lactobacillus rhamnosus and Bifidobacterium lactis on gingival health, dental plaque, and periodontopathogens in adolescents: A randomised placebo‑controlled clinical trial.\n",
      "Benef Microbes 2018;9:593‑602.\n",
      "---\n",
      "REFERENCES > 32. Caglar E\n",
      "40.\n",
      "Invernici MM, Furlaneto FA, Salvador SL, Ouwehand AC, Salminen S, Mantziari A, et al.\n",
      "Bifidobacterium animalis subsp lactis HN019 presents antimicrobial potential against periodontopathogens and modulates the immunological response of oral mucosa in periodontitis patients.\n",
      "PLoS One 2020;15:e0238425.\n",
      "---\n",
      "REFERENCES > 32. Caglar E\n",
      "41.\n",
      "Gueimonde L, Vesterlund S, García‑Pola MJ, Gueimonde M, Söderling E, Salminen S. Supplementation of xylitol‑containing chewing gum with probiotics: A double blind, randomised pilot study focusing on saliva flow and saliva properties.\n",
      "Food Funct 2016;7:1601‑9.\n",
      "---\n",
      "REFERENCES > 32. Caglar E\n",
      "42.\n",
      "Ishikawa KH, Mayer MP, Miyazima TY, Matsubara VH, Silva EG, Paula CR, et al.\n",
      "A multispecies probiotic reduces oral Candida colonization in denture wearers.\n",
      "J Prosthodont 2015;24:194‑9.\n",
      "---\n",
      "REFERENCES > 32. Caglar E\n",
      "43.\n",
      "Tehrani MH, Akhlaghi N, Talebian L, Emami J, Keyhani SE.\n",
      "Effects of probiotic drop containing Lactobacillus rhamnosus, Bifidobacterium infantis, and Lactobacillus reuteri on salivary Streptococcus mutans and Lactobacillus levels.\n",
      "Contemp Clin Dent 2016;7:469‑74.\n",
      "---\n",
      "REFERENCES > 32. Caglar E\n",
      "44.\n",
      "Jindal G, Pandey RK, Agarwal J, Singh M. A comparative evaluation of probiotics on salivary mutans streptococci counts in Indian children.\n",
      "Eur Arch Paediatr Dent 2011;12:211‑5.\n",
      "---\n",
      "REFERENCES > 32. Caglar E\n",
      "45.\n",
      "Yousuf A, Sidiq M, Ganta S, Nagaraj A, Vishnani P, Jan I. Effect\n",
      "---\n",
      "REFERENCES > 32. Caglar E\n",
      "11Dental Research Journal\n",
      "---\n",
      "REFERENCES > 32. Caglar E\n",
      "of freeze dried powdered probiotics on gingival status and plaque inhibition: A randomized, double‑blind, parallel study.\n",
      "Contemp Clin Dent 2017;8:116‑21.\n",
      "46.\n",
      "Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ et al.\n",
      "Cochrane handbook for systematic reviews of interventions.\n",
      "wiley, 2019.\n",
      "694 p. doi: 10.1002/9781119536604.\n",
      "47.\n",
      "Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al; Cochrane Bias Methods Group; Cochrane Statistical Methods Group.\n",
      "The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.\n",
      "BMJ.\n",
      "2011;343:d5928.\n",
      "---\n",
      "REFERENCES > 48. Ryan, R\n",
      "and Hill, S. How to GRADE the Quality of the Evidence.\n",
      "Cochrane Consumers and Communication Group.\n",
      "2016.\n",
      "Available from: http://cccrg.cochrane.org/author‑resources.\n",
      "Version 3.0.\n",
      "[Last accessed on 2022 Jan 02].\n",
      "---\n",
      "Systemic corticosteroids in treatment of chronic rhinosinusitis—A systematic review\n",
      "Sarah Tamenea, Kim Dalhoff b, Peter Schwarzc, Vibeke Backera,d and Kasper Aanaesa aDepartment of Otorhinolaryngology, Head & Neck Surgery and Audiology, Rigshospitalet and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; bDepartment of Clinical Pharmacology, Bispebjerg and Frederiksberg University Hospital, Copenhagen, Denmark; cDepartment of Endocrinology, Rigshospitalet and Faculty of Health Sciences, University of Copenhagen, Denmark, Copenhagen; dCenter of Physical Activity Research (CFAS), Rigshospitalet, University Hospital, Copenhagen, Denmark\n",
      "---\n",
      "Systemic corticosteroids in treatment of chronic rhinosinusitis—A systematic review > ABSTRACT\n",
      "Purpose: When first-line chronic rhinosinusitis (CRS) treatment fails, patients can either be treated with oral or injected systemic corticosteroids.\n",
      "Although the EPOS and international guidelines for CRS do not mention injected corticosteroids, it is commonly used by ear, nose, and throat specialists.\n",
      "---\n",
      "Systemic corticosteroids in treatment of chronic rhinosinusitis—A systematic review > ABSTRACT\n",
      "While the risks of systemic corticosteroids, in general, are known, the pros and cons of injected and oral corticosteroids (OCS) in CRS treatment are unclear.\n",
      "Methods: A systematic review of studies that report the effects and/or side effects of injected and oral corticosteroids in the treatment of CRS was made according to the PRISMA guidelines.\n",
      "---\n",
      "Systemic corticosteroids in treatment of chronic rhinosinusitis—A systematic review > ABSTRACT\n",
      "Results: Altogether, 48 studies were included, only five studies reported on injected corticosteroids, and five attended with side effects.\n",
      "---\n",
      "Systemic corticosteroids in treatment of chronic rhinosinusitis—A systematic review > ABSTRACT\n",
      "Three studies found beneficial effects of OCS perioperatively on sinus surgery, while four articles found no effect.\n",
      "Nineteen articles reported that OCS resulted in an improvement in symptoms.\n",
      "Two articles presented a longer-lasting effect of injected corticosteroids than OCS.\n",
      "Three studies reported adverse side effects of systemic corticosteroids, while two studies showed no adverse side effects.\n",
      "One study showed less adrenal suppression after injected corticosteroids compared to OCS.\n",
      "---\n",
      "Systemic corticosteroids in treatment of chronic rhinosinusitis—A systematic review > ABSTRACT\n",
      "The evidence is not strong but shows a positive effect of systemic corticosteroids that lasts longer with injections.\n",
      "---\n",
      "Systemic corticosteroids in treatment of chronic rhinosinusitis—A systematic review > ABSTRACT\n",
      "Conclusion: Although systemic corticosteroids are widely used to treat CRS, there is a lack of studies comparing the OCS and injected corticosteroids.\n",
      "The evidence is sparse, however, injected steroids show longer effects with fewer side effects.\n",
      "An RCT study is needed to compare OCS and injected corticosteroids.\n",
      "---\n",
      "Systemic corticosteroids in treatment of chronic rhinosinusitis—A systematic review > ABSTRACT > ARTICLE HISTORY > Received 19 March 2023 Accepted 20 July 2023\n",
      "KEYWORDS\n",
      "---\n",
      "Introduction\n",
      "Chronic rhinosinusitis (CRS) is a highly prevalent inflammatory disease of the upper airways.\n",
      "---\n",
      "Introduction\n",
      "CRS can be challenging to treat, and appropriate use of medical treatments is required to optimize patients’ daily functions and their quality of life (QoL).\n",
      "When patients have tried and failed standard local treatment or still have severe symptoms (VAS ≥5), treatment with a short course of systemic steroids may be used [3–5].\n",
      "Treatment with systemic corticosteroids almost always results in an improvement of symptoms, by reducing the inflammatory response, reducing polyp size, re-establishing normal mucosal function, and thereby improving sinus drainage and improving nasal airflow and reducing obstruction of the olfactory area; however, often the effect is transient [3].\n",
      "When corticosteroid injections are chosen as the treatment plan for CRS 14 mg of Betamethasone (Diprofos ®) is used as a single injection in Denmark, which compares to 88 mg equivalent dose of prednisolone (Table 1).\n",
      "When OCS is used, a 14-day treatment plan with 50 mg prednisolone daily (700 mg in total) could be cho- sen [7].\n",
      "New treatment options with monoclonal anti- bodies (biologicals) may in some countries be offered to CRS with nasal polyps (CRSwNP) to avoid the use of systemic corticosteroids or revision sinus surgery.\n",
      "---\n",
      "Introduction\n",
      "The risks of adverse side effects heighten with increasing cumulative exposure and increasing mean daily exposure to systemic corticosteroids [9].\n",
      "The short- and long-term risks are summarized in CONTACT Sarah Tamene sarah.tamene@yahoo.dk Department of Otolaryngology, Head & Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, Inge Lehmannsvej 7, Copenhagen DK-2100, Denmark EUROPEAN CLINICAL RESPIRATORY JOURNAL 2023, VOL.\n",
      "10, 2240511 https://doi.org/10.1080/20018525.2023.2240511 © 2023 The Author(s).\n",
      "Published by Informa UK Limited, trading as Taylor & Francis Group.\n",
      "This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.\n",
      "The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.\n",
      "---\n",
      "Introduction\n",
      " | Table 2. Even though systemic corticosteroids are recommended as standard treatment for CRS, there seems to be a lack of recommendations concerning the choice of drug, choice of treatment method (injec- tion or oral corticosteroids (OCS)), dose, and duration of treatment. OCS is only sparsely mentioned in the 2020 edition of the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) and corticos- teroid injections are not mentioned at all [3]. Therefore, this review was made in an attempt to enhance the EPOS guidelines with a focus on the current evidence of effects and side effects of treating CRS with systemic corticosteroids and especially injected corticosteroids. | In Denmark, you need a prescription for buying systemic steroids.\n",
      "According to Amgros, who secure supplies of medicines for public hospitals, a total amount of 29.073 doses of 2 mL Diprofos was bought for Danish hospitals and pharmacies in 2020 (Amgros).\n",
      "We believe that the 1 ml packages are used by rheu- matologists, orthopedists, and in sports medicine, whereas the 2 mL packages primarily are used by ENT physicians.\n",
      "Hence, we assume that corticosteroid injections have regularly been used as a treatment for allergic rhinitis, non-allergic rhinitis, and CRS.\n",
      "Figure 1 shows that injected corticosteroids are still used in Denmark but also show a decrease after 2012.\n",
      "The drop in injected corticosteroids in 2013\n",
      "\n",
      "---\n",
      "Introduction\n",
      "Table 1.\n",
      "Characteristics of various corticosteroids [8].\n",
      "---\n",
      "Introduction\n",
      " | Compound | Equivalent Dose | Anti-inflammatory potency | Mineralocorticoid Potency | Biological Half-life\n",
      " | --- | --- | --- | --- | ---\n",
      " | Hydrocortisone (Cortisol) | 350 mg | 1 | 1 | Short\n",
      " | Cortisone | 438 mg | 0.8 | 0.8 | Short\n",
      " | Prednisone | 88 mg | 4 | 0.6 | Intermediate\n",
      " | Prednisolone | 88 mg | 4 | 0.6 | Intermediate\n",
      " | Triamcinolone | 70 mg | 5 | 0 | Intermediate\n",
      " | Methylprednisolone | 70 mg | 5 | 0.25 | Intermediate\n",
      " | Betamethasone | 14 mg | 25 | 0 | Long\n",
      " | Dexamethasone | 14 mg | 25 | 0 | Long\n",
      " | Fludrocortisone | N/A | 0 | 125 | Intermediate\n",
      " | Deflazacort [6] | 132 mg | N/A | N/A | N/A\n",
      "\n",
      "---\n",
      "Introduction\n",
      "Table 2.\n",
      "Side effects to systemic corticosteroids [15,17,20].\n",
      "---\n",
      "Introduction\n",
      " | Short term use | Long term use\n",
      " | Psychiatric manifestations [10]. Hypertension [11] Corticosteroid induced diabetes/poorer treatment decreases of existing diabetes [12] Infection [13] Dermatological adverse effects [14] Subcutaneous atrophy at the insertion site of injected corticosteroids [15] | Reduced sex hormones [16] Osteoporosis [17] Avascular bone necrosis [17] Subcapsular cataract [17] Glaucoma [17] Peptic ulcer disease [17] Adrenal suppression [18] Corticosteroid induced lipodystrophy [19]. Dermatological adverse effects [14]\n",
      "\n",
      "---\n",
      "Introduction\n",
      "Figure 1.\n",
      "The development of the total sold Betamethasone, 7 mg/ml, 2 ml from 2011 to 2021 in Denmark to the pharmacies and hospitals*.\n",
      "---\n",
      "Introduction\n",
      "*Numbers and figure obtained from Amgros.\n",
      "---\n",
      "Introduction\n",
      "corresponds to an increase in nonsystemic corticosteroid symptomatic treatment [21].\n",
      "Our general experience (jet unpublished data) is that patients also report a longer lasting and better effectof injections than oral corticosteroids.\n",
      "---\n",
      "Materials and methods > Data sources and search strategy\n",
      "We performed a systematic search on the PUBMED and EMBASE databases.\n",
      "---\n",
      "Materials and methods > Data sources and search strategy\n",
      "A search strategy was designed and used for each database to detect all articles concerning CRS and systemic corticosteroid treatment (Appendix 1 and 2).\n",
      "We conducted a broad search including allergic rhinitis to obtain all articles dealing with systemic corticosteroid treatment and/or side effects.\n",
      "---\n",
      "Materials and methods > Data sources and search strategy\n",
      "A systematic review was performed to identify all studies that reported the use of systematic corticosteroids and either the effects or side effects of the used medical therapy.\n",
      "This review was done accordingly to the elements in the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) by using the 27-item checklist for items to include in a systematic review and a four-phase diagram illustrating the flow of information [23].\n",
      "---\n",
      "Study selection\n",
      "The studies were reviewed by two independent authors (STA and KA) and were selected by the inclusion and exclusion criteria.\n",
      "Titles and abstracts were screened using the web-based Covidence program for systematic review management.\n",
      "All our search results were uploaded to the program and assessed individually by the two authors.\n",
      "Conflicts were solved by full-text screening with STA. A fulltext review was performed in the next phase, and the studies were analyzed and included if meeting the selection criteria.\n",
      "Finally, missing studies were searched manually and accessed from the library paper edition if possible.\n",
      "---\n",
      "Eligibility criteria\n",
      "The selected inclusion criteria were: Only papers from 1987 and forward were included.\n",
      "Patients with diffuse primary CRS (eosinophilic chronic rhinosinusitis (eCRS)/non-eosinophilic chronic rhinosinusitis (Non-eCRS)/chronic rhinosinusitis with nasal polyps (CRSwNP)/chronic rhinosinusitis without nasal polyps (CRSsNP)/Central compartment atopic disease (CCAD)) and/or allergic rhinitis (Appendix 3) according to the EPOS [3] AND, OR\n",
      "---\n",
      "Eligibility criteria\n",
      "(1) Papers reporting of effect, efficacy, and/or side effects of systemic corticosteroids AND,\n",
      "---\n",
      "Eligibility criteria\n",
      "(2) Papers published from 1987 and forward AND, EITHER,\n",
      "---\n",
      "Eligibility criteria\n",
      "The exclusion criteria were:\n",
      "---\n",
      "Eligibility criteria > (1) Non-English\n",
      "(2) Case reports < 5 patients\n",
      "---\n",
      "Eligibility criteria > (4) Localized CRS\n",
      "(5) Allergic fungal and fungal sinusitis\n",
      "---\n",
      "Eligibility criteria > (4) Localized CRS\n",
      "(6) Patients <18 years of age\n",
      "---\n",
      "Eligibility criteria > (4) Localized CRS\n",
      "(7) Only local treatment with corticosteroids\n",
      "---\n",
      "Eligibility criteria > (4) Localized CRS\n",
      "(8) Only local injection with corticosteroids in nasal polyps\n",
      "---\n",
      "Eligibility criteria > (4) Localized CRS\n",
      "(9) Papers where both drug name and dosage/ treatment length are not given\n",
      "---\n",
      "Eligibility criteria > (4) Localized CRS\n",
      "(10) Letters, reviews, and animal studies\n",
      "---\n",
      "Eligibility criteria > (4) Localized CRS\n",
      "Furthermore, studies by the same authors, from the same area or possibly overlapping in time were closely reviewed to avoid any patient group overlap.\n",
      "---\n",
      "Data extraction\n",
      "A data sheet was made to extract relevant data, and the following was entered into tables: author name, publication year, study design, studied drug/treatment plan, side effects, conclusions and quality of evidence.\n",
      "---\n",
      "Data extraction\n",
      "For the data to be considered complete, it required a profound description of the treatment plan, its effects, or side effects.\n",
      "When the initial selection was done, the references cited in the authors’ articles were assessed to examine each article.\n",
      "A final data set was made once the articles were assessed for eligibility.\n",
      "---\n",
      "Data extraction\n",
      "Details of the data and characteristics of the studies are summarized in tables.\n",
      "---\n",
      "Data extraction\n",
      "A flow chart of our study retrieval and selection process is provided in Figure 2.\n",
      "---\n",
      "Results\n",
      "Of the 1,177 identified articles 48 were selected for further review.\n",
      "The included studies have been divided and summarized into five tables:1) systemic corticosteroids perioperatively (n = 7; Table 3), 2) the effect of oral corticosteroids (n = 20; Table 4), 3) the effect of injected corticosteroids (n = 5; Table 5), 4) side effects to systemic corticosteroids (n = 5; Table 6), 5) other effects of corticosteroids (n = 11; Table 7).\n",
      "---\n",
      "Results > Identification of studies via databases\n",
      "Records identified from: PubMed (n = 1064) Embase (n = 113) Total (n = 1177)\n",
      "---\n",
      "Results > Identification of studies via databases\n",
      "Records screened (n = 1087) Records removed before screening:\n",
      "---\n",
      "Results > Identification of studies via databases\n",
      "Duplicate records removed (n = 90) Records marked as ineligible by automation tools (n = 0)\n",
      "---\n",
      "Results > Identification of studies via databases\n",
      "Records excluded; criteria applied (n = 989)\n",
      "---\n",
      "Results > Identification of studies via databases\n",
      "Reports not retrieved (n = 2)[1, 2] Reports sought for retrieval (n = 98)\n",
      "---\n",
      "Results > Identification of studies via databases\n",
      "Reports assessed for eligibility (n = 96) Reports excluded, with reasons (n = 48)\n",
      "---\n",
      "Results > Identification of studies via databases\n",
      "Table 3.\n",
      "Systemic corticosteroids perioperatively (n = 7)\n",
      "---\n",
      "Results > Identification of studies via databases\n",
      "Table 4.\n",
      "Effect of oral systemic corticosteroids (n = 20)\n",
      "---\n",
      "Results > Identification of studies via databases\n",
      "Table 5.\n",
      "Effect of injected systemic corticosteroids (n = 5)\n",
      "---\n",
      "Results > Identification of studies via databases\n",
      "Table 6.\n",
      "Side effects to systemic corticosteroids (n = 5)\n",
      "---\n",
      "Results > Identification of studies via databases\n",
      "Table 7.\n",
      "Other effects of systemic corticosteroids (n = 11) Studies included in review (n = 48) Figure 2.\n",
      "Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram.\n",
      "PRISMA flowchart depicting the selection process in this study [1,2,24].\n",
      "---\n",
      "Discussion\n",
      "Although the use of systemic corticosteroids is a recommended treatment for CRS, there is a lack of a standardized prescribing regimen for oral and injected corticosteroids.\n",
      "In our study, we found 20 studies reporting the effects of OCS, but we only found five studies concerning injected corticosteroids although injected corticosteroids are frequently used [21] (Figure 1).\n",
      "---\n",
      "Discussion\n",
      "It is noteworthy that the choice of OCS dosage and length of treatment seems to reflect personal experience, as we found that very different dosages have been\n",
      "---\n",
      "Discussion\n",
      "3. Summary of results: systemic corticosteroids perioperatively.\n",
      "---\n",
      "Discussion > Impact of Preoperative Systemic Corticosteroids on the Histology and Diagnosis of Eosinophilic Chronic Rhinosinusitis [25] > Akiyama 2019\n",
      "Type of study\n",
      "---\n",
      "Discussion > Impact of Preoperative Systemic Corticosteroids on the Histology and Diagnosis of Eosinophilic Chronic Rhinosinusitis [25] > Akiyama 2019\n",
      " | Case series | 44 | Preoperative oral |  |  | \n",
      " | --- | --- | --- | --- | --- | ---\n",
      " |  | Number of patients Investigated drug |  | Side effects | Conclusions | Quality of evidence\n",
      " | 100 Oral prednisolone (30 mg/day) for 2 weeks after surgery.\n",
      " |  |  |  | Not mentioned. | Oral prednisolone did | \n",
      " |  |  |  | Not mentioned. | Olfactory recovery | \n",
      "\n",
      "---\n",
      "Discussion > Low\n",
      "prednisolone (0.3 mg/kg as a guide).\n",
      "not appear to markedly affect the tissue eosinophil count.\n",
      "---\n",
      "Discussion > Low\n",
      "greater than 50% after a course of OCS therapy may be a predictor of better subjective postoperative recovery.\n",
      "---\n",
      "Discussion > Low\n",
      "Prospective evaluation of oral corticosteroid as a predictor of postoperative olfactory recovery after functional endoscopic surgery for nasal polyposis [26] Differential effects of postoperative oral corticosteroid on eosinophilic vs. noneosinophilic CRSwNP subtypes [27] Rives 2019 Prospective 119 Oral prednisolone Shen 2019 Randomized controlled trial 1 mg/kg/day for 5 days preoperatively.\n",
      "---\n",
      "Discussion > Low\n",
      "prednisolone and 90 mg lactose for 7 days, reduced to one pill taken every other day preoperatively.\n",
      "---\n",
      "Discussion > Low\n",
      " |  |  | No severe side effects. | \n",
      " | --- | --- | --- | ---\n",
      " |  |  | Not mentioned. | \n",
      " | Moderate\n",
      " | Effect of steroids for nasal polyposis surgery: A placebo- controlled, randomized, double- blind study [28] |  |  | \n",
      " | Impact of perioperative systemic steroids on surgical outcomes in patients with chronic rhinosinusitis with polyposis: evaluation with the novel Perioperative Sinus Endoscopy (POSE) scoring system [29]\n",
      " | Ecevit 2015 Randomized controlled trial\n",
      " | Wright 2007\n",
      " |  |  | 22 Six pills of 10 mg | \n",
      " |  |  | 26 30 mg of | \n",
      "\n",
      "---\n",
      "Discussion > Low\n",
      "administration of systemic corticosteroids improves the perioperative visibility by reducing blood loss and shortens the operation time.\n",
      "---\n",
      "Discussion > Low\n",
      "systemic corticosteroids appears to confer the advantages of facilitating surgery and results in endoscopically healthier sinus cavities in the short term.\n",
      "---\n",
      "Discussion > Low\n",
      "Randomized controlled trial\n",
      "---\n",
      "Discussion > Low\n",
      "Randomized controlled trial\n",
      "---\n",
      "Discussion > Low\n",
      " | Not mentioned. | Pretreatment with\n",
      " | Not mentioned. | Oral prednisone\n",
      " | Moderate\n",
      " | Moderate\n",
      "\n",
      "---\n",
      "Discussion > Low\n",
      "prednisone for 5 days preoperatively and 9 days postoperatively.\n",
      "---\n",
      "Discussion > Clinical Trial [30]\n",
      "Lack of additive benefit of oral steroids on short-term postoperative outcomes in nasal polyposis [31] Chang 2021 Randomized controlled trial\n",
      "---\n",
      "Discussion > Clinical Trial [30] > Arancibia 2020\n",
      " | 72 | 12-day\n",
      " | 70 | Postoperative 30 mg of oral postoperative\n",
      "\n",
      "---\n",
      "Discussion > Clinical Trial [30] > Arancibia 2020\n",
      "taper of oral prednisone: 30 mg, 4 days; 20 mg, 4 days; and 10 mg 4 days.\n",
      "following endoscopic sinus surgery conferred no additional benefit over placebo.\n",
      "These results suggest that the risks of oral corticosteroids may outweigh the benefits.\n",
      "---\n",
      "Discussion > Clinical Trial [30] > Arancibia 2020\n",
      "add-on treatment for CRSwNP patients does not improve sinonasal and QoL outcomes;\n",
      "---\n",
      "Discussion > Clinical Trial [30] > Arancibia 2020\n",
      "Not mentioned.\n",
      "Postoperative OCS as an\n",
      "---\n",
      "Discussion > Clinical Trial [30] > Arancibia 2020\n",
      "prednisone for 1 week, 20 mg for 1 week, 10 mg for 1 week, and finally 5 mg for 1 week.\n",
      "thus, they should not be routinely recommended.\n",
      "---\n",
      "Discussion > Clinical Trial [30] > Moderate\n",
      "5. Summary of results: effect of systemic injected corticosteroids.\n",
      "---\n",
      "Discussion > Name\n",
      "Expression of genes that encode the annexin-1 and galectin-1 proteins in nasal polyposis and their modulation by glucocorticoid [51] Author and publication date\n",
      "---\n",
      "Discussion > Fernandes 2010\n",
      "Type of study\n",
      "---\n",
      "Discussion > Fernandes 2010\n",
      " | Prospective | 11 | A 1 ml ampoule of\n",
      " | --- | --- | ---\n",
      " | Number of patients | Investigated drug | Side effects | Conclusions | Quality of evidence\n",
      " | --- | --- | --- | --- | ---\n",
      " | 36 Oral prednisolone\n",
      " |  |  | Not mentioned. | When subjects were given | \n",
      " |  |  | Not mentioned. | Specific immunotherapy | \n",
      "\n",
      "---\n",
      "Discussion > Moderate\n",
      "betamethasone acetate/ betamethasone sodium phosphate administered intramuscularly five days before surgery.\n",
      "systemic corticosteroids, the mean gene expression of the anti- inflammatory protein annexin-1 decreased significantly.\n",
      "---\n",
      "Discussion > Moderate\n",
      "can greatly reduce the need for corticosteroids.\n",
      "---\n",
      "Discussion > Moderate\n",
      "Specific immunotherapy can greatly reduce the need for systemic steroids in allergic rhinitis [21]\n",
      "---\n",
      "Discussion > Moderate\n",
      "Evolution of symptoms associated to nasal polyposis following oral steroid treatment and nasalization of the ethmoid–radical ethmoidectomy is functional surgery for NPS [52]\n",
      "---\n",
      "Discussion > Jankowski 2003\n",
      "Retrospective 39 173 93.1% received only injected Depomedrol, Diprospan or Lederspan and 6.9% received subcutaneous immunotherapy and/ or corticosteroids.\n",
      "---\n",
      "Discussion > Jankowski 2003\n",
      "Case series 24 Prednisolone 60 mg/ Low\n",
      "---\n",
      "Discussion > Low\n",
      "day for 7 days + the day before surgery and triamcinolone 80 mg depot injection the day after surgery.\n",
      "---\n",
      "Discussion > Low\n",
      "No side effects or complications were reported.\n",
      "---\n",
      "Discussion > Low\n",
      "No side effects or complications were reported.\n",
      "---\n",
      "Discussion > Low\n",
      " |  |  | Systemic corticosteroids are highly effective to relief symptoms associated to nasal polyposis, but their efficacy disappears over time. 5/6 who poorly responded to OCS had better effect after triamcinolone depot injection and remained stable for 12 months.\n",
      " | --- | --- | ---\n",
      " | Olfaction in patients with nasal polyposis: effects of systemic steroids and radical ethmoidectomy with middle turbinate resection (nasalization) [22] |  | Following the 7-day treatment with systemic corticosteroids the olfactory score increased significantly but decreased in the following two months. It re-increased after the depot injection of 80 mg triamcinolone and was stable 12 months after.\n",
      " | Intramuscular betamethasone dipropionate vs. oral prednisolone in hay fever patients [53]\n",
      " | Jankowski 2003\n",
      " | Laursen 1987\n",
      " | Case series | 56 | Prednisolone 60 mg/\n",
      "\n",
      "---\n",
      "Discussion > Low\n",
      "Randomized controlled trial day for 7 days and depot injection of 80 mg triamcinolone.\n",
      "---\n",
      "Discussion > Low\n",
      "7.5 mg/day for 3 weeks or injection with depot betamethasone dipropionate 2 ml.\n",
      "No severe side effects.\n",
      "The injection seems to be as effective as the oral treatment, and after 3 weeks treatment with depot steroids, in contrast to oral treatment, there seems to be no suppression of the hypothalamic pituitary-adrenal axis.\n",
      "---\n",
      "Discussion > Low\n",
      "given with a dosing interval from 0.25 mg to 50 mg daily and a treatment length interval from 5 days to 4 weeks for the OCS (Table 3, 4, 5, 6, 7).\n",
      "One injection of 14 mg betamethasone corresponds to only 88 mg pre- dnisolone (Table 1), which is a much lower dose than the usual given oral treatment course (for example 37.5 mg/d for 10 days).\n",
      "Given that OCS is widely used with different doses and treatment lengths and injected cor- ticosteroids are also frequently used, it would be intui- tive to assume that systemic corticosteroids are efficacious and relatively safe to use.\n",
      "However, as our results show, there is a lack of high-level evidence to support the use of systemic corticosteroids.\n",
      "No study has studied the efficacy and side effects of OCS com- pared to injected corticosteroid use in CRS patients or any of the subgroups from our inclusions.\n",
      "---\n",
      "Discussion > Low\n",
      "Of the 20 studies regarding the effect of OCS, 19 reported beneficial effects and/or symptom improvements and one concluded that the effect of OCS was similar to topical corticosteroids (Table 4).\n",
      "However, in the study by Karaki et.\n",
      "al, the dose of OCS for seasonal allergic rhinitis was very low (0.25 mg twice daily), and corticosteroids, but the period for this effect is also addressed in some studies.\n",
      "Two studies have reported symptom relief from OCS use [36,52].\n",
      "However, Jankowski et al.\n",
      "addressed a longer-lasting effect from administrating patients with depot injection of triamcinolone 80 mg than oral prednisolone as the VAS score decreased from 6.4 to 2.0 (mean values) after the injection and stayed stable between 2.0 and 2.6 (mean values) in the next 12 months compared to the re-increase of VAS from 3.2 to 6.4 (mean values) 2 months after the oral treatment [52].\n",
      "---\n",
      "Discussion > Low\n",
      "6. Summary of results: side effects of systemic corticosteroids.\n",
      "---\n",
      "Discussion > Long-Term Therapy with Corticosteroids in Nasal Polyposis: A Bone Metabolism Assessment [54]\n",
      "Author and publication date\n",
      "---\n",
      "Discussion > Long-Term Therapy with Corticosteroids in Nasal Polyposis: A Bone Metabolism Assessment [54]\n",
      " | Gelardi 2019 Case control | 40 | Prednisone. Dose unknown. | No complications occurred after chronic treatment |  | \n",
      " | --- | --- | --- | --- | --- | ---\n",
      " | Type of study\n",
      " | Case series | 51 | A history of at least two |  |  | \n",
      " |  | Number of patients | Investigated drug | Side effects | Conclusions | Quality of evidence\n",
      "\n",
      "---\n",
      "Discussion > Long-Term Therapy with Corticosteroids in Nasal Polyposis: A Bone Metabolism Assessment [54]\n",
      "with OCS(hypertension, type 2 diabetes mellitus, gastric ulcer, cataracts and glaucoma).\n",
      "No increased risk of osteoporosis or osteopenia.\n",
      "---\n",
      "Discussion > Long-Term Therapy with Corticosteroids in Nasal Polyposis: A Bone Metabolism Assessment [54]\n",
      "No high risk of osteoporosis or osteopenia.\n",
      "---\n",
      "Discussion > Long-Term Therapy with Corticosteroids in Nasal Polyposis: A Bone Metabolism Assessment [54]\n",
      "Treatment with corticosteroids did not increase the likelihood of being affected by osteopenia or osteoporosis.\n",
      "---\n",
      "Discussion > Long-Term Therapy with Corticosteroids in Nasal Polyposis: A Bone Metabolism Assessment [54]\n",
      "2–3 moderate courses of OCS annually may be used without high risk of causing osteopenia/ osteoporosis in patients with CRSwNP.\n",
      "---\n",
      "Discussion > Very low\n",
      "Very low Does the oral steroid treatment of patients with nasal polyposis cause osteopenia or osteoporosis?\n",
      "[55] Cross-reactions to systemic corticosteroids in patients contact sensitized to budesonide [56]\n",
      "---\n",
      "Discussion > Sahlstrand- Johnson 2019\n",
      " | Hansel 2020 | Prospective | 23 | Systemic |  | \n",
      " | --- | --- | --- | --- | --- | ---\n",
      " | courses of Prednisone equivalents during\n",
      " | the last year.\n",
      " | Mean intake =\n",
      " | 891 mg.\n",
      " |  |  |  |  |  | \n",
      "\n",
      "---\n",
      "Discussion > Sahlstrand- Johnson 2019\n",
      "Osteoporosis and adrenal insufficiency.\n",
      "---\n",
      "Discussion > Low\n",
      "hydrocortisone 21sodium hemisuccinate, methylprednisolone, methylprednisolone sodium succinate, prednisone, triamcinolone.\n",
      "---\n",
      "Discussion > Low\n",
      "consumption during the past year was greater than three short courses of reactions to systemic corticosteroids.\n",
      "---\n",
      "Discussion > Low\n",
      "Patients with severe nasal polyposis and a high corticosteroid consumption have a high prevalence of glucocorticoid-induced osteoporosis and secondary adrenal insufficiency.\n",
      "Adrenal suppression and osteoporosis after treatment of nasal polyposis [18]\n",
      "---\n",
      "Discussion > Very low\n",
      "Prevalence of metabolic bone disease among chronic rhinosinusitis patients treated with oral glucocorticoids [57] Bonfils 2006 Prospective 46 Oral corticosteroid\n",
      "---\n",
      "Discussion > Rajasekaran 2010\n",
      "prednisolone 1 mg/ kg/day.\n",
      "---\n",
      "Discussion > Rajasekaran 2010\n",
      "Retrospective 197 History of oral corticosteroid usage (>5 mg daily for at least 3 months).\n",
      "Osteoporosis, osteopenia, and low bone density.\n",
      "---\n",
      "Discussion > Rajasekaran 2010\n",
      "Patients with CRS with/ without polyposis treated with oral corticosteroids were found to have a high prevalence of low bone density.\n",
      "---\n",
      "Discussion > Rajasekaran 2010\n",
      "this could explain their results pointing to no signifi- cant effect of OCS [34].\n",
      "Several studies have presented evidence that corticosteroids are beneficial for CRS patients concerning improving symptoms and quality of life (Table 4).\n",
      "There seems to be support for the positive effect on olfactory function after systemic cor- ticosteroids.\n",
      "Three studies have found an improvement in olfactory function with systemic corticosteroids [22,42,49].\n",
      "Shriver et al.\n",
      "reported that 26.6% of 425 patients showed an improvement in smell function after treatment with oral methylprednisolone, but the effect was transient [49].\n",
      "Yet, the efficacy of injected corticosteroids is implied to be bigger and longer last- ing [22].\n",
      "Overall, there is a lot of data reporting on the improvement of symptoms with systemic In a study by Aasbjerg et al., it is reported that on average 1.6 corticosteroid injections are prescribed each year for patients with allergic rhinitis [21].\n",
      "This speaks for injected corticosteroids being used\n",
      "---\n",
      "Discussion > Rajasekaran 2010\n",
      " | 7. | Summary of results: other effects of systemic corticosteroids.\n",
      " | --- | ---\n",
      " | Name | Author and publication date | Type of study | Number of patients | Investigated drug | Side effects | Conclusions |  | Quality of evidence\n",
      " | --- | --- | --- | --- | --- | --- | --- | --- | ---\n",
      " | Increased ILC2s in the eosinophilic nasal polyp endotype are associated with corticosteroid responsiveness [58] | Walford 2014 | Case series | 25 | Prednisone dose greater than 30 mg daily for a minimum of 5 days, or equivalent methylprednisolone daily dose. | Not mentioned. There were fewer ILC2s in eosinophilic nasal polyps from patients treated with systemic corticosteroid compared with polyps from patients not treated with systemic corticosteroid. |  |  | Very low\n",
      " | Increased neutrophilia in nasal polyps reduces the response to oral corticosteroid therapy [59] | Wen 2012 | Case series | 266 | 30 mg prednisone once daily for seven days. | Not mentioned. Patients with the neutrophilic phenotype have less response to treatment with corticosteroids based on symptom scores. |  |  | Low\n",
      " | Increased serum amyloid A in nasal polyps is associated with systemic corticosteroid insensitivity in patients with chronic rhinosinusitis with nasal polyps: a pilot study [60] | Lu 2018 | Case series | 32 | Oral prednisolone (30 mg daily for 2 weeks). | Not mentioned. The results indicate that increased serum amyloid A (SAA) in nasal polyposis is associated with reduced response to oral corticosteroids in CRSwNP. |  |  | Very low\n",
      " | Nasal IL-25 predicts the response to oral corticosteroids in chronic rhinosinusitis with nasal polyps [61] | Hong 2018 | Case series | 52 | 2-weeks oral prednisolone. | Not mentioned. There were 29 corticosteroid- sensitive patients with CRSwNP where IL-25 increased (tissue level and serum level). |  |  | Very low\n",
      " | Mucin 1 downregulation associates with corticosteroid resistance in chronic rhinosinusitis with nasal polyps [62] | Milara 2015 | Case series | 73 | Oral deflazacort 1 mg/ kg/day for 8 days followed by 0.5 mg/ kg/day for 7 days. | Not mentioned. Mucin 1 expression is associated with corticosteroid efficacy in patients with CRSwNP. |  |  | Low\n",
      " | MUC4 impairs the anti- inflammatory effects of corticosteroids in patients with chronic rhinosinusitis with nasal polyps [63] | Milara 2017 | Case series | 81 | Oral deflazacort 1 mg/ kg/day for 8 days followed by 0.5 mg/ kg/day for 7 days. | Not mentioned. 22 had nasal polyps resistant to OCS. Mucin 4 (MUC4) expression was upregulated in these patients. |  |  | \n",
      " | MUC4 impairs the correct anti-inflammatory effects of corticosteroids.\n",
      " | Low\n",
      " | Short Term Pre-Operative Oral Corticosteroids-Tissue Remodeling in Chronic Rhinosinusitis with Nasal Polyps [64] | Radajewski 2021 | Prospective | 65 | Oral 40 mg prednisolone at least 7 days preoperatively. | Not mentioned. The number of eosinophil fibrosis decreased in the nasal polyp’s tissue. |  |  | Very low\n",
      " | Systemic prednisone administration selectively alters granulocyte subsets in nasal polyps from aspirin-exacerbated respiratory disease and chronic rhinosinusitis patients [65] | Edward 2013 | Prospective | 33 | Oral prednisolone 30 mg/day 1 week prior to surgery. | Not mentioned. Granulocyte subpopulations are focally affected within NPs by systemic corticosteroid exposure. |  |  | Low\n",
      " | Surfactant protein A and D in chronic rhinosinusitis with nasal polyposis and corticosteroid response [66] | Salman 2012 | Prospective | 36 | 3 weeks oral methylprednisolone 1 mg/kg. | Not mentioned. The surfactant protein A and D levels decreased more in patients in the CRSwNP group after methylprednisolone. |  |  | Low\n",
      " | The effects of systemic, topical, and intralesional steroid treatments on apoptosis level of nasal polyps [67] | Kapucu 2012 | Randomized controlled trial | 48 | Oral methylprednisolone 1 mg/kg/day. | No systemic or local side effects of steroid treatment were seen in any patients. | Systemic glucocorticoids induced apoptosis in nasal polyp tissue when compared with the control group. Systemic corticosteroid treatment induced the most apoptosis. |  | Low\n",
      "\n",
      "---\n",
      "Very low\n",
      "The effects of corticosteroid on tissue lactoferrin in patients with nasal polyposis [68] Acıoğlu 2012 Prospective 41 1 mg/kg/day oral methylprednisolone decreasing by 10 mg every 3rd day.\n",
      "Not mentioned.\n",
      "Patients with NP have a lower level of tissue lactoferrin (LF).\n",
      "Corticosteroid treatment has no effect on tissue LF concentrations.\n",
      "---\n",
      "Very low\n",
      "frequently and being effective.\n",
      "Essentially, the Norwegian criteria for treatment with monoclonal antibodies for nasal polyps include having had treatment with systemic corticosteroids within the past year [69].\n",
      "Similarly, it is also a criterion in Denmark.\n",
      "Having had treatment with systemic corticosteroids in the past year gives points for treatment with monoclonal antibodies [70].\n",
      "---\n",
      "Very low\n",
      "It has been reported that the injected and oral treatments with corticosteroids affect adrenal function differently.\n",
      "In a study by Laursen et al., they concluded that the adrenal gland function decreased after oral prednisolone treatment in contrast to the injected Betamethasone [53].\n",
      "However, it is not mentioned whether the adrenal gland function continues to be low or returns to normal.\n",
      "---\n",
      "Very low\n",
      "The results of our study imply a positive effect on symptom relief with systemic corticosteroids and a better and longer-lasting effect with injection.\n",
      "Yet, it is noteworthy that none of the studies have studied the efficacy of single-modality oral and injected corticosteroid use and there has been no RCT that has examined the efficacy, duration of effect, or side effects of systemic corticosteroids in CRS or allergic rhinitis patients.\n",
      "In addition, some further limitations were detected in the body of identified evidence stemming from a focus on surrogate outcomes rather than patient-important ones’ and trials’ size.\n",
      "Limited studies were also discovered in our review, mostly with lowquality evidence, making it difficult to draw scientific conclusions with high levels of evidence.\n",
      "Thus, there is a lack of strong evidence to support recommendations for systemic corticosteroids, but the existing literature points to symptom relief with systemic corticosteroid use and a longer-lasting effect and lower accumulated doses with injected corticosteroids compared to OCS.\n",
      "---\n",
      "Very low\n",
      "We found seven studies concerning the administration of systemic corticosteroids perioperatively (Table 3).\n",
      "All seven articles concerned OCS.\n",
      "Three of these concluded that there were beneficial effects after OCS treatment mostly regarding the facilitation of surgery, while four articles concluded that there was no effect of the treatment.\n",
      "Keeping in mind the limited found studies with varying levels of evidence, there seems to be no definitive recommendations in the literature regarding OCS or injected corticosteroids perioperatively.\n",
      "---\n",
      "Very low\n",
      "Our results showed that 11 studies focused on other effects of systemic corticosteroids.\n",
      "Different inflammatory markers have been reported to be regulated by systemic corticosteroids [32,35,43,44,48,51,68], and different factors have been addressed to have an impact on the responsiveness to systemic corticosteroids [59,60,62,63,66].\n",
      "This suggests there is a possibility to determine which patients are fitted for systemic corticosteroids to ensure the beneficial effects of the treatment and avoid the risks of side effects for those unresponsive to systemic corticosteroids [61].\n",
      "However, studies have shown low or very low-quality evidence, making it unmanageable to make recommendations based on the scientific conclusions.\n",
      "---\n",
      "Very low\n",
      "With prolonged or short-term use of systemic corticosteroids, there are well-known side effects (Table 2).\n",
      "Corticosteroid use can cause metabolic effects, osteoporosis, and infections, among other things.\n",
      "It has been reported that 15% of the patients presented with truncal adiposity, facial adiposity (moon face), and dorsocervical adiposity (buffalo hump) after prednisolone treatment (10—30 mg/day) after short-term therapy (<3 months) [19].\n",
      "Also, the risk of hospital admission for sepsis has been reported to be 0.05% for systemic corticosteroid users even at relatively low doses compared with 0.02% for non-corticosteroid users [71].\n",
      "The risks of adverse side effects heighten with increasing cumulative exposure and increasing mean daily exposure to systemic corticosteroids [9].\n",
      "Hence, it is relevant to consider the equivalent dose of OCS which is higher compared to injected corticosteroids (Table 1).\n",
      "---\n",
      "Very low\n",
      "While the risks of long-term systemic corticosteroids are well known, from other diseases, there is a lack of studies concerning this in rhinitis and CRS treatment.\n",
      "We found five studies focusing on the side effects of systemic corticosteroids and three of these articles presented adverse side effects to OCS, while two studies concluded on no adverse side effects (Table 6).\n",
      "Among the severe side effects, it has been shown that there is an increased risk of bone loss and adrenal insufficiency.\n",
      "Bonfils et al.\n",
      "reported that only 39% had normal lumbar bone mineral density (BMD) and only 56% had normal BMD of the femoral neck out of 46 patients treated with OCS [18]; their included patients had an oral corticosteroid consumption during the past year that was greater than three short courses of systemic corticosteroid treatments.\n",
      "This should be compared with a prevalence of osteoporosis of 18.3% in the general population [72].\n",
      "It is highly recommended to perform DXA evaluation if a cumulated prednisolone dosage of 350 mg is reached within 1 year i.e.\n",
      "35 mg of prednisolone for 10 days [73].\n",
      "Also, guidelines in Denmark recommend performing a DXA evaluation if patients receive 5 mg of prednisolone daily for 3 months or treatment with corticosteroids equivalent to at least 5 mg daily with an accumulated dose equivalent to 450 mg in 1 year [74].\n",
      "The American College of Rheumatology’s (ACR) Glucocorticoid-Induced Osteoporosis Guideline (GIOP) recommends that all patients continuing corticosteroid therapy ≥2.5 mg/day for >3 months or having a high dose of OCS defined as >30 mg/d or an accumulated dose of >5 g/d should have a DXAevaluation [75].\n",
      "Another severe side effect has been reported to be adrenal insufficiency.\n",
      "In the study by Bonfils et al., 48.8% of 41 patients were found to have adrenal insufficiency after OCS intake [18], while the study by Laursen et al.\n",
      "[53] showed adrenal suppression with OCS but not with injected steroids.\n",
      "Among the side effects of injected corticosteroids, subcutaneous atrophy at the insertion site has been reported [15].\n",
      "Other side effects regarding the injected corticosteroids have also been addressed, namely avascular bone necrosis.\n",
      "Nasser et al.\n",
      "reported that a man with severe hay fever was given at least one depot corticosteroid injection each year for 11 years, leading to avascular necrosis of both femoral heads [76].\n",
      "These studies outline the risks of corticosteroid injections.\n",
      "On the other hand, fewer injections may cause fewer complications with lower risks of side effects.\n",
      "It was reported by Ostergaard and colleagues in a study that included 1,362 patients that a single injection of corticosteroids have no complications and supported no concern for adrenal suppression, osteoporosis, or serious tissue atrophy [77].\n",
      "Other authors have foreseen the actual safety of systemic corticosteroids without the reported side effects [43,54,55].\n",
      "---\n",
      "Very low\n",
      "In summary, there is a lack of studies that report on the prevalence of side effects of systemic corticosteroids.\n",
      "Only osteoporosis, adrenal insufficiency, risk of allergy, and tissue atrophy after injections are mentioned in the reviewed studies.\n",
      "There is especially a deficiency in the literature concerning dosage and treatment length to avoid any adverse side effects and there are no studies that report on how long it takes for side effects to arise after ending treatment with systemic corticosteroids.\n",
      "It can be critically discussed whether many of the studies were not citing side effects after systemic treatment with corticosteroids simply because rhinologists do not see them.\n",
      "Patients go to their ophthalmologists to have their glaucoma treatment, others go to the emergency room if they have (pathological) fractures, GP for diabetes, etc.\n",
      "---\n",
      "Very low\n",
      "10.1016/j.aorl.2009.03.005 [3] Fokkens WJ, Lund VJ, Hopkins C, et al.\n",
      "Executive summary of EPOS 2020 including integrated care pathways.\n",
      "Rhinology.\n",
      "2020;58(2):82–111.\n",
      "doi: 10.4193/ Rhin20.601 [4] Hellings PW, Klimek L, Cingi C, et al.\n",
      "Non-allergic rhinitis: position paper of the european academy of allergy and clinical immunology.\n",
      "Allergy.\n",
      "2017;72 (11):1657–1665.\n",
      "doi: 10.1111/all.13200 [5] Hellings PW, Scadding G, Bachert C, et al.\n",
      "EUFOREA treatment algorithm for allergic rhinitis.\n",
      "Rhinology.\n",
      "2020;58(6):618–622.\n",
      "doi: 10.4193/Rhin20.376 Parente L. Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids.\n",
      "BMC Pharmacol Toxicol.\n",
      "2017;18(1):1. doi: 10.1186/s40360-016-0111-8 [7] Kirtsreesakul V, Wongsritrang K, Ruttanaphol S. Clinical efficacy of a short course of systemic steroids in nasal polyposis.\n",
      "Rhinology.\n",
      "2011;49(5):525–532.\n",
      "doi:\n",
      "---\n",
      "Very low\n",
      "Limited studies have been discovered in our paper implicating the lack of high level of evidence of the efficacy, duration of effect, and side effects of OCS and injected corticosteroids.\n",
      "Also, the limited number of studies indicates no strong evidence for the scientific conclusions emphasizing the need for a well-conducted RCT regarding this topic.\n",
      "---\n",
      "Conclusions\n",
      "Oral and injected glucocorticosteroids are often effectively used in CRS treatment.\n",
      "Nevertheless, evidence of drug of choice, dosage, treatment length, number of treatment courses pr.\n",
      "year, side effects, and treatment methods are surprisingly poor.\n",
      "The only side effects reported were osteoporosis and adrenal insufficiency.\n",
      "A careful estimate shows that the effect of OCS lasts 2 months and a little longer for injected corticosteroids.\n",
      "Additionally, the corticosteroid injection has a much lower dose compared to OCS with less adrenal suppression, but the effect cannot be stopped if side effects occur.\n",
      "Altogether, the presented data indicate that an RCT study is needed to compare OCS and injected corticosteroids, focusing on their efficacy, duration of effect and side effects.\n",
      "---\n",
      "Acknowledgments\n",
      "The authors would like to thank Jeppe Skou Petersen, seniorspecialist, from Amgros for providing data.\n",
      "---\n",
      "Disclosure statement\n",
      "No potential conflict of interest was reported by the author(s).\n",
      "---\n",
      "Funding\n",
      "There has been no funding for this work.\n",
      "---\n",
      "Thank References\n",
      "[1] Ho J, Li W, Grayson JW, et al.\n",
      "Systemic medication requirement in post-surgical patients with eosinophilic chronic rhinosinusitis.\n",
      "Rhinology.\n",
      "2021;59(1):59–65.\n",
      "doi: 10.4193/Rhin20.073 [2] Giordano J, Darras J, Chevalier D, et al.\n",
      "Preoperative corticosteroid treatment and nasal polyposis.\n",
      "Ann Otolaryngol Chir Cervicofac.\n",
      "2009;126(3):120–124.\n",
      "doi:\n",
      "---\n",
      "Thank References\n",
      "10.4193/Rhino11.140 [8] ClinCals.\n",
      "(2015, October 24).\n",
      "Corticosteroid Conversion Calculator.\n",
      "Retrieved from ClinCals: https://clincalc.\n",
      "com/corticosteroids/ [9] Price DB, Trudo F, Voorham J, et al.\n",
      "Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study.\n",
      "J Asthma Allergy.\n",
      "2018;11:193–204.\n",
      "doi: 10.2147/JAA.S176026 [10] Warrington TP, Bostwick JM.\n",
      "Psychiatric adverse effects of corticosteroids.\n",
      "Mayo Clin Proc.\n",
      "2006;81 (10):1361–1367.\n",
      "doi: 10.4065/81.10.1361 [11] Goodwin JE, Geller DS.\n",
      "Glucocorticoid-induced hypertension.\n",
      "Pediatr Nephrol.\n",
      "2012;27(7):1059–1066.\n",
      "doi: 10.1007/s00467-011-1928-4 [12] Hirsch IB, Paauw DS.\n",
      "Diabetes management in special situations.\n",
      "Endocrinol Metab Clin North Am.\n",
      "1997;26 (3):631–645.\n",
      "doi: 10.1016/S0889-8529(05)70271-1 [13] Segal BH, Sneller MC.\n",
      "Infectious complications of immunosuppressive therapy in patients with rheumatic diseases.\n",
      "Rheum Dis Clin North Am.\n",
      "1997;23 (2):219–237.\n",
      "doi: 10.1016/S0889-857X(05)70327-6 [14] Da Silva JA, Jacobs JW, Kirwan JR, et al.\n",
      "Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.\n",
      "Ann Rheum Dis.\n",
      "2006;65(3):285–293.\n",
      "doi: 10.1136/ard.2005.\n",
      "038638 [15] Ameratunga R. Gluteal subcutaneous atrophy after depot steroid injection for allergic rhinitis.\n",
      "World Allergy Organ J.\n",
      "2012;5(11):168–169.\n",
      "doi: 10.1097/ WOX.0b013e3182758d80 [16] Stanbury RM, Graham EM.\n",
      "Systemic corticosteroid ther- apy–side effects and their management.\n",
      "Br J Ophthalmol.\n",
      "1998;82(6):704–708.\n",
      "doi: 10.1136/bjo.82.6.704 [17] Keenan GF.\n",
      "Management of complications of glucocor- ticoid therapy.\n",
      "Clin Chest Med.\n",
      "1997;18(3):507–520.\n",
      "doi: 10.1016/S0272-5231(05)70398-1 [18] Bonfils P, Halimi P, Malinvaud D. Adrenal suppression and osteoporosis after treatment of nasal polyposis.\n",
      "Acta Otolaryngol.\n",
      "2006;126(11):1195–1200.\n",
      "doi: 10.1080/ 00016480600672667 [19] Fardet L, Kassar A, Cabane J, et al.\n",
      "Corticosteroid- induced adverse events in adults: frequency, screening and prevention.\n",
      "Drug Saf.\n",
      "2007;30(10):861–881.\n",
      "doi: 10.\n",
      "2165/00002018-200730100-00005 [20] Buchman AL.\n",
      "Side effects of corticosteroid therapy.\n",
      "J Clin Gastroenterol.\n",
      "2001;33(4):289–294.\n",
      "doi: 10.1097/ 00004836-200110000-00006 [21] Aasbjerg K, Torp-Pedersen C, Backer V. Specific immu- notherapy can greatly reduce the need for systemic steroids in allergic rhinitis.\n",
      "Allergy.\n",
      "2012;67 (11):1423–1429.\n",
      "doi: 10.1111/all.12023 [22] Jankowski R, Bodino C. Olfaction in patients with nasal polyposis: effects of systemic steroids and radical eth- moidectomy with middle turbinate resection (nasalization).\n",
      "Rhinology.\n",
      "2003;41(4):220–230.\n",
      "Moher D, Liberati A, Tetzlaff J, et al.\n",
      "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.\n",
      "PLOS Med.\n",
      "2009;6(7):e1000097.\n",
      "doi: 10.1371/journal.pmed.1000097 [24] Page MJ, Moher D, Bossuyt PM, et al.\n",
      "PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews.\n",
      "BMJ.\n",
      "2021;372:n160.\n",
      "doi: 10.1136/bmj.n160 [25] Akiyama K, Makihara S, Uraguchi K, et al.\n",
      "Impact of preoperative systemic corticosteroids on the histology and diagnosis of eosinophilic chronic rhinosinusitis.\n",
      "Int Arch Allergy Immunol.\n",
      "2019;179(2):81–88.\n",
      "doi: 10.\n",
      "1159/000496437 [26] Rives P, Espitalier F, Michel G, et al.\n",
      "Prospective evalua- tion of oral corticosteroid as a predictor of postoperative olfactory recovery after functional endoscopic surgery for nasal polyposis.\n",
      "Eur Arch Otorhinolaryngol.\n",
      "2019;276(12):3359–3366.\n",
      "doi: 10.1007/s00405-019- 05537-y [27] Shen KH, Wang YH, Hsu TW, et al.\n",
      "Differential effects of postoperative oral corticosteroid on eosinophilic vs. non-eosinophilic CRSwNP subtypes.\n",
      "Am J Otolaryngol.\n",
      "2019;40(1):22–29.\n",
      "doi: 10.1016/j.\n",
      "amjoto.2018.09.005 [28] Ecevit MC, Erdag TK, Dogan E, et al.\n",
      "Effect of steroids for nasal polyposis surgery: A placebo-controlled, ran- domized, double-blind study.\n",
      "Laryngoscope.\n",
      "2015;125 (9):2041–2045.\n",
      "doi: 10.1002/lary.25352 [29] Wright ED, Agrawal S. Impact of perioperative systemic steroids on surgical outcomes in patients with chronic rhinosinusitis with polyposis: evaluation with the novel Perioperative Sinus Endoscopy (POSE) scoring system.\n",
      "Laryngoscope.\n",
      "2007;117(11 Pt 2 Suppl 115):1–28.\n",
      "doi:\n",
      "10.1097/MLG.0b013e31814842f8 [30] Chang MT, Noel J, Ayoub NF, et al.\n",
      "Oral corticosteroids following endoscopic sinus surgery for chronic rhinosinusitis without nasal polyposis: a randomized clinical trial.\n",
      "JAMA Otolaryngology–Head & Neck Surg.\n",
      "2021;147(5):434–441.\n",
      "doi: 10.1001/jamaoto.\n",
      "2021.0011 [31] Arancibia C, Langdon C, Mullol J, et al.\n",
      "Lack of additive benefit of oral steroids on short-term postoperative outcomes in nasal polyposis.\n",
      "Laryngoscope.\n",
      "2020;130 (12):2742–2747.\n",
      "doi: 10.1002/lary.28347 [32] Workman AD, Miyake MM, Nocera AL, et al.\n",
      "Unexpected effects of systemic steroids on the CRSwNP proteome: is protein upregulation more important than inhibition?\n",
      "Int Forum Allergy Rhinol.\n",
      "2020;10(3):334–342.\n",
      "doi: 10.1002/alr.22497 [33] Watanabe S, Pinto JM, Bashir ME, et al.\n",
      "Effect of prednisone on nasal symptoms and peripheral blood T-cell function in chronic rhinosinusitis.\n",
      "Int Forum Allergy Rhinol.\n",
      "2014;4(8):609–616.\n",
      "doi: 10.1002/alr.21336 [34] Karaki M, Akiyama K, Mori N. Efficacy of intranasal steroid spray (mometasone furoate) on treatment of patients with seasonal allergic rhinitis: comparison with oral corticosteroids.\n",
      "Auris Nasus Larynx.\n",
      "2013;40 (3):277–281.\n",
      "doi: 10.1016/j.anl.2012.09.004 [35] Ekinci A. The effects of systemic steroid therapy on macrophage migration inhibitory factor concentrations in patients with nasal polyps.\n",
      "J Laryngol Otol.\n",
      "2018;132 (10):891–895.\n",
      "doi: 10.1017/S0022215118001652 Grammer LC.\n",
      "Doxycycline or oral corticosteroids for nasal polyps.\n",
      "J Allergy Clin Immunol Pract.\n",
      "2013;1 (5):541–542.\n",
      "doi: 10.1016/j.jaip.2013.04.010 [37] De Silva AP, Schembri MA, Sarah AH, et al.\n",
      "Short-term Oral Steroids Significantly Improves Chronic Rhinosinusitis without Nasal Polyps.\n",
      "Laryngoscope.\n",
      "2021;131(10):E2618–e26.\n",
      "doi: 10.1002/lary.29495 [38] Yigit O, Acioğlu E, Gelişgen R, et al.\n",
      "The effect of corticosteroid on metalloproteinase levels of nasal polyposis.\n",
      "Laryngoscope.\n",
      "2011;121(3):667–673.\n",
      "doi: 10.\n",
      "1002/lary.21462 [39] Vaidyanathan S, Williamson P, Anderson K, et al.\n",
      "Effect of systemic steroids on humming nasal nitric oxide in chronic rhinosinusitis with nasal polyposis.\n",
      "Ann Allergy Asthma Immunol.\n",
      "2010;105(6):412–417.\n",
      "doi: 10.1016/j.\n",
      "anai.2010.08.017 [40] Won TB, Jang E, Min SK, et al.\n",
      "Treatment outcomes and predictors for systemic steroids in nasal polyposis.\n",
      "Acta Otolaryngol.\n",
      "2012;132 Suppl 1:S82–7.\n",
      "doi: 10.3109/ 00016489.2012.659753 [41] Yazici D, Ü T, Uğuz A. The effect of corticosteroid therapy on cyclooxygenase 2, vascular endothelial growth factor, and inducible nitric oxide synthase expression levels in nasal polyposis.\n",
      "Eur Arch Otorhinolaryngol.\n",
      "2014;271(6):1541–1547.\n",
      "doi: 10.\n",
      "1007/s00405-013-2718-3 [42] Goektas O, Lau L, Olze H. Treatment of chronic rhinosinusitis with pressure-pulsed corticosteroid inhalation.\n",
      "---\n",
      "Thank References\n",
      "Indian J Otolaryngol Head Neck Surg.\n",
      "2013;65(Suppl 2):402–405.\n",
      "doi: 10.1007/s12070-013-0625-y [43] Lennard CM, Mann EA, Sun LL, et al.\n",
      "Interleukin-1 beta, interleukin-5, interleukin-6, interleukin-8, and tumor necrosis factor-alpha in chronic sinusitis:\n",
      "---\n",
      "Thank References\n",
      "response to systemic corticosteroids.\n",
      "Am J Rhinol.\n",
      "---\n",
      "Thank References\n",
      "2000;14(6):367–373.\n",
      "doi: 10.2500/105065800779 954329 [44] Bolger WE, Joshi AS, Spear S, et al.\n",
      "Gene expression analysis in sinonasal polyposis before and after oral corticosteroids: a preliminary investigation.\n",
      "---\n",
      "Thank References\n",
      "Otolaryngol Head Neck Surg.\n",
      "2007;137(1):27–33.\n",
      "doi:\n",
      "10.1016/j.otohns.2007.01.023 [45] Tuncer U, Soylu L, Aydogan B, et al.\n",
      "The effectiveness of steroid treatment in nasal polyposis.\n",
      "Auris Nasus Larynx.\n",
      "2003;30(3):263–268.\n",
      "doi: 10.1016/S0385-8146 (03)00051-8 [46] Hissaria P, Smith W, Wormald PJ, et al.\n",
      "Short course of systemic corticosteroids in sinonasal polyposis: a double-blind, randomized, placebo-controlled trial with evaluation of outcome measures.\n",
      "J Allergy Clin Immunol.\n",
      "2006;118(1):128–133.\n",
      "doi: 10.1016/j.jaci.\n",
      "2006.03.012\n",
      "8.e5.\n",
      "doi: 10.1016/j.jaci.2012.01.079 [60] Lu H, Lin XS, Yao DM, et al.\n",
      "Increased serum amyloid a in nasal polyps is associated with systemic corticosteroid insensitivity in patients with chronic rhinosinusitis with nasal polyps: a pilot study.\n",
      "Eur Arch Otorhinolaryngol.\n",
      "2018;275(2):401–408.\n",
      "doi: 10.1007/ s00405-017-4809-z [61] Hong H, Chen F, Sun Y, et al.\n",
      "Nasal IL-25 predicts the response to oral corticosteroids in chronic rhinosinusitis with nasal polyps.\n",
      "J Allergy Clin Immunol.\n",
      "2018;141(5):1890–1892.\n",
      "doi: 10.1016/j.jaci.2017.10.050 Milara J, Peiró T, Armengot M, et al.\n",
      "Mucin 1 downregulation associates with corticosteroid resistance in chronic rhinosinusitis with nasal polyps.\n",
      "J Allergy Clin Immunol.\n",
      "2015;135(2):470–476.\n",
      "doi: 10.1016/j.jaci.2014.07.011 [63] Milara J, Morell A, Ballester B, et al.\n",
      "MUC4 impairs the anti-inflammatory effects of corticosteroids in patients with chronic rhinosinusitis with nasal polyps.\n",
      "J Allergy Clin Immunol.\n",
      "2017;139(3):855–62.e13.\n",
      "doi: 10.1016/j.\n",
      "jaci.2016.06.064 [64] Radajewski K, Kalińczak-Górna P, Zdrenka M, et al.\n",
      "Short Term Pre-Operative Oral Corticosteroids— Tissue Remodeling in Chronic Rhinosinusitis with Nasal Polyps.\n",
      "J Clin Med.\n",
      "2021;10(15):3346. doi: 10.\n",
      "3390/jcm10153346 [65] Edward JA, Sanyal M, Ramakrishnan VR, et al.\n",
      "Systemic prednisone administration selectively alters granulocyte subsets in nasal polyps from aspirin-exacerbated respiratory disease and chronic rhinosinusitis patients.\n",
      "Int Forum Allergy Rhinol.\n",
      "2013;3(11):866–876.\n",
      "doi: 10.1002/alr.21221 [66] Salman S, Akpinar ME, Yigit O, et al.\n",
      "Surfactant protein a and D in chronic rhinosinusitis with nasal polyposis and corticosteroid response.\n",
      "Am J Rhinol Allergy.\n",
      "2012;26(2):e76–80.\n",
      "doi: 10.2500/ajra.2012.26.3739 [67] Kapucu B, Cekin E, Erkul BE, et al.\n",
      "The effects of systemic, topical, and intralesional steroid treatments on apoptosis level of nasal polyps.\n",
      "Otolaryngol Head Neck Surg.\n",
      "2012;147(3):563–567.\n",
      "doi: 10.1177/ 0194599812446678 [68] Acıoğlu E, Yigit O, Alkan Z, et al.\n",
      "The effects of corticosteroid on tissue lactoferrin in patients with nasal polyposis.\n",
      "Am J Rhinol Allergy.\n",
      "2012;26(1):e28–31.\n",
      "doi: 10.2500/ajra.2012.26.3735 [69] Legemiddelverk S (18 Oct 2022).\n",
      "Nye Metoder.\n",
      "---\n",
      "Thank References\n",
      "[47] Berkiten G, Salturk Z, Topaloğlu İ. Efficacy of systemic steroid treatment in sinonasal polyposis.\n",
      "J Craniofac Surg.\n",
      "2013;24(3):e305–8.\n",
      "doi: 10.1097/SCS.0b013e 31828f261f [48] Woodworth BA, Joseph K, Kaplan AP, et al.\n",
      "Alterations in eotaxin, monocyte chemoattractant protein-4, interleukin-5, and interleukin-13 after systemic steroid treatment for nasal polyps.\n",
      "Otolaryngol Head Neck Surg.\n",
      "2004;131(5):585–589.\n",
      "doi: 10.1016/j.otohns.2004.\n",
      "---\n",
      "Thank References\n",
      "05.028\n",
      "---\n",
      "Thank References\n",
      "[49] Schriever VA, Merkonidis C, Gupta N, et al.\n",
      "Treatment of smell loss with systemic methylprednisolone.\n",
      "---\n",
      "Thank References\n",
      "Rhinology.\n",
      "2012;50(3):284–289.\n",
      "doi: 10.4193/Rhino.\n",
      "11.207 [50] Benítez P, Alobid I, de Haro J, et al.\n",
      "A short course of oral prednisone followed by intranasal budesonide is an effective treatment of severe nasal polyps.\n",
      "Laryngoscope.\n",
      "2006;116(5):770–775.\n",
      "doi: 10.1097/01.mlg.0000205218.\n",
      "37514.0f [51] Fernandes AM, Babeto E, Rahal P, et al.\n",
      "Expression of genes that encode the annexin-1 and galectin-1 proteins in nasal polyposis and their modulation by glucocorticoid.\n",
      "Braz J Otorhinolaryngol.\n",
      "2010;76 (2):213–218.\n",
      "doi: 10.1590/S1808-86942010000200011 [52] Jankowski R, Bodino C. Evolution of symptoms associated to nasal polyposis following oral steroid treatment and nasalization of the ethmoid–radical ethmoidectomy is functional surgery for NPS.\n",
      "Rhinology.\n",
      "2003;41(4):211–219.\n",
      "[53] Laursen LC, Faurschou P, Pals H, et al.\n",
      "Intramuscular betamethasone dipropionate vs. oral prednisolone in hay fever patients.\n",
      "Allergy.\n",
      "1987;42(3):168–172.\n",
      "doi: 10.\n",
      "1111/j.1398-9995.1987.tb02194.x [54] Gelardi M, Barbara F, Covelli I, et al.\n",
      "Long-Term Therapy with Corticosteroids in Nasal Polyposis: A Bone Metabolism Assessment.\n",
      "Indian J Otolaryngol Head Neck Surg.\n",
      "2019;71(Suppl 3):2050–2056.\n",
      "doi: 10.\n",
      "1007/s12070-018-1466-5 [55] Sahlstrand-Johnson P, Holmström M, Ehnhage A. Does the oral steroid treatment of patients with nasal polyposis cause osteopenia or osteoporosis?\n",
      "Clinical Otolaryngology: Official Journal Of ENT-UK; Official Journal Of Netherlands Society For Oto-RhinoLaryngology & Cervico-Facial Surgery.\n",
      "2019;44 (6):1011–1016.\n",
      "doi: 10.1111/coa.13431 [56] Hansel K, Marietti R, Bianchi L, et al.\n",
      "Cross-reactions to systemic corticosteroids in patients contact sensitized to budesonide.\n",
      "Contact Dermatitis.\n",
      "2020;83(4):321–324.\n",
      "doi: 10.1111/cod.13597 [57] Rajasekaran K, Seth R, Abelson A, et al.\n",
      "Prevalence of metabolic bone disease among chronic rhinosinusitis patients treated with oral glucocorticoids.\n",
      "Am J Rhinol Allergy.\n",
      "2010;24(3):215–219.\n",
      "doi: 10.2500/ajra.2010.24.\n",
      "3445 [58] Walford HH, Lund SJ, Baum RE, et al.\n",
      "Increased ILC2s in the eosinophilic nasal polyp endotype are associated with corticosteroid responsiveness.\n",
      "Clin Immunol.\n",
      "2014;155(1):126–135.\n",
      "doi: 10.1016/j.clim.2014.09.007 [59] Wen W, Liu W, Zhang L, et al.\n",
      "Increased neutrophilia in nasal polyps reduces the response to oral corticosteroid therapy.\n",
      "J Allergy Clin Immunol.\n",
      "2012;129(6):1522– Medicinrådet.\n",
      "(26 Oct 2022).\n",
      "Medicinrådet.\n",
      "Retrieved from medicinraadet.dk: https://medicinraadet.dk/ media/tx2aecsh/medicinrådets-samling-af-vurderingervedr-svær-crswnp-vers-1-1.pdf [71] Waljee AK, Rogers MA, Lin P, et al.\n",
      "Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study.\n",
      "BMJ.\n",
      "2017;357:j1415.\n",
      "[72] Salari N, Ghasemi H, Mohammadi L, et al.\n",
      "The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis.\n",
      "J Orthop Surg Res.\n",
      "2021;16(1):609. doi: 10.1186/s13018021-02772-0 [73] Walsh LJ, Lewis SA, Wong CA, et al.\n",
      "The impact of oral corticosteroid use on bone mineral density and vertebral fracture.\n",
      "Am J Respir Crit Care Med.\n",
      "2002;166 (5):691–695.\n",
      "doi: 10.1164/rccm.2110047 [74] Selskab DE (10 2020).\n",
      "Glukokortikoid-Induceret Osteoporose.\n",
      "Retrieved from Dansk Endokrinologisk Selskab: https://endocrinology.dk/nbv/calcium-ogknoglemetabolisme/4-glukokortikoid-induceretosteoporose/ [75] Buckley L, Guyatt G, Fink HA, et al.\n",
      "2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.\n",
      "Arthritis & Rheumat.\n",
      "2017;69(8):1521–1537.\n",
      "doi: 10.\n",
      "1002/art.40137 [76] Nasser SM, Ewan PW.\n",
      "Lesson of the week: Depot corticosteroid treatment for hay fever causing avascular necrosis of both hips.\n",
      "BMJ.\n",
      "2001;322(7302):1589–1591.\n",
      "doi: 10.1136/bmj.322.7302.1589 [77] Østergaard MS, Østrem A, Söderström M. Hay fever and a single intramuscular injection of corticosteroid: a systematic review.\n",
      "Prim Care Respir J.\n",
      "2005;14 (3):124–130.\n",
      "doi: 10.1016/j.pcrj.2004.08.001 Retrieved from nyemetoder.no: https://nyemetoder.no/ metoder/dupilumab-dupixent-indikasjon-iv\n",
      "---\n",
      "Appendices Appendix 1: Search history in PubMed\n",
      " | Number | Search details | Results\n",
      " | --- | --- | ---\n",
      " | 1 | Chronic rhinosinusitis*[Title/Abstract] | 7,605\n",
      " | 2 | CRS[Title/Abstract] | 12,753\n",
      " | 3 | Nasal polyps*[Title/Abstract] | 5,258\n",
      " | 4 | Nasal polyp*[Title/Abstract] | 7,729\n",
      " | 5 | Allergy*[Title/Abstract] | 82,107\n",
      " | 6 | #1 OR #2 OR #3 OR #4 OR #5 | 102,756\n",
      " | 7 | Systemic glucocorticoids*[Title/Abstract] | 512\n",
      " | 8 | Systemic glucocorticoid*[Title/Abstract] | 856\n",
      " | 9 | Oral glucocorticoid*[Title/Abstract] | 858\n",
      " | 10 | Oral glucocorticoids*[Title/Abstract] | 577\n",
      " | 11 | inj. glucocorticoid*[Title/Abstract] | 5\n",
      " | 12 | inj. glucocorticoids*[Title/Abstract] | 3\n",
      " | 13 | injected glucocorticoids*[Title/Abstract] | 5\n",
      " | 14 | injected glucocorticoid*[Title/Abstract] | 8\n",
      " | 15 | injection glucocorticoids*[Title/Abstract] | 2,961\n",
      " | 16 | injection glucocorticoid*[Title/Abstract] | 5,905\n",
      " | 17 | Hay fever* [Title/Abstract] | 3,887\n",
      " | 18 | #7 #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 | 7,458\n",
      " | 19 | #6 AND #18 | 83\n",
      " | 20 | Systemic corticosteroid*[Title/Abstract] | 6,481\n",
      " | 21 | Systemic corticosteroids*[Title/Abstract] | 4,797\n",
      " | 22 | Systemic steroids*[Title/Abstract] | 2,860\n",
      " | 23 | Systemic steroid*[Title/Abstract] | 4,148\n",
      " | 24 | OCS[Title/Abstract] | 7,330\n",
      " | 25 | Oral corticosteroid*[Title/Abstract] | 5,244\n",
      " | 26 | Oral corticosteroids*[Title/Abstract] | 3,805\n",
      " | 27 | Oral steroids*[Title/Abstract] | 2,658\n",
      " | 28 | Oral steroid*[Title/Abstract] | 3,815\n",
      " | 29 | Inj. steroid*[Title/Abstract] | 30\n",
      " | 30 | Inj. steroids*[Title/Abstract] | 12\n",
      " | 31 | Inj. corticosteroid*[Title/Abstract] | 14\n",
      " | 32 | Inj. corticosteroids*[Title/Abstract] | 6\n",
      " | 33 | Injected steroid*[Title/Abstract] | 57\n",
      " | 34 | Injected steroids*[Title/Abstract] | 40\n",
      " | 35 | Injected corticosteroid*[Title/Abstract] | 67\n",
      " | 36 | Injected corticosteroids*[Title/Abstract] | 50\n",
      " | 37 | Injection steroid*[Title/Abstract] | 18\n",
      " | 38 | Injection steroids*[Title/Abstract] | 1\n",
      " | 39 | Injection corticosteroid*[Title/Abstract] | 1\n",
      " | 40 | Injection corticosteroids*[Title/Abstract] | 5,238\n",
      " | 41 | Oral prednisolone* [Title abstract] | 3,121\n",
      " | 42 | #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 | 30,363\n",
      " | 43 | #6 AND #42 | 1,064\n",
      "\n",
      "---\n",
      "Appendices Appendix 1: Search history in PubMed > Appendix 2: Search history in Embase\n",
      " | Search no. Search details |  |  | Results Limits\n",
      " | --- | --- | --- | ---\n",
      " | 1 | Chronic rhinosinusitis or CRS or Nasal polyps or Chronic rhinosinusit or allergy | 14857 | Exclude MEDLINE\n",
      " | journals Human English language Abstracts\n",
      " | 2 systemic glucocorticoid or systemic glucocorticoids or oral glucocorticoid or oral glucocorticoids or inj |  |  | \n",
      " | glucocorticoid or inj glucocorticoids or injected glucocorticoid or injected glucocorticoids or injection glucocorticoid or injection glucocorticoids or systemic corticosteroid or systemic corticosteroids or oral corticosteroid or oral corticosteroids or inj corticosteroid or inj corticosteroids or injected corticosteroid or injected corticosteroids or injection corticosteroid or injection corticosteroid or systemic steroid or systemic steroids or oral steroid or oral steroids or inj steroid or inj steroids or incected steroid or injected steroids or injection steroid or injection steroids or OCS\n",
      " | 3573\n",
      " | 3 1 and 2 |  |  | 238\n",
      " | 4 Filters: Adult, 1990–2023, articles |  |  | 113\n",
      "\n",
      "---\n",
      "Appendices Appendix 1: Search history in PubMed > Appendix 3. ICD 10.diagnosis codes\n",
      " | Allergic rhinitis | CRS | CRSwNP:\n",
      " | --- | --- | ---\n",
      " | J30, J301, J302, J303, J304 | J320, J321, J322, J323, J324 | J330, J331, J338, J339\n",
      "\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática\n",
      "Danielle Cristina Guimarães da Silvaa,*, Marcela de Sá Barreto da Cunhaa, Amanda de Oliveira Santanaa, Augusto Matheus dos Santos Alvesa, Marcos Pereira Santosa\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática >  ABSTRACT\n",
      "Objective: To systematically review the literature in search of the most suitable and effective nutritional interventions and indications for the nutritional treatment of children and adolescents with cerebral palsy (CP).\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática >  ABSTRACT > RESUMO\n",
      "Objetivo: Revisar sistematicamente a literatura em busca das intervenções e indicações nutricionais mais adequadas e eficazes para o tratamento nutricional de crianças e adolescentes com paralisia cerebral (PC).\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática >  ABSTRACT > RESUMO\n",
      "Data source: This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta- Analyses (PRISMA) guidelines.\n",
      "The articles were selected from seven databases (Cochrane, Literatura Latino-Americana e do Caribe em Ciências da Saúde — Lilacs, Embase, United States National Library of Medicine — PubMed, Scientific Electronic Library Online — SciELO, Scopus, and Web of Science).\n",
      "Studies from a pediatric group (0 to 18 years old) diagnosed with CP were included and the search strategy included the descriptors: “children” OR “childhood” AND “nutritional therapy” OR “nutritional intervention” OR “nutrition” OR “nutritional support” OR “diet” AND “cerebral palsy” OR “cerebral injury”.\n",
      "Methodological quality was assessed using the checklist for cross-sectional analytical studies, the Newcastle-Ottawa scale or the Cochrane Collaboration tool for clinical trials.\n",
      "Data synthesis: Fifteen studies (n=658) published from 1990 to 2020 met the inclusion criteria.\n",
      "All of them had a low risk of bias.\n",
      "The data showed that children and adolescents with CP have worse nutritional status than those normally developed.\n",
      "Those who received hypercaloric and hyperprotein nutritional supplementation benefited from its use.\n",
      "Studies indicate that enteral nutrition should be considered when nutritional needs are not met by the oral diet, especially in cases where oral motor functions are impaired.\n",
      "In addition, there was a direct relationship between the consistency of food, the level of motor function and nutritional status.\n",
      "Fontes de dados: Esta revisão foi conduzida de acordo com as diretrizes Preferred Reporting Items for Systematic Reviews and Meta-Analyses — PRISMA.\n",
      "Os artigos foram selecionados em sete bases de dados (Cochrane, Literatura Latino-Americana e do Caribe em Ciências da Saúde — Lilacs, Embase, United States National Library of Medicine — PubMed, Scientific Electronic Library Online — SciELO, Scopus, and Web of Science).\n",
      "Foram incluídos estudos de um grupo pediátrico (zero a 18 anos) com diagnóstico de PC e a estratégia de busca incluiu os descritores: “children” OR “childhood” AND “nutritional therapy” OR “nutritional intervention” OR “nutrition” OR “nutritional support” OR “diet” AND “cerebral palsy” OR “cerebral injury”.\n",
      "A qualidade metodológica foi avaliada utilizando a lista de verificação para estudos transversais analíticos, escala Newcastle- Ottawa ou ferramenta da Cochrane Collaboration, para ensaios clínicos.\n",
      "Síntese dos dados: Quinze estudos (n=658) publicados de 1990 a 2020 preencheram os critérios de inclusão.\n",
      "Todos tiveram baixo risco de viés.\n",
      "Os dados mostraram que crianças e adolescentes com PC apresentam pior estado nutricional do que os normalmente desenvolvidos.\n",
      "Aqueles que receberam suplementação nutricional hipercalórica e hiperproteica beneficiaram-se de seu uso.\n",
      "Estudos demonstram que a nutrição enteral deve ser considerada quando as necessidades nutricionais não são supridas pela dieta oral, principalmente nos casos em que as funções oromotoras estão prejudicadas.\n",
      "Além disso, houve relação direta entre a consistência dos alimentos, o nível de função motora e o estado nutricional.\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática >  ABSTRACT > RESUMO > Corresponding author. E-mail: daniellenut@hotmail.com (D. C. G. Silva).\n",
      "aUniversidade Federal do Oeste da Bahia, Barreiras, BA, Brasil.\n",
      "Received on June 14, 2022; approved on February 05, 2023.\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática >  ABSTRACT > RESUMO > Corresponding author. E-mail: daniellenut@hotmail.com (D. C. G. Silva).\n",
      "Conclusions: Children and adolescents with CP have a greater risk of malnutrition.\n",
      "The use of nutritional supplementation may help with weight gain.\n",
      "In addition, enteral nutrition and modification of food texture have been used to improve the nutritional status of this group.\n",
      "Keywords: Cerebral palsy; Nutritional therapy; Malnutrition; Review.\n",
      "Conclusões: Crianças e adolescentes com PC têm maior risco de desnutrição.\n",
      "O uso de suplementação nutricional pode auxiliar no ganho de peso desses pacientes.\n",
      "Além disso, a nutrição enteral e a modificação da textura dos alimentos têm sido artifícios utilizados para a melhora do estado nutricional neste grupo.\n",
      "Palavras-chave: Paralisia cerebral; Terapia nutricional; Desnutrição; Revisão.\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION\n",
      "Nutritional interventions in children and adolescents with cere- bral palsy (CP) are an important strategy for maintaining the overall health of this group, with a view to preventing nutri- tional deficiencies and malnutrition and promoting health.\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION\n",
      "CP was described for the first time in 1843, after a study was conducted of 47 children with a similar clinical status who suffered from seizures at birth.\n",
      "Currently, CP is defined as a group of postural and movement disorders that limit activities.\n",
      "It occurs due to non-progressive alterations in the development of the fetus’ or infant’s brain.1,2 According to World Cerebral Palsy, around 17 million people around the world have CP and the disorder affects two in every thousand live births.3-5 Generally, the diet of individuals with CP should be similar to that of healthy people, given that their needs involve main- taining adequate nutrition in terms of quantity and quality.6 However, in situations of gastroesophageal reflux or difficulties with chewing and swallowing, diet modifications are needed.7 It should be noted that the type and severity of CP can directly influence nutritional status.\n",
      "Moreover, abnormal muscle tone can cause greater energy expenditure.8 National and international studies have shown that chil- dren and adolescents with CP have an increased risk of mal- nutrition.7-11 Thus, it is essential to identify risk factors for this clinical condition early in order to improve the progno- sis of these individuals.\n",
      "Epidemiological investigations have presented different behaviors for the nutritional therapy of individuals with CP, ranging from recommending the use of nutritional supplements to the best route for administer- ing the diet.\n",
      "These indications directly influence the choice of nutritional therapy that will be used, as starting the ideal nutritional behavior early is essential to improve the progno- sis of the group in question.12-14 Despite the importance of this topic, there are a limited number of systematic review studies on the behaviors and influ- ence of nutritional interventions on nutritional outcomes, for example nutritional deficiencies and malnutrition, in cases of CP.\n",
      "Therefore, the main objective of this review is to present the most suitable and effective nutritional interventions and indications for the nutritional treatment of children and ado- lescents with CP.\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > METHOD\n",
      "This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guide- lines,15 using studies that have assessed nutritional interventions, dietary characteristics, and recommended nutritional therapies for CP in infants.\n",
      "The protocol for this systematic review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) database (CRD 42020175068).\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > METHOD\n",
      "Articles, theses, and dissertations were chosen that used observational studies or clinical trials to assess the efficacy of nutritional interventions or therapies and their effect in children and adolescents (zero to 18 years old) with CP from around the world.\n",
      "Books, book reviews, editorials, review articles, and case reports were excluded.\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > METHOD\n",
      "Electronic searches were carried out in the Cochrane, Literatura Latino-Americana e do Caribe em Ciências da Saúde — Lilacs, Embase, United States National Library of Medicine — PubMed, Scientific Electronic Library Online — SciELO, Scopus, and Web of Science electronic databases, and in the lists of bibliographical references of the articles and other reviews on the subject, in order to identify works that were not indexed in the databases, but that would be important to include in this review (Figure 1)1.\n",
      "Published articles registered in the databases until October 2020 in Portuguese, English and Spanish, were included.\n",
      "They were identified using the descriptors (“children” OR “childhood”) AND (“nutritional therapy” OR “nutritional intervention” OR “nutrition” OR “nutritional support” OR “diet”) AND (“cerebral palsy” OR “cerebral injury”).\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > METHOD\n",
      "Two independent reviewers identified, selected, and extracted the data from the eligible studies.\n",
      "First, they screened the articles by reading the titles and abstracts.\n",
      "Then they read the eligible ones in full, in order to make the final selection.\n",
      "The review- ers discussed the eligibility and exclusion criteria and defined\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > METHOD\n",
      "Figure 1.\n",
      "Flow diagram of literature search and selection criteria.\n",
      "the final selection by consensus.\n",
      "Some relevant information (authors, year of publication, country of publication, sample size, study type, age and sex of the children, feeding route, nutritional recommendations used, and main results) were systematically organized on an Excel spreadsheet.\n",
      "All the ref- erences were managed using the Rayyan application, devel- oped by the Qatar Computing Research Institute (QCRI).16 The data were presented via descriptive tables containing the main results of the studies.\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > METHOD\n",
      "The risk of bias was assessed using the following proto- cols: the checklist for analytical cross-sectional studies,17 crit- ical appraisal of cohort studies, critical appraisal of case-con- trol studies, the Newcastle-Ottawa scale,18 and the Cochrane Collaboration tool for assessing risks of bias in clinical trials.19\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > METHOD\n",
      "n=178 Lilacs n=105 Embase n=437 PubMed n=519 SciELO n=01 Scopus n=847 Web of Science n=119\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > METHOD\n",
      "Records identiﬁed through database searching (n=2,206)\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > METHOD\n",
      "Records after duplicates removed (n=1,425)\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > METHOD\n",
      "Records screened from databases (n=1,425)\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > METHOD\n",
      "Full-text articles assessed for eligibility (n=33)\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > METHOD\n",
      "Additional studies identiﬁed from reference lists (n= 4)\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > METHOD\n",
      "Total of full-text articles assessed for eligibility (n=37)\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > METHOD\n",
      "Reasons for exclusion after full reading – Infants without a diagnosis of CP (n=7) – Summary (n=5) – Case study (n=1) – Technical comment (n=1) – Articles without nutritional intervention (n=7) – Unavailability of access (n=1)\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > METHOD\n",
      "Studies included in qualitative synthesis (n=15) Cochrane\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > RESULTS\n",
      "A total of 2,206 articles were identified, of which 1,425 were duplicates.\n",
      "After the initial screening, 748 were excluded by reading the titles and abstracts.\n",
      "The researchers examined the references of the 33 articles chosen to read in full, which led to the identification of four more studies, resulting in 37 inclu- sions (Figure 1).\n",
      "Of these publications, 15 were eligible for the study12-14,20-31 as they contained information about nutritional interventions or indications for nutritional therapies for infants with CP.\n",
      "The main reasons for exclusion were the following: infants with no diagnosis of CP (n=7), abstracts lacking infor- mation (n=5), case study (n=1), technical commentary (n=1), articles with no nutritional intervention (n=7), and not avail- able to access (n=1).\n",
      "The eligible studies were carried out in six countries: Australia,13,22,28,31 Brazil,23,24 the United States,27 Mexico,12,21,25 the United Kingdom,26,29,30 and Turkey.14,20 A predominance of cohort studies was verified, which accounted for seven publications,14,21,25-27,29,30 followed by three studies characterized as case-control,13,20,31 three cross-sectional studies,22-24 and two randomized clinical trials.12,28 There was a predominance of publications that addressed the types of spas- tic, dyskinetic and ataxic CP13,20-24,27-29,31 and five studies pre- sented information only on spastic CP.12,14,25,26,30 The studies analyzed involved a total of 658 children and adolescents, aged between zero and 18 years old, of both sexes, diagnosed with CP.\n",
      "Studies published between 1990 and 2020 were included, with a predominance of publications between 2008 and 2020 (73%).\n",
      "The population was recruited through the tertiary healthcare network or through the institutions where the subjects were receiving or had received some type of care.\n",
      "Twelve publications were identified in which the participants received their nutritional therapy at home and were monitored in hospital visits.12,13,20-24,27-30 In two studies, the participants received their nutritional therapy at home and were monitored in hospi- tal visits or home visits by the team responsible for the study,14,26 and only in one did the children and adolescents receive their nutritional therapy and monitoring at a hospital institution.25 In relation to the methodological quality of the studies, for the cross-sectional studies it was verified that all three (100%) publications clearly defined the inclusion criteria, they described the subjects and scenarios in detail, they measured exposure in a valid and reliable way, they used objective and standard criteria to measure the condition of the children, and they measured the results in a valid and reliable way.22-24 In only one publi- cation (33.3%) was it identified that strategies were used to address confounding factors22 and two studies (66.6%)22,24 used appropriate statistical analysis to address the confounding fac- tors.\n",
      "No study was excluded due to its methodological quality.\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > RESULTS\n",
      "According to the Newcastle-Ottawa scale used to assess methodological quality, the scores varied between 6 and 8, so all the articles had a low risk of bias.\n",
      "The main problems with the methodological quality of the cohort and case-control studies were related to category 2 (comparability between the exposed and non-exposed individuals), as 90% (n=9) of these did not address this.13,14,20,21,25-27,29-31 The risk of bias assessment of the clinical trials is summa- rized in Figure 2.32 Two clinical trials12,28 were assessed using Random sequence generation (selection bias) Allocation concealment (selection bias) Blinding of participants and personnel (performance bias) Blinding of outcome assessment (detection bias) Incomplete outcome data (attrition bias) Selective reporting (reporting bias)\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > RESULTS > Other bias\n",
      "100%75%50%25%0%\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > RESULTS > Other bias\n",
      "Low risk of bias Unclear risk of bias High risk of bias Figure 2.\n",
      "Risk of bias for clinical trials using the Cochrane risk-of-bias tool for randomized trials (RoB 2).32\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > RESULTS > Other bias\n",
      " | the Cochrane risk-of-bias tool for randomized trials (RoB 2).32 In the generation of a random sequence domain, only one of the studies12 described the random selection of the sample. For the concealed allocation domain, none of the studies clearly described the form of allocation concealment. For performance bias, although one of the studies28 reported being double blind, there were no details about the blinding of participants and of professionals, and it was classified as “uncertain risk of bias.” In the study of Leal-Martínez et al.,12 there was no mention of blinding of professionals or of participants, and it was classified as “high risk of bias”. Due to a sampling loss of around 15%, which could influence the statistical analyses of the outcomes, one of the studies was classified as having a high risk of attri- tion bias.28 Finally, all the studies included in this review were free of reports of selective outcomes, because this bias was one of the exclusion criteria. Figure 312,28 presents a detailed assess- ment for each domain of risk of bias in the studies. | This review identified nutritional interventions that used only the oral route in five articles12,14,20,21,26 and interventions that used only the enteral route in six publications,23,25,27-30 two of which used a nasogastric tube or gastrostomy25,27 and four of which used gastronomy. The other four publications used a combination of the oral and enteral routes.13,22,24,31 Six eligible studies proposed some type of nutritional supplementation for CP (Table 1).12-14,20-31 | With respect to the motor skills and limitations in the feeding process of the children and adolescents, nine publica- tions12-14,20,25,28-31 used the Gross Motor Function Classification System (GMFCS) criterion to analyze these and in four studies all the children’s ability to eat was severely compromised.13,25,28,31 Six publications did not mention the use of criteria to classify the motor function of children and adolescents with CP. One publication employed the Development of Care for Individuals with Serious Deficiencies (Dash-2) method,21 and four studies applied no methodologies to calculate motor func- tion, basing their assessments on brain damage and nutritional status diagnoses.23,24,27,29 Regarding the intervention based on daily elemental iron supplementation indicated by García-Contreras et al.,25 no inherent benefits of its used were demonstrated; however, there was an improvement in the nutritional status and an increase in the weight of the children and adolescents. After supplement- ing the normal diet of children with CP using a hypercaloric and hyperproteic dietary formula with a high biological value, combined with oral motor physiotherapy, Barrón-Garza et al.21 identified an increase in weight, which was significantly higher for those who carried out their physiotherapy at the clinic com- pared to those who did it at home with their parents. Kibirige26 identified greater weight gain in the infants who, besides a normal diet, received supplementation with a hyperca- loric and normoproteic formula. Vernon-Roberts et al.30 found a significant increase in body weight and other anthropometric measures after supplementing children with CP with a hypo- caloric and nutritionally complete enteral formula. Brant et al.23 found a significant increase in body weight from using a nutritionally complete normocaloric formula, maize flour, and oatmeal in combination with a normal diet or a diet composed of soybean oil, albumin, sugar, and soymilk, together with a mineral and vitamin supplement. Leal-Martínez et al.12 identified that the diet based on homemade shakes with functional foods (a large amount of vegetables, fruits, cereals, roots, and fish) was positively reflected in improved motor parameters such as walking and standing up. Two publications analyzed the textures and consistencies of the foods provided to children with CP. Arslan et al.20 note that foods with liquid or pasty textures are unable to meet the caloric and nutritional needs of children with CP. For Benfer et al.,22 children with CP are unable to eat many foods due to their textures, but such modifications guarantee a more effi- cient calorie intake, even if it is densely inferior. Although eight studies did not seek to evaluate the textures and consistencies of the foods provided using specific methods,12,13,23,27-31 general motor functions served as parameters to define them. In those cases, enteral feeding was often related to severe cases of CP in\n",
      " | --- | --- | ---\n",
      " | + ? | ? ? | - ? | - ? | + - | + + | ? ?\n",
      " | --- | --- | --- | --- | --- | --- | ---\n",
      "\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > RESULTS > Other bias\n",
      "Leal-Martínez et al.12 Savage et al.28 Figure 3.\n",
      "Summary of risk of bias.\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > RESULTS > Other bias\n",
      "children and adolescents, and even for those who ate orally, their care was intensified in order to avoid dysphagia and choking.\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > DISCUSSION\n",
      " | The results of this study indicate that children and adolescents with CP have a more compromised nutritional status that those who do not have the disorder. Nutritional supplementation of a normal diet leads to weight gain and improved nutritional status in this group. We observed that enteral feeding was used as the main behavior for nutritional treatment. Moreover, the modification of the texture of foods, transforming them into purees and/or semi-solids, was essential for improving the nutritional status of this infant group and for better adapting them to oral consumption. In a case-control study carried out in Turkey using 85 chil- dren with CP, Arslan et al.20 identified a greater prevalence of malnutrition and a lower height in children with CP than in the control group. The case-control study of Arrowsmith et al.33 Table 1. Results of studies. | carried out in Australia using 167 children corroborates the results of Arslan et al.,20 given that the outcome of their study showed that children with CP had a lower body weight, height, and body fat percentage than children without CP. It is sug- gested that these results are due to the difficulties with chew- ing and swallowing and the gastrointestinal problems that this population often has.7 Another point to mention is that the different feeding routes can directly influence the nutritional therapy of children with CP.34 Sullivan et al.29 reported that patients who use gas- trostomy (GTT) had a greater daily dietary intake, achieving 69% of the recommended energy value, while those fed orally achieved 57% of the recommended energy intake, with less than 10% difference being identified between the two groups. In line with the previous findings, Caselli et al.24 analyzed 54 patients with CP fed via different routes — 25 fed via GTT and 29 orally — and concluded that there was no significant difference regarding the prevalence of malnutrition in relation to weight or body mass index. Thus, it is suggested that children\n",
      " | --- | ---\n",
      " | Reference | Interventions (feeding route, nutritional recommendations used)\n",
      " | Arslan et al.,20 | Oral feeding. Normal diet for the children in the control group. Differentiated consistency diet for the children in the orally fed case group.\n",
      " | Barrón-Garza et al.,21 | Oral feeding for 3 years and 9 months. Hypercaloric diet, with 50% carrying out oral motor therapy with their parents at home and the other half doing so at a clinic.\n",
      " | Benfer et al.,22 | Oral feeding (n=87) and enteral feeding (n=12).\n",
      " | Brant et al.,23 | Enteral feeding via gastrostomy, with a mean monitoring period of 5.9 months.\n",
      " | Caselli et al.,24 | Enteral feeding via gastrostomy (n=25) and oral feeding (n=29).\n",
      " | García-Contreras et al.,25 | Enteral feeding via nasogastric tube (n=8) and gastrostomy (n=5) for 4 weeks. Use of a lactose- free infant formula (Nestlé®), adding corn syrup to the formula to increase the energy density.\n",
      " | Kibirige26 | Oral feeding for 8 weeks. 4 children received liquid nutrition and supplementation.\n",
      " | Leal-Martínez et al.,12 | Oral feeding. Use of 3 liquid diets, 2 administered at breakfast and 1 at dinner. Follow-up group (FG) (n=10): normal diet. Control group (CG) (n=10): vermifugated and received a nutritional therapy recommended by the WHO (2010). Intervention group (IG) (n=10): vermifugated and received the Nutritional Support System (NSS).\n",
      " | Sanders et al.,27 | Enteral feeding via nasogastric tube (n=4) and gastrostomy (47) for 6 months. The dietary formulas used were Complete Modified Formulas (Sandoz) or lsocal (Mead Johnson), each one providing 1 kcal/mL.\n",
      " | Savage et al.,28 | Enteral feeding by nasogastric tube (n=1) and percutaneous endoscopic gastrostomy (n=12). Standard enteral formula based on casein and another with 50% whey and 50% total casein protein for 1 week (n=7), and a formula based on partially hydrolyzed whey protein (n=6) .\n",
      " | Schoendorfer et al.,31 | Children with CP (case group): percutaneous (n=9) and oral (12) enteral feeding.\n",
      " | Schoendorfer et al.,13 | Enteral (n=9) and oral (n=15) feeding.\n",
      " | Soylu et al.,14 | Oral feeding for 6 months.\n",
      " | Sullivan et al.,29 | Enteral feeding by gastrostomy for 12 months.\n",
      " | Vernon-Roberts et al.,30 | Enteral feeding by gastrostomy for 6 months. An enteral feeding of low caloric energy (Kcal), complete with micronutrients and rich in fiber, was administered.\n",
      "\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > DISCUSSION\n",
      "with GTT experience less energy expenditure as a result of the lower demand for energy than those fed orally.35,36 Regarding the use of supplementation, we observed an improvement in the nutritional status of the children that used nutritional supplementation, especially when the weight gain factor is analyzed.23,25,27,28 From this perspective, Vernon-Roberts et al.30 carried out a cohort study in the United Kingdom of 14 children with CP and identified body weight gain and lin- ear growth as a result of supplementation with a hypercaloric enteral formula (0.75 kcal/mL) that was nutritionally com- plete and rich in fibers.\n",
      "The randomized clinical trial carried out in Mexico by Leal-Martínez et al.12 found that nutritional supplementation in the form of homemade shakes with func- tional foods (a large amount of vegetables, fruits, cereals, roots and fish) significantly improved the motor function of children with CP.\n",
      "In a study on the nutritional management of children with CP, Bell et al.35 note that first-line treatment involves the inclusion of oral nutritional support adapted to the individual needs of each child, provided they can consume a diet orally without the risk of aspiration or greater complications.\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > DISCUSSION\n",
      "The administration of nutritional support should be adapted to the physical status of the children, their capacity to consume foods, and the possibility of oral ingestion, as their diet needs to be adapted in order to maximize dietary efficiency and reduce fatigue during meals, thus leading to a greater dietary intake.10,35 For this, the use of enteral nutrition should be considered when oral feeding does not satisfy their needs and in the case of severe malnutrition and deglutination disorder.\n",
      "This can also be used to complement oral nutrition.29,35,37 It is important to stress that nutritional supplementation can improve the prognosis of the group studied and provide a better quality of life.\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > DISCUSSION\n",
      "It is worth highlighting that in the absence of specific nutri- tional recommendations for children with CP, it is appropriate to use guidelines and nutritional evidence for children with neurological disorders.\n",
      "It also warrants mentioning that mal- nutrition and nutritional deficiencies in the population studied can be influenced by nutritional and non-nutritional factors.38 In their guide “Recommendations for Nutritional Management of Children with Neurological Impairment (NI),” the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) discusses recommendations regarding the nutri- tional needs of children with intellectual impairment and pro- vides alternative recommendations for children with CP, which can be used when there are no specific parameters for this pop- ulation.39 However, as an alternative for supplementation, foods rich in nutrients that are lacking in the patient can be added to the diet.\n",
      "Nutritional deficiency should be diagnosed via labora- tory tests and it is only after identifying a particular deficiency that some type of supplementation should be prescribed.35,40 Choosing the right nutritional formula is extremely import- ant for the effectiveness of the nutritional treatment of children with CP.\n",
      "A variety of products is used for nutrition, including polymeric, semi-elemental, and elemental formulas adapted to every need and different life phases.\n",
      "Most enteral foods are formulated to serve as a source of complete nutrition, provid- ing all the nutrients needed for the day-to-day maintenance of the body.41 Vernon-Roberts et al.30 note that nutritional treat- ment should be based on the provision of a diet with a standard energy density calculated based on the patient’s age.\n",
      "This should evolve to a high-density formula when the child does not tol- erate large quantities of a food.\n",
      "Finally, a lower energy density formula can be used in those who present more rapid weight gain.\n",
      "Thus, it is stressed that the nutritional behavior should be individualized and prescribed according to the particular- ities of each child.\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > DISCUSSION\n",
      "Some nutritional interventions for CP can be carried out by modifying the textures/consistencies of foods.\n",
      "Such alter- ations may be recommended to provide safety and efficiency during meals or to stimulate the development of motor oral skills in this population.42 In a study of 99 children with CP, Benfer et al.22 identified that modifying the texture of foods/ fluids in 39% of the population studied led to an improvement in energy and nutritional intake and more autonomy among the children.\n",
      "The authors also showed that the children with modified diets had greater gross motor limitations and were therefore unable to feed themselves with foods in their normal textures.\n",
      "Similarly, Arslan et al.20 identified that children with CP who consumed liquid, pasty, or minced diets achieved greater growth and nutritional status, as well as having fewer dietary problems.\n",
      "Thus, exploring the textures of the foods consumed by children with CP will support better management decisions regarding the nutritional therapy and recovery of these patients.\n",
      "This review study has some limitations.\n",
      "The summary of the results of studies using different methodological approaches was complex and impeded a meta-analysis from being carried out.\n",
      "On the other hand, the age range (0–18 years old) makes it hard to compare and summarize the results.\n",
      "These limitations notwithstanding, we adopted consistent methodological pro- cedures performed by independent reviewers and assessed the studies that fulfilled the eligibility criteria in order to reduce the possibility of bias.\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > DISCUSSION\n",
      "It is concluded that children and adolescents with CP have a greater risk of malnutrition and that the use of nutritional sup- plementation may help with weight gain.\n",
      "In addition, enteral nutrition and modification of food texture have been used to improve the nutritional status of this group.\n",
      "The nutritional treatment of CP should be multi-factorial and aim to promote a better quality of life and improvement in the prognosis of these individuals, given that diet is an essential factor for the recovery and repair of these patients.\n",
      "To guarantee the success of interventions, nutritional status should be periodically mon- itored by a multidisciplinary team.\n",
      "For this, we recommend conducting more studies on nutritional interventions in chil- dren and adolescents with CP, given that more information is needed to achieve precise and adequate nutritional behavior for this target population.\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > DISCUSSION > Conflict of interests\n",
      "The authors declare there is no conflict of interests.\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > DISCUSSION > Authors’ contribuition\n",
      "Study design: Silva DCG, Cunha MSB.\n",
      "Data collection: Silva DCG, Santana AO, Alves AMS. Data analysis: Silva DCG, Cunha MSB, Santos MP.\n",
      "Manuscript writing: Silva DCG, Santana AO, Alves AMS. Manuscript revision: Silva DCG, Cunha MSB, Santos MP.\n",
      "Study supervision: Silva DCG, Santos MP.\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > DISCUSSION > Funding\n",
      "The survey received funding by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) — pro- cess no 443018/2019-7.\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > DISCUSSION > Declaration\n",
      "The database that originated the article is available with the corresponding author.\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil\n",
      "Ministério da Saúde.\n",
      "Secretaria de Atenção à Saúde.\n",
      "10.\n",
      "Marques JM, Sá LO.\n",
      "Feeding a child with cerebral palsy:\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil\n",
      "Departamento de Ações Programáticas Estratégicas.\n",
      "Diretrizes de atenção à pessoa com paralisia cerebral.\n",
      "Brasília: Ministério da Saúde; 2013. parents’ difficulties.\n",
      "Rev Enf Ref.\n",
      "2016;4:11-9. http://dx.doi.\n",
      "org/10.12707/RIV16041\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 11. Kuperminc MN, Stevenson RD\n",
      "Growth and nutrition 2.\n",
      "Rosenbaum P, Paneth N, Leviton A, Goldstein M, Bax M, Damiano D, et al.\n",
      "A report: the definition and classification of cerebral palsy April 2006.\n",
      "Dev Med Child Neurol Suppl.\n",
      "2007;109:8-14.\n",
      "PMID: 17370477 disorders in children with cerebral palsy.\n",
      "Dev Disabil Res Rev.\n",
      "2008;14:137-46. https://doi.org/10.1002/ddrr.14 12.\n",
      "Leal-Martínez F, Franco D, Peña-Ruiz A, Castro-Silva F,\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 3. O’Shea TM\n",
      "Diagnosis, treatment, and prevention of cerebral\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 3. O’Shea TM\n",
      " | palsy. Clin Obstet Gynecol. 2008;51:816-28. https://doi. org/10.1097/GRF.0b013e3181870ba7 Christine C, Dolk H, Platt MJ, Colver A, Prasauskiene A, |  | Escudero-Espinosa AA, Rolón-Lacarrier OG, et al. Effect of a nutritional support system (diet and supplements) for improving gross motor function in cerebral palsy: an exploratory randomized controlled clinical trial. Foods. 2020;9:1449. https://doi.org/10.3390/foods9101449\n",
      " | --- | --- | ---\n",
      " | Krägeloh-Mann I, et al. Recommendations from the SCPE collaborative group for defining and classifying cerebral palsy. Dev Med Child Neurol Suppl. 2007;109:35-8. https:// doi.org/10.1111/j.1469-8749.2007.tb12626.x. | 13. | Schoendorfer N, Tinggi U, Sharp N, Boyd R, Vitetta L,\n",
      "\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 5. World Cerebral Palsy Day [homepage on the Internet]\n",
      "About Davies SM.\n",
      "Protein levels in enteral feeds: do these meet requirements in children with severe cerebral palsy?\n",
      "Br J Nutr.\n",
      "2012;107:1476-81. https://doi.org/10.1017/ S0007114511004533 world cerebral palsy day [cited 2020 Nov 20].\n",
      "Available from: https://worldcpday.org/ 14.\n",
      "Soylu OB, Unalp A, Uran N, Dizdarer G, Ozgonul FO, Conku 6.\n",
      "Gomes V, Campos MA, Gregório MJ.\n",
      "Relação entre função motora, competências alimentares e peso de crianças e adolescents com paralisia cerebral.\n",
      "Acta Port Nutr.\n",
      "2016;6:20-3. https://dx.doi.org/10.21011/apn.2016.0604 A, et al.\n",
      "Effect of nutritional support in children with spastic quadriplegia.\n",
      "Pediatr Neurol.\n",
      "2008;39:330-4. https://doi.\n",
      "org/10.1016/j.pediatrneurol.2008.07.020 15.\n",
      "Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA\n",
      "Feeding disorders in children with gastro-esophageal reflux disease.\n",
      "Pro Fono.\n",
      "2007;19:59-66. https://doi.org/10.1590/s0104-56872007000100007 TC, Mulrow CD, et al.\n",
      "The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.\n",
      "Int J Surg.\n",
      "2021;88:105906. https://doi.org/10.1016/j.\n",
      "ijsu.2021.105906 16.\n",
      "Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A.\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA\n",
      "8. Fung EB, Samson-Fang L, Stallings VA, Conaway M, Liptak G, Henderson RC, et al.\n",
      "Feeding dysfunction is associated with poor growth and health status in children with cerebral palsy.\n",
      "J Am Diet Assoc.\n",
      "2002;102:361-73. https://doi.org/10.1016/ s0002-8223(02)90084-2 Rayyan-a web and mobile app for systematic reviews.\n",
      "Syst Rev.\n",
      "2016;5:210. https://doi.org/10.1186/s13643- 016-0384-4\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA > 17. Joanna Briggs Institute [homepage on the Internet]\n",
      "The M, et al [homepage on the Internet].\n",
      "The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses [cited 2019 Apr 20].\n",
      "Available from: http://www.ohri.ca/programs/clinical_epidemiology/ oxford.asp 9.\n",
      "Adamu AS, Sabo UA, Gwarzo GD, Belonwu RO.\n",
      "Nutritional status in cerebral palsy: a cross-sectional comparative survey of children in Kano, Nigeria.\n",
      "Niger Postgrad Med J.\n",
      "2018;25:156-60. https://doi.org/10.4103/npmj.npmj_67_18 Joanna Briggs Institute Critical Appraisal tools for use in JBI Systematic Reviews.\n",
      "Checklist for qualitative research [cited 2019 Apr 20].\n",
      "Available from: https://jbi.global/sites/ default/files/2019-06/JBI_Critical_Appraisal-Checklist_for_ Qualitative_Research2017.docx 18.\n",
      "Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos 19.\n",
      "Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ,\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA > 17. Joanna Briggs Institute [homepage on the Internet]\n",
      "et al [homepage on the Internet].\n",
      "Cochrane Handbook for Systematic Reviews of Interventions version 6.0 [cited 2019 Apr 20].\n",
      "Available from: www.training.cochrane.org/handbook 20.\n",
      "Arslan SS, Ilgaz F, Demir N, Karaduman AA.\n",
      "The effect of\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA > 17. Joanna Briggs Institute [homepage on the Internet]\n",
      "the inability to intake chewable food texture on growth, dietary intake and feeding behaviors of children with cerebral palsy.\n",
      "J Dev Phys Disabil.\n",
      "2018;30:205-14. https:// doi.org/10.1007/s10882-017-9580-y 21.\n",
      "Barrón-Garza F, Robles-Montiel A, Elizondo-Vázquez JB,\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA > 17. Joanna Briggs Institute [homepage on the Internet]\n",
      "Riquelme-Heras MA, Riquelme-Heras H. Oromotortherapy and dietary supplement, improve feeding skills and nutrition of patients with cerebral palsy.\n",
      "Rev Esp Nutr Comunitária.\n",
      "2017;23:160-5.\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA > 17. Joanna Briggs Institute [homepage on the Internet]\n",
      "22.\n",
      "Benfer KA, Weir KA, Ware RS, Davies PS, Arvedson J, Boyd\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA > 17. Joanna Briggs Institute [homepage on the Internet]\n",
      "RN, et al.\n",
      "Parent-reported indicators for detecting feeding and swallowing difficulties and undernutrition in preschool- aged children with cerebral palsy.\n",
      "Dev Med Child Neurol.\n",
      "2017;59:1181-7. https://doi.org/10.1111/dmcn.13498 23.\n",
      "Brant CQ, Stanich P, Ferrari Jr AP.\n",
      "Improvement of children’s\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA > 17. Joanna Briggs Institute [homepage on the Internet]\n",
      "nutritional status after enteral feeding by PEG: an interim report.\n",
      "Gastrointest Endosc.\n",
      "1999;50:183-8. https://doi.\n",
      "org/10.1016/s0016-5107(99)70222-1 24.\n",
      "Caselli TB, Lomazi EA, Montenegro MA, Bellomo-Brandão\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA > 17. Joanna Briggs Institute [homepage on the Internet]\n",
      "MA.\n",
      "Comparative study on gastrostomy and orally nutrition of children and adolescents with tetraparesis cerebral palsy.\n",
      "Arq Gastroenterol.\n",
      "2017;54:292-6. https://doi.org/10.1590/ S0004-2803.201700000-48 25.\n",
      "García-Contreras AA, Vásquez-Garibay EM, Romero-Velarde\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA > 17. Joanna Briggs Institute [homepage on the Internet]\n",
      "E, Ibarra-Gutiérrez AI, Troyo-Sanromán R, Sandoval-Montes IE.\n",
      "Intensive nutritional support improves the nutritional status and body composition in severely malnourished children with cerebral palsy.\n",
      "Nutr Hosp.\n",
      "2014;29:838-43. https://doi.org/10.3305/nh.2014.29.4.7247\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA > 26. Kibirige MS\n",
      "Kibirige MS. Weight gain and severe cerebral palsy.\n",
      "J Nutr Med.\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA > 26. Kibirige MS\n",
      "1992;3:137-43. https://doi.org/10.3109/13590849208997971 27.\n",
      "Sanders KD, Cox K, Cannon R, Blanchard D, Pitcher J,\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA > 26. Kibirige MS\n",
      "Papathakis P, et al.\n",
      "Growth response to enteral feeding by children with cerebral palsy.\n",
      "JPEN J Parenter Enteral Nutr.\n",
      "1990;14:23-6. https://doi.org/10.1177/014860719001400123 28.\n",
      "Savage K, Kritas S, Schwarzer A, Davidson G, Omari T.\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA > 26. Kibirige MS\n",
      "Whey- vs casein-based enteral formula and gastrointestinal function in children with cerebral palsy.\n",
      "JPEN J Parenter Enteral Nutr.\n",
      "2012;36(Suppl1):118S-23S.\n",
      "https://doi.\n",
      "org/10.1177/0148607111428139 29.\n",
      "Sullivan PB, Juszcczak E, Bachlet AM, Lambert B, Vernon-\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA > 26. Kibirige MS\n",
      "Roberts A, Grant HW, et al.\n",
      "Gastrostomy tube feeding in children with cerebral palsy: a prospective, longitudinal study.\n",
      "Dev Med Child Neurol.\n",
      "2005;47:77-85. https://doi.\n",
      "org/10.1017/s0012162205000162 30.\n",
      "Vernon-Roberts A, Wells J, Grant H, Alder N, Vadamalayan\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA > 26. Kibirige MS\n",
      "B, Eltumie M, et al.\n",
      "Gastrostomy feeding in cerebral palsy: enough and no more.\n",
      "Dev Med Child Neurol.\n",
      "2010;52:1099- 105. https://doi.org/10.1111/j.1469-8749.2010.03789.x 31.\n",
      "Schoendorfer N, Tinggi U, Sharp N, Boyd R, Vitetta L, Davies\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA > 26. Kibirige MS\n",
      "SM.\n",
      "Micronutrient intakes in enterally and orally fed children with severe cerebral palsy.\n",
      "E Spen Eur E J Clin Nutr Metab.\n",
      "2011;6:e259-63.\n",
      "https://doi.org/10.1016/j.eclnm.2011.09.003 32.\n",
      "Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA > 26. Kibirige MS\n",
      "AD, et al.\n",
      "The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.\n",
      "BMJ.\n",
      "2011;343:d5928.\n",
      "https://doi.org/10.1136/bmj.d5928 33.\n",
      "Arrowsmith FE, Allen JR, Gaskin KJ, Somerville H, Birdsall J,\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA > 26. Kibirige MS\n",
      "Barzi F, et al.\n",
      "Nutritional rehabilitation increases the resting energy expenditure of malnourished children with severe cerebral palsy.\n",
      "Dev Med Child Neurol.\n",
      "2012;54:170-5. https:// doi.org/10.1111/j.1469-8749.2011.04166.x 34.\n",
      "Strauss DJ, Shavelle RM, Anderson TW.\n",
      "Life expectancy of\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA > 26. Kibirige MS\n",
      "children with cerebral palsy.\n",
      "Pediatr Neurol.\n",
      "1998;18:143-9. https://doi.org/10.1016/s0887-8994(97)00172-0\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA > 26. Kibirige MS > 35. Bell KL, Samson-Fang L\n",
      "Nutritional management of children with cerebral palsy.\n",
      "Eur J Clin Nutr.\n",
      "2013;67 Suppl2:S13-6.\n",
      "https://doi.org/10.1038/ejcn.2013.225 36.\n",
      "Caselli TB, Lomazi EA, Montenegro MA, Bellomo-\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA > 26. Kibirige MS > 35. Bell KL, Samson-Fang L\n",
      "Brandão.\n",
      "Assessment of nutritional status of children and adolescents with spastic quadriplegic cerebral palsy.\n",
      "Arq Gastroenterol.\n",
      "2017;54:201-5. https://doi.org/10.1590/ S0004-2803.201700000-32\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA > 26. Kibirige MS > 37. ASPEN Board of Directors and the Clinical Guidelines Task\n",
      "Force.\n",
      "Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients.\n",
      "JPEN J Parenter Enteral Nutr.\n",
      "2002;26(1 Suppl):1SA-138SA.\n",
      "PMID: 11841046 38.\n",
      "Penagini F, Mameli C, Fabiano V, Brunetti D, Dilillo D, Zuccotti\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA > 26. Kibirige MS > 37. ASPEN Board of Directors and the Clinical Guidelines Task\n",
      "GV.\n",
      "Dietary intakes and nutritional issues in neurologically impaired children.\n",
      "Nutrients.\n",
      "2015;7:9400-15. https://doi.\n",
      "org/10.3390/nu7115469 39.\n",
      "Romano C, van Wynckel M, Hulst J, Broekaert I, Bronsky\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA > 26. Kibirige MS > 37. ASPEN Board of Directors and the Clinical Guidelines Task\n",
      "J, Dall’Oglio L, et al.\n",
      "European Society for Paediatric Gastroenterology, hepatology and nutrition guidelines for the evaluation and treatment of gastrointestinal and nutritional complications in children with neurological impairment.\n",
      "J Pediatr Gastroenterol Nutr.\n",
      "2017;65:242-64. https://doi.org/10.1097/MPG.0000000000001646 40.\n",
      "Hillesund E, Skranes J, Trygg KU, Bøhmer T. Micronutrient status\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA > 26. Kibirige MS > 37. ASPEN Board of Directors and the Clinical Guidelines Task\n",
      "in children with cerebral palsy.\n",
      "Acta Paediatr.\n",
      "2007;96:1195-8. https://doi.org/10.1111/j.1651-2227.2007.00354.x 41.\n",
      "Braegger C, Decsi T, Dias JA, Hartman C, Kolacek S, Koletzko\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA > 26. Kibirige MS > 37. ASPEN Board of Directors and the Clinical Guidelines Task\n",
      "B, et al.\n",
      "Practical approach to paediatric enteral nutrition: a comment by the ESPGHAN committee on nutrition.\n",
      "J Pediatr Gastroenterol Nutr.\n",
      "2010;51:110-22. https://doi.\n",
      "org/10.1097/MPG.0b013e3181d336d2\n",
      "---\n",
      "Nutritional interventions in children and adolescents with cerebral palsy: systematic review > Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática > INTRODUCTION > REFERENCES > 1. Brazil > 7. Drent LV, Pinto EA > 26. Kibirige MS > 37. ASPEN Board of Directors and the Clinical Guidelines Task > 42. Dietitians Association of Australia\n",
      "The Speech Pathology Association of Australia Limited.\n",
      "Texture-modified foods and thickened fluids as used for individuals with dysphagia: Australian standardised labels and definitions.\n",
      "Nutr Diet.\n",
      "2007;64:S53-76.\n",
      "https://doi.org/10.1111/j.1747-0080.2007.00153.x © 2023 Sociedade de Pediatria de São Paulo.\n",
      "Published by Zeppelini Publishers.\n",
      "This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).\n"
     ]
    }
   ],
   "source": [
    "for block in blocks:\n",
    "  print(\"---\")\n",
    "  print(block.to_context_text())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "--- Doc ---\n",
      "{'metadata': ['Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review', 'M.Y Jayachandra, R. Gayathiri, C.N.Aruna, Padma K. Bhat, P.M. Arumugam']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review', 'ABSTRACT']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review', 'ABSTRACT', 'Address for correspondence:']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review', 'ABSTRACT', 'Address for correspondence:']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review', 'ABSTRACT', 'Address for correspondence:']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review', 'INTRODUCTION']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review', 'INTRODUCTION', 'Access this article online']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review', 'INTRODUCTION', 'Access this article online']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review', 'INTRODUCTION', 'Access this article online']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review', 'INTRODUCTION', 'Access this article online']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Clinical effects of Bifidobacterium as a probiotic on oral health: A systematic review', 'Objectives']}\n",
      "--- Doc ---\n",
      "{'metadata': ['MATERIALS AND METHODS', 'Protocol development and registration']}\n",
      "--- Doc ---\n",
      "{'metadata': ['MATERIALS AND METHODS', 'Eligibility criteria']}\n",
      "--- Doc ---\n",
      "{'metadata': ['MATERIALS AND METHODS', 'Information sources and search strategy']}\n",
      "--- Doc ---\n",
      "{'metadata': ['MATERIALS AND METHODS', 'Study selection and data collection']}\n",
      "--- Doc ---\n",
      "{'metadata': ['DATA ITEMS', 'Risk of bias in individual studies']}\n",
      "--- Doc ---\n",
      "{'metadata': ['DATA ITEMS', 'Summary measures', 'Planned methods of analysis']}\n",
      "--- Doc ---\n",
      "{'metadata': ['DATA ITEMS', 'Summary measures', 'Risk of bias across studies and additional analyses']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study selection']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', '1) Ice cream']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', '2) Yogurt']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', '2) Yogurt']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', '3) Tablet']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', '4) Lozenges']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', '5) Chewing gum']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', '6) Capsule']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', '7) Probiotic drop']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', '8) Freeze‑dried powder']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', 'Participants']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', 'Participants']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', 'Intervention']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', 'Outcomes']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:', '1) Ice cream']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:', '1) Ice cream', 'Table 1: Risk of bias within studies ‑ Parallel trials']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:', '1) Ice cream', 'Table 1: Risk of bias within studies ‑ Parallel trials']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:', '2) Yogurt']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:', '2) Yogurt']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:', '3) Tablet']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:', '4) Lozenges']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:', '4) Lozenges']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:', '5) Chewing gum']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:', '6) Capsule']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:', '7) Probiotic drop']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:', '8) Freeze dried powder']}\n",
      "--- Doc ---\n",
      "{'metadata': ['RESULTS', 'Study characteristics', 'Risk of bias within studies:', 'Risk of bias across studies and additional analyses']}\n",
      "--- Doc ---\n",
      "{'metadata': ['DISCUSSION', 'Summary of evidence']}\n",
      "--- Doc ---\n",
      "{'metadata': ['DISCUSSION', 'Summary of evidence']}\n",
      "--- Doc ---\n",
      "{'metadata': ['DISCUSSION', 'Summary of evidence']}\n",
      "--- Doc ---\n",
      "{'metadata': ['DISCUSSION', 'Summary of evidence']}\n",
      "--- Doc ---\n",
      "{'metadata': ['DISCUSSION', 'Summary of evidence', 'Table 3: Quality of available evidence']}\n",
      "--- Doc ---\n",
      "{'metadata': ['DISCUSSION', 'Summary of evidence', 'Table 3: Quality of available evidence']}\n",
      "--- Doc ---\n",
      "{'metadata': ['DISCUSSION', 'Summary of evidence', 'Table 3: Quality of available evidence']}\n",
      "--- Doc ---\n",
      "{'metadata': ['DISCUSSION', 'Summary of evidence', 'Table 3: Quality of available evidence']}\n",
      "--- Doc ---\n",
      "{'metadata': ['DISCUSSION', 'Summary of evidence', 'Table 3: Quality of available evidence']}\n",
      "--- Doc ---\n",
      "{'metadata': ['DISCUSSION', 'Summary of evidence', 'Table 3: Quality of available evidence']}\n",
      "--- Doc ---\n",
      "{'metadata': ['DISCUSSION', 'Summary of evidence', 'Table 3: Quality of available evidence']}\n",
      "--- Doc ---\n",
      "{'metadata': ['DISCUSSION', 'Summary of evidence', 'Table 3: Quality of available evidence']}\n",
      "--- Doc ---\n",
      "{'metadata': ['DISCUSSION', 'Summary of evidence', 'Table 3: Quality of available evidence']}\n",
      "--- Doc ---\n",
      "{'metadata': ['DISCUSSION', 'Strengths and limitations']}\n",
      "--- Doc ---\n",
      "{'metadata': ['DISCUSSION', 'Recommendations for future research']}\n",
      "--- Doc ---\n",
      "{'metadata': ['DISCUSSION', 'Recommendations for future research']}\n",
      "--- Doc ---\n",
      "{'metadata': ['CONCLUSION']}\n",
      "--- Doc ---\n",
      "{'metadata': ['CONCLUSION', 'Financial support and sponsorship']}\n",
      "--- Doc ---\n",
      "{'metadata': ['CONCLUSION', 'Conflicts of interest']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '1. FAO/WHO']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '1. FAO/WHO']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '2. FAO/WHO']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '3. Fuller R, Gibson GR']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '4. Haukioja A']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '4. Haukioja A']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '4. Haukioja A']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '4. Haukioja A']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '4. Haukioja A']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '4. Haukioja A']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '4. Haukioja A']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '4. Haukioja A']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '4. Haukioja A']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '4. Haukioja A']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '4. Haukioja A']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '4. Haukioja A']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '4. Haukioja A']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '4. Haukioja A']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '4. Haukioja A']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '4. Haukioja A']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '19. Mendi A, Aslım B']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '19. Mendi A, Aslım B']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '21. Bohora A, Kokate S']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '21. Bohora A, Kokate S']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '21. Bohora A, Kokate S']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '21. Bohora A, Kokate S']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '21. Bohora A, Kokate S']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '21. Bohora A, Kokate S']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '21. Bohora A, Kokate S']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '21. Bohora A, Kokate S']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '21. Bohora A, Kokate S']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '21. Bohora A, Kokate S']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '21. Bohora A, Kokate S']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '32. Caglar E']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '32. Caglar E']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '32. Caglar E']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '32. Caglar E']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '32. Caglar E']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '32. Caglar E']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '32. Caglar E']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '32. Caglar E']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '32. Caglar E']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '32. Caglar E']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '32. Caglar E']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '32. Caglar E']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '32. Caglar E']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '32. Caglar E']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '32. Caglar E']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '32. Caglar E']}\n",
      "--- Doc ---\n",
      "{'metadata': ['REFERENCES', '48. Ryan, R']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Systemic corticosteroids in treatment of chronic rhinosinusitis—A systematic review']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Systemic corticosteroids in treatment of chronic rhinosinusitis—A systematic review', 'ABSTRACT']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Systemic corticosteroids in treatment of chronic rhinosinusitis—A systematic review', 'ABSTRACT']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Systemic corticosteroids in treatment of chronic rhinosinusitis—A systematic review', 'ABSTRACT']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Systemic corticosteroids in treatment of chronic rhinosinusitis—A systematic review', 'ABSTRACT']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Systemic corticosteroids in treatment of chronic rhinosinusitis—A systematic review', 'ABSTRACT']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Systemic corticosteroids in treatment of chronic rhinosinusitis—A systematic review', 'ABSTRACT']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Systemic corticosteroids in treatment of chronic rhinosinusitis—A systematic review', 'ABSTRACT', 'ARTICLE HISTORY', 'Received 19 March 2023 Accepted 20 July 2023']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Introduction']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Introduction']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Introduction']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Introduction']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Introduction']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Introduction']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Introduction']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Introduction']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Introduction']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Introduction']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Introduction']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Materials and methods', 'Data sources and search strategy']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Materials and methods', 'Data sources and search strategy']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Materials and methods', 'Data sources and search strategy']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Study selection']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Eligibility criteria']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Eligibility criteria']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Eligibility criteria']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Eligibility criteria']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Eligibility criteria', '(1) Non-English']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Eligibility criteria', '(4) Localized CRS']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Eligibility criteria', '(4) Localized CRS']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Eligibility criteria', '(4) Localized CRS']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Eligibility criteria', '(4) Localized CRS']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Eligibility criteria', '(4) Localized CRS']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Eligibility criteria', '(4) Localized CRS']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Eligibility criteria', '(4) Localized CRS']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Data extraction']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Data extraction']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Data extraction']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Data extraction']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Results']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Results', 'Identification of studies via databases']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Results', 'Identification of studies via databases']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Results', 'Identification of studies via databases']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Results', 'Identification of studies via databases']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Results', 'Identification of studies via databases']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Results', 'Identification of studies via databases']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Results', 'Identification of studies via databases']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Results', 'Identification of studies via databases']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Results', 'Identification of studies via databases']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Results', 'Identification of studies via databases']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Results', 'Identification of studies via databases']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Impact of Preoperative Systemic Corticosteroids on the Histology and Diagnosis of Eosinophilic Chronic Rhinosinusitis [25]', 'Akiyama 2019']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Impact of Preoperative Systemic Corticosteroids on the Histology and Diagnosis of Eosinophilic Chronic Rhinosinusitis [25]', 'Akiyama 2019']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Clinical Trial [30]']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Clinical Trial [30]', 'Arancibia 2020']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Clinical Trial [30]', 'Arancibia 2020']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Clinical Trial [30]', 'Arancibia 2020']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Clinical Trial [30]', 'Arancibia 2020']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Clinical Trial [30]', 'Arancibia 2020']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Clinical Trial [30]', 'Moderate']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Name']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Fernandes 2010']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Fernandes 2010']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Moderate']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Moderate']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Moderate']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Moderate']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Jankowski 2003']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Jankowski 2003']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Long-Term Therapy with Corticosteroids in Nasal Polyposis: A Bone Metabolism Assessment [54]']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Long-Term Therapy with Corticosteroids in Nasal Polyposis: A Bone Metabolism Assessment [54]']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Long-Term Therapy with Corticosteroids in Nasal Polyposis: A Bone Metabolism Assessment [54]']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Long-Term Therapy with Corticosteroids in Nasal Polyposis: A Bone Metabolism Assessment [54]']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Long-Term Therapy with Corticosteroids in Nasal Polyposis: A Bone Metabolism Assessment [54]']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Long-Term Therapy with Corticosteroids in Nasal Polyposis: A Bone Metabolism Assessment [54]']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Very low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Sahlstrand- Johnson 2019']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Sahlstrand- Johnson 2019']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Very low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Rajasekaran 2010']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Rajasekaran 2010']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Rajasekaran 2010']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Rajasekaran 2010']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Discussion', 'Rajasekaran 2010']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Very low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Very low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Very low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Very low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Very low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Very low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Very low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Very low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Very low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Very low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Very low']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Conclusions']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Acknowledgments']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Disclosure statement']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Funding']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Thank References']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Thank References']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Thank References']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Thank References']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Thank References']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Thank References']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Thank References']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Thank References']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Thank References']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Thank References']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Appendices Appendix 1: Search history in PubMed']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Appendices Appendix 1: Search history in PubMed', 'Appendix 2: Search history in Embase']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Appendices Appendix 1: Search history in PubMed', 'Appendix 3. ICD 10.diagnosis codes']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'ABSTRACT']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'ABSTRACT', 'RESUMO']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'ABSTRACT', 'RESUMO']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'ABSTRACT', 'RESUMO', 'Corresponding author. E-mail: daniellenut@hotmail.com (D. C. G. Silva).']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'ABSTRACT', 'RESUMO', 'Corresponding author. E-mail: daniellenut@hotmail.com (D. C. G. Silva).']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'METHOD']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'RESULTS']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'RESULTS']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'RESULTS', 'Other bias']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'RESULTS', 'Other bias']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'RESULTS', 'Other bias']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'RESULTS', 'Other bias']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'RESULTS', 'Other bias']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'DISCUSSION']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'DISCUSSION']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'DISCUSSION']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'DISCUSSION']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'DISCUSSION']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'DISCUSSION']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'DISCUSSION', 'Conflict of interests']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'DISCUSSION', 'Authors’ contribuition']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'DISCUSSION', 'Funding']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'DISCUSSION', 'Declaration']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '11. Kuperminc MN, Stevenson RD']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '3. O’Shea TM']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '3. O’Shea TM']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '5. World Cerebral Palsy Day [homepage on the Internet]']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '17. Joanna Briggs Institute [homepage on the Internet]']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '17. Joanna Briggs Institute [homepage on the Internet]']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '17. Joanna Briggs Institute [homepage on the Internet]']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '17. Joanna Briggs Institute [homepage on the Internet]']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '17. Joanna Briggs Institute [homepage on the Internet]']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '17. Joanna Briggs Institute [homepage on the Internet]']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '17. Joanna Briggs Institute [homepage on the Internet]']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '17. Joanna Briggs Institute [homepage on the Internet]']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '17. Joanna Briggs Institute [homepage on the Internet]']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS', '35. Bell KL, Samson-Fang L']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS', '35. Bell KL, Samson-Fang L']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS', '37. ASPEN Board of Directors and the Clinical Guidelines Task']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS', '37. ASPEN Board of Directors and the Clinical Guidelines Task']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS', '37. ASPEN Board of Directors and the Clinical Guidelines Task']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS', '37. ASPEN Board of Directors and the Clinical Guidelines Task']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS', '37. ASPEN Board of Directors and the Clinical Guidelines Task']}\n",
      "--- Doc ---\n",
      "{'metadata': ['Nutritional interventions in children and adolescents with cerebral palsy: systematic review', 'Intervenções nutricionais em crianças e adolescentes com paralisia cerebral: revisão sistemática', 'INTRODUCTION', 'REFERENCES', '1. Brazil', '7. Drent LV, Pinto EA', '26. Kibirige MS', '37. ASPEN Board of Directors and the Clinical Guidelines Task', '42. Dietitians Association of Australia']}\n"
     ]
    }
   ],
   "source": [
    "for doc in documents:\n",
    "    print(\"--- Doc ---\")\n",
    "    print(doc.metadata)\n",
    "    # print(\"---\")\n",
    "    # print(doc.text)\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
